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Nigeria has the second largest burden of HIV in the world with about 1.9 million 
individuals living with HIV. With only 12% of total funding from domestic sources, the country 
depends primarily on foreign donors for funding of the HIV program. About 50% of individuals 
needing HIV treatment are unable to access required services primarily due to lack of financial 
capacity of the Nigerian HIV program. The broad aim of this research is to inform the 
development of a sustainable financing approach to increase access to HIV treatment services 
in Nigeria. This study sought answers to the following research questions: 1) What proportion of 
people living with HIV are willing to pay for such services, 2) What factor influence willingness to 
pay for HIV treatment services in Nigeria, and 3) How can patients’ willingness to pay and other 
sources of funding be used to improve sustainability of funding for HIV treatment services in 
Nigeria. We used mixed method design involving a survey of 400 individuals living with HIV 
followed by interviews of 30 key informants selected from donor and government agencies, HIV 
program managers, civil society groups and people living with HIV and their networks. We found 
that 92% of patients were willing to pay for HIV treatment. The availability of financial support 
from family and friends, having a source of income, increase in monthly income and earnings 
above the minimum wage were correlated with willingness to pay for services. Sustainable 
funding for HIV treatment services could be achieved through the creation of targeted funding   
iv 
through strategic domestic resource mobilization; improvement of cost effectiveness; support for 
local manufacture of HIV related commodities; and segmentation of patients based on 
willingness/capacity. Identified facilitators and barriers to effective implementation of proffered 
solutions include the need for objectivity in decision making; improved accountability by 
government agencies; exploring current momentum around health insurance schemes and 
utilizing dwindling foreign donor funding as opportunity to improve cost effectiveness of the 
program. Effective shared leadership, communication and engagement with relevant 
stakeholders are key to driving the required change while guiding against negative 
consequences of planned change. 
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CHAPTER 1: INTRODUCTION 
Background 
Nigeria is among the countries with the highest number of people living with the Human 
Immunodeficiency Virus (HIV) in the world (NACA, 2019a). The country’s 1.4% HIV prevalence 
in the adult population is considered low, but due to the large population of over 180 million 
people, there are about 1.9 million people living with HIV in 2019 (NACA, 2019a). Despite 
recording a 13% reduction in new infection in the last ten years, about 53,000 and 45,000 
deaths were reported from HIV related illnesses in 2018 and 2019 respectively (UNAIDS, 2020). 
Data also indicates that Nigeria accounts for 2 out of every 3 new HIV infection in west and 
central Africa in 2019 (UNAIDS, 2020) 
In 2014, the Joint United Nations Program on HIV/AIDS (UNAIDS) issued treatment 
goals for HIV, called the 90-90-90 target. The treatment goal specifies that by 2020, 90% of 
individuals living with HIV should know their HIV status, 90% of people with diagnosed HIV 
infection should receive antiretroviral treatment (ART), and 90% of those taking ART should be 
virally suppressed (Granich et al., 2017). As the end of year 2020 approaches, the country has 
not been able to achieve the target with current progress put at 73%: 89%: 67% (Avert.org, 
2020; FMOH,2020). Therefore, efforts are now geared towards the achievement of the 95:95:95 
target by 2030 (UNAIDS, 2020). 
In 2011, the United Nations political declaration on HIV/AIDS called on the international 
community to mobilize between US$22 – 24 billion for the global response to HIV/AIDS in low- 
and middle-income countries by 2015; however, this target was not achieved as only about 
US$19.1 billion was made available by the end of 2016 (UNAIDS & The Henry Kaiser family 
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foundation, 2017). Based on UNAIDS estimates, a new funding target indicated that about 
US$26.2 billion will be required by 2020 to enable the world to be on course to end HIV/AIDS a 
public health threat in low- and middle-income countries by 2030 (UNAIDS, 2017). Therefore, 
the currently available resources must increase by US$1.5 billion annually from 2016 to enable 
the funding target of 2020 to be achieved (Health Gap, 2017).  
In addition, the World Health Organization (WHO) strategy of “test and treat” 
recommends initiation of treatment immediately after a patient is diagnosed with HIV infection 
as part of the efforts to improve health outcomes of people living with HIV (WHO, 2015). 
Therefore, it is critical that patients promptly initiate treatment and remain adherent to 
medication after an HIV diagnosis.   
Context of HIV/AIDS Funding in Nigeria 
A review of national expenditures on HIV in Nigeria between 2009 and 2016 indicates 
that international funding from the United States President’s Emergency Plan for AIDS Relief 
(PEPFAR) and the Global Funds for AIDS Tuberculosis and Malaria (GFATM) accounted for 
about 88% of total funding for HIV in Nigeria (NACA, 2018). The government of Nigeria, private 
philanthropy, and the private sector including out of pocket payments provided the remainder of 
the funding for HIV services. However, only about 50% of those living with HIV/AIDS in Nigeria 
are currently able to access antiretroviral treatment (NACA, 2019b). Limited access to treatment 
is due primarily to lack of financial capacity of the HIV program in Nigeria to provide 
antiretroviral therapy and laboratory monitoring for those in need of these services (NACA, 
2013). According to the National Agency for the Control of AIDS, international funding for HIV 
response in Nigeria was about US$255 million in 2007 (NACA, 2018). This grew over the years 
to about US$700 million in 2013 followed by a dip to just below US$450 million in 2014. 
Similarly, the Government of Nigeria increased its funding from about US$44 million in 2007 to 
slightly more than US$171 million in 2014. Due to huge funding gaps between availability and 
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need, donor funding is now prioritized to ensure that clients who are already on treatment have 
unhindered access to treatment, rather than spending such funds for widespread HIV screening 
in those who do not know their HIV status which will increase the number of new patients who 
will require treatment in the future. 
Based on the estimated gap between the number of people receiving treatment for HIV 
and total number of individuals who require treatment, about one million additional patients 
require treatment from 2020 (NACA, 2019b). The average cost of accessing antiretroviral (ARV) 
drugs alone is US$96 per year per patient (US$8 per month), while the average cost of HIV 
treatment services (including ARVs and laboratory services and staff salary) is estimated at 
US$134 per year per patient (NACA, 2018). Current estimates indicate that an additional US$58 
million will be required annually to add about 440,000 people living with HIV into treatment 
services as planned by the Nigerian government (NACA, 2018).  
Based on the recommendations of the National Council on Health of Nigeria (the highest 
decision-making body on health in Nigeria), in 2018 the federal government of Nigeria 
committed to set aside about 0.5 – 1% of federal monthly funds to be allocated to finance HIV 
treatment in Nigeria (NACA, 2018). In addition, each of the thirty-six states in Nigeria will set 
aside a similar ratio of the state monthly allocation to be used for HIV prevention and treatment 
services (NACA, 2018). If these commitments are fulfilled, this will improve access to HIV 
treatment to about 440,000 people living with HIV but still leave a gap of about 500,000 patients 
to reach the 90-90-90 target by end of 2020.  
Aims and Research Questions 
The main objective of the research is to help inform the development of a sustainable 
financing approach to increase access to HIV treatment services in Nigeria by exploring 
patients’ willingness to pay for HIV treatment services and the factors that influence their 
willingness to pay. The study will gather opinions of people living with HIV, policy makers, HIV 
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program managers and senior officials from the Ministry of Health, HIV Control Program, donor 
organizations and HIV intervention implementing organizations and civil society groups on how 
funding for HIV treatment services can be made more sustainable using a combination of 
funding mechanisms. 
The research questions and aims include: 
Question 1: What proportion of people living with HIV are willing to pay for HIV treatment 
services in Nigeria? 
Aim 1: To determine the proportion of people living with HIV who currently receive free HIV 
treatment services who would be willing to pay for such services. This will enable the estimation 
of additional resources required to support HIV treatment services. 
Question 2: What factors influence willingness to pay for HIV treatment services by people 
living with HIV/AIDS in Nigeria? 
Aim 2: To explore and obtain in-depth understanding of the factors that influence the willingness 
of people living with HIV to pay for HIV treatment. 
Question 3: How can patient willingness to pay and other sources of funding be used to 
improve sustainability of funding for HIV treatment services in Nigeria? 
Aim 3: To explore alternative methods for structuring funding for HIV treatment services in 
Nigeria. 
Aim 4: To develop a plan for change to improve sustainability of funding for HIV treatment 
services in Nigeria. 
Significance of Proposed Study 
At the end of 2018, about one million Nigerians living with HIV could not access 
treatment due to funding challenges (NACA, 2019b). This research is significant because the 
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HIV program in Nigeria is seeking sources of funding outside of international donors and 
government of Nigeria to achieve sustained universal access to HIV treatment and achieve the 
95-95-95 targets of UNAIDS by 2030 as the 90:90:90 target for the year 2020 could not be 
achieved. 
Sustainable financing is defined as the capacity of a program to continue to deliver its 
intended benefits over a long period of time (Bamberger et al, 1990). Sustainable financing is 
required to ensure an effective and efficient healthcare system. An efficient healthcare system is 
one that produces good health outcomes, affordable services, satisfied clients, and providers, in 
addition to medical and financial equity (World Bank, 1987).  Universal access to HIV treatment 
is required to prevent reversal of achievements in the control of HIV in Nigeria and to achieve 
the 90-90-90 and 95-95-95 targets of UNAIDS aside the huge economic, social and health 
benefits of investments in HIV response (Bor, et al, 2012). Failure to put such a plan in place will 
limit the capacity to end HIV as a public health threat in Nigeria by 2030 (UNAIDS, 2017). It is 
hoped that this research will produce greater understanding of factors that influence willingness 
to pay (defined below) for HIV treatment. The findings will guide the development of pathways 
for viable and sustainable financing options to complement current donor and government 
funding for HIV treatment services in Nigeria. 
Due to the chronic nature of HIV infection, there are long term implications for treatment 
cost as treatment is for the entire life of the patient. In addition, the cost of treatment increases 
as the patient is switched from a first line treatment regimen – the initial treatment with safe, 
effective and convenient treatment with antiretroviral therapy for people living with HIV but who 
have never taken antiretroviral medicines before – through second line treatment, to a salvage 
treatment regimen – i.e., therapy given when the first and second line treatments for HIV are no 
longer effective usually due to toxicity or development of resistance to many of the 
antiretrovirals. At the current annual cost of HIV treatment of US$134 per patient, the funding 
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needs to achieve universal access to HIV treatment in Nigeria is about US$254.6 million 
annually ($134 x 1.9million patients). In addition, as people with HIV live longer, requirements 
for sustainable financing will likely continue to increase, especially if the incidence of new HIV 
infection is not controlled.  
Despite the commitment of additional funding for HIV by federal and state governments 
in Nigeria, experience suggests that adequate government funding cannot be assured.  Funding 
may fall short because of the country’s dependence on international crude oil prices (which 
usually fluctuates), and competing funding needs for other sectors, such as infrastructure 
development.  Therefore, there is a need to put in place a long-term funding sustainability plan. 
This requires that in addition to increased funding from the government of Nigeria and the 
private sector, supplementary sources of funding should be explored, including the potential for 
patients to pay for treatment.  
Financing Options for HIV/AIDS Treatment Services in Low Income Countries 
Health financing experts have suggested several financing mechanisms to ensure the 
sustainability of HIV/AIDS treatment programs and other health interventions.  These are 
summarized below. 
Increasing Government Revenue (Taxes) 
Health systems in low and middle-income countries are in large part funded through 
government revenues, mostly generated from taxes. Such funding can be increased by raising 
the tax rate or improving the effectiveness of tax collection. Due to the relatively low number of 
people who pay taxes and poor collection processes, it usually takes several years for tax 
revenue to provide large additional revenue required in low- and middle-income countries to 
finance needed health services (World Bank, 2005). Tax collection systems in many countries 
are weak and time is required to improve tax collection processes, and to enforce tax laws.  
Also, most countries may be unwilling to introduce tax reforms solely to accommodate 
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increased health expenditures (World Bank, 2005). Therefore, the tax increase accrued is 
shared by all sectors rather than the health sector alone. Countries such as the Republic of 
Benin, Ghana and Zimbabwe achieved positive outcomes in their health systems from 
increased tax collection (World Bank, 2017). 
Use of Earmarked Taxes 
The use of earmarked taxes involves increasing government funds available for specific 
use through the increase of specific tax revenues (Katz et al., 2014). This option has been 
applied to air travel and tobacco products in some countries (Prakongsai et al., 2008). The 
advantage of this option is that taxpayers are more likely to pay such taxes because it is 
understood that this revenue will be used solely for health interventions which will impact 
people’s lives. However, such funds may be mismanaged or diverted to other uses. This 
financing option was implemented in Nigeria between 2012 and 2015 when revenue obtained 
from petrol sales in Nigeria were used to support the HIV program through the Subsidy 
Reinvestment and Empowerment Program (SURE-P) which was targeted at infrastructure 
development and HIV treatment and prevention interventions. However, this was truncated in 
2015 due to a change in policy of the new federal government. Similarly, Gabon introduced a 
1.5% levy on post tax profit on company that provide money transfer services and a 10% tax on 
mobile operators in the country. In 2009, these two forms of earmarked taxes generated a 
combined US$30 million which was used to protect the lowest income group in the country 
against financial risk due to illness and to improve access to healthcare services (WHO, 2013). 
Risk Pooling Schemes and Social Assistance Programs 
Risk pooling schemes involve the use of health insurance which is an organizational 
arrangement created to offer financial protection to a large group of individuals against the cost 
associated with treatment of illnesses (Katz et al., 2014). Risk pooling ensures the risk of 
financial burden due to ill health is dispersed in the population. The healthy population helps to 
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subsidize care for the sick and the rich subsidize care for the poor. However, there must be a 
willingness and capacity to pay health insurance premiums. Risk pooling also requires a large 
number of insured and a diverse mix of healthy and sick individuals as well as a mix of income 
levels for sustainability. 
The Nigeria Health Insurance Scheme consists of three programs. The first program 
designed for the formal sector is called the Social Health Insurance Program (SHIP). This was 
designed for the employees in the public and organized sector (NHIS, 2012). It is funded 
through a pre-determined percentage contribution from both the employers and employees in 
the formal sector. Although, the policy which guides the implementation of the program makes 
participation in the program compulsory for all organizations with at least 10 employees, 
participation has been very low (Odeyemi and Nixon, 2013). The other two programs were 
designed for the informal sector. The programs include the Rural Community Social Health 
Insurance Program and the Urban Self-employed Social Health Program. The community-based 
health insurance programs were introduced to help mitigate some of the problems associated 
with payment of user fees at the point of accessing healthcare services. However, the program 
has a drawback of the likelihood of disproportionate enrolment of large number of high-risk 
members and smaller number of low-risk individuals (Carrin et al, 2005). There is scant 
published literature examining the extent to which private insurance packages include HIV 
treatment and testing benefits in sub-Saharan Africa (Talib & Laurel, 2013). The literature 
indicates that less than 5% of Nigerians have any form of health insurance coverage with most 
of the enrollees in the formal sector and operated by private health maintenance organizations 
(HMO) (Uzochukwu et al., 2015). Unlike countries such as Kenya and Uganda where health 
insurance covers HIV treatment services, health insurance in Nigeria covers voluntary HIV 
counselling and testing services while treatment services that include the provision of 
antiretrovirals are not covered. People who are covered by insurance and in need of HIV 
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treatment services are referred to public and private hospitals who offer donor and government 
funded HIV treatment services free of charge. When referred to private hospitals, such patients 
are billed for laboratory tests and physician services but not the medicines (Feeley, 2007).  
Debt Conversion for Social Investment 
Debt conversion is the exchange of debt – typically at a substantial discount – for equity, 
or counterpart domestic currency funds to be used to finance a specific project or policy (OECD, 
2013). Debt conversion for social investment is usually targeted at heavily indebted poor 
countries (HIPC) whereby debt relief is linked to poverty reduction. Under this arrangement, a 
creditor is convinced by a third party to forgo a portion of their claims on the condition that the 
debtor country will invest an agreed amount in health interventions including the control of 
HIV/AIDS, tuberculosis and/or malaria programs. The Global Fund for HIV/AIDS, Tuberculosis 
and Malaria (GFATM) has implemented this financing option for HIV interventions in Pakistan, 
Côte d’Ivoire, Egypt, and Indonesia as beneficiary countries, with Germany and Australia as 
creditor countries. This requires an approved grant for such nations to implement debt 
conversion (World Bank, 2017).  
Concessionary Loans  
Concessionary loans involve the approval of loans for health interventions by financial 
institutions including the World Bank, International Monetary Funds (IMF) and regional 
development banks such as the African Development Bank (ADB). These loans come with 
favorable terms of payments, such as low interest or deferred payment schedules. This 
financing option has been implemented for various health programs in several countries 
including Nigeria, Kenya, and Ethiopia (Katz et al., 2014). Similar to debt conversion, the 
application of the concessionary financing option is limited because such loans are not recurring 
and therefore have limited sustainability. In addition, when the funding is large, these 
arrangements may negatively impact the economy because funds may be unavailable for other 
10 
government priorities.   
Grants/Donor Funds 
Donor funding plays a critical role in financing health services in low- and middle-income 
countries. This is especially true in sub-Saharan African countries where about 20 –30% of total 
health expenditures are provided from external funding (WHO, 2013). A major challenge 
associated with donor funding is sustainability due to the volatility and the short-term nature of 
funding.  Despite this challenge, low- and medium-income countries have continued to benefit 
from donor funding to scale up healthcare services, including HIV treatment services. Donor 
funds can be put into better use by targeting financing to the country’s priorities and filling gaps 
in funding from local sources. 
Donor funds are received from donor countries, private organizations, and foundations. 
Funds received from donor governments are received either as bilateral or multilateral 
assistance. Bilateral assistance is funding disbursed by a donor country to a recipient country 
for the purpose of addressing specific issues. In 2017, about US$6.3 billion bilateral assistance 
disbursement was made to low- and medium-income countries for HIV/AIDS interventions.  
As stated earlier, US PEPFAR provides the largest bilateral assistance with over US$58 
billion spent globally since its inception in 2003 through 2017 to combat HIV/AIDS (PEPFAR, 
2017). This has resulted in about 14 million people living with HIV receiving free lifesaving 
antiretroviral treatment in addition to other related interventions (PEPFAR, 2018). 
Furthermore, multilateral assistance is provided by donor governments to multilateral 
organizations which use funds for specific interventions. Multilateral assistance for HIV is 
received by organizations such as GFATM and UNITAIDS and other United Nations 
organizations (UNAIDS, 2018). Bilateral and multilateral assistance worldwide increased to 
US$8.1 billion in 2017 from US$7.5 billion in 2015 and US$7.0 billion in 2016. It is expected that 
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future disbursement will likely fall back to pre-2016 levels.  
Private philanthropies include foundations, corporations, faith-based organisations, non-
government organisations, and individuals. As well as providing funding for the global HIV 
response, many of these organisations provide price reductions for HIV commodities (UNAIDS, 
2018). They provided about US$680 million for HIV programs around the world in 2016, a 2% 
increase from 2015 (UNAIDS, 2018). The largest contributors from the private philanthropic 
organizations in 2016 were the Bill and Melinda Gates Foundation and Gilead Sciences, which 
together accounted for more than 50% of all philanthropic funding in 2016 (UNAIDS, 2016). 
Of note, among other challenges in recent years, donor funding for HIV has faced 
competing demands for increased refugee and humanitarian aid, putting long term priorities 
under pressure (OECD DAC, 2018). 
Out of Pocket Payments 
Out of pocket payments refer to patients paying for services at the point where services 
are provided. These payments may be made for privately and publicly provided services. Out of 
pocket payments cover both direct and indirect costs and are provided by patients directly or by 
family members (World Bank, 2017). Most commonly, out of pocket payments are used for 
medicines, diagnostic tests, and physician care. Although the use of out-of-pocket payments for 
health services is usually very controversial because of its inequitable impact on poor people, it 
is a common source of funding for health care services in sub-Saharan African countries. 
Similarly, out of pocket payment for health services has widespread application in such 
countries as China and Cambodia (World Bank, 2017). Application of out-of-pocket payments to 
settle user fees for health services are considered viable funding options as they support and 
help improve the quality of services (Schieber et al, 2006). However, the major limitation of out-
of-pocket payments is the potential to increase health inequities due to the inability of the very 
poor to pay such fees (Palmer et al, 2004). Indeed, out of pocket payments tend to make the 
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poor poorer, thus increasing health inequality. As part of efforts to limit such problems, the 
introduction of user fees must be accompanied by appropriate systems of waivers and targeted 
affordable prices to protect the poor (Dao et al, 2008). 
The various financing options discussed above have been implemented in several low 
and middle-income countries with mixed results. Katz et al. (2008) indicate that none of these 
funding sources applied as a single source could generate up to 50% of the funds required for 
HIV programs in the countries studied. Zakumumpa et al. (2017) reports that HIV programs with 
multiple sources of funding are more likely to be sustainable than those with a single source. 
Willingness of Patients to Pay for HIV/AIDS Treatment Services 
An effective and sustainable funding strategy for HIV/AIDS treatment services in Nigeria 
and other low- and middle-income countries will require some level of commitment by patients 
to pay for services. Although there are people in Nigeria living with HIV who pay for services at 
private hospitals, reliable data on the number of patients paying for HIV treatment services is 
scant as several private hospitals also benefit from donor and government provided 
antiretroviral services. The willingness to pay by clients could be expressed in the form of 
paying an insurance premium or paying out of pocket for the full or subsidized cost of services. 
The concept of willingness to pay for services is based on welfare economic theory. The 
theory relies on the assumption that the value to an individual of a health improvement or 
technology can be measured by the maximum amount of money an individual is willing to pay 
for such health improvement or technology (Hammitt, 2002). Willingness to pay is analogous to 
cost -benefit analysis in the economic evaluation of healthcare technology (O’ Brien & 
Gafni,1996). This form of evaluation is based on user preferences. In addition, findings from 
willingness to pay studies are useful for price setting and in estimating the expected revenue 
that can accrue to a program based on the proportion of users who are willing to pay at different 
price points (Foreit and Foreit, 2004). While it is acknowledged that the findings from willingness 
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to pay studies do not give a perfect prediction, willingness to pay however, provides information 
that can help to predict responses to price changes for a product or service. 
The assessment of willingness to pay can be achieved by the direct method which 
involves determining the expressed value the user places on the service. It can also be 
achieved by the indirect method which involves determining tradeoffs between the valued 
effects of an intervention and the monetary amount involved from which willingness to pay 
measures are derived (Johannesson, 1996). The most used method in determining willingness 
to pay for healthcare is the contingent valuation method (CVM). This is a direct, hypothetical, 
survey-based method used for eliciting a monetary value of a healthcare service or technology 
(Klose, 1999). Although the method was originally used in environmental studies, it has been 
applied in healthcare (Bateman et al., 1993). The prospective technique determines willingness 
to pay based on a hypothesized market presented to respondents. 
Conceptual Framework 
The conceptual framework underpinning the proposed study is the framework for 
healthcare financing in the 21st century developed by Schieber et al, (2006). The framework was 
adopted to highlight the sources of funding for HIV treatment services in Nigeria (Figure 1). As 
observed in health systems in other low- and middle- income countries, funding sources can be 
divided into three groups: (1) public sector (general government revenues); (2) private sector, 
which includes out of pocket payments and private insurance premiums; and (3) external 
sources, including grants, loans, and other funding from international funding agencies. Current 
sources of funding for HIV treatment services in Nigeria are primarily from external sources and 
the public sector. These sources are being negatively affected by the global economy. Funding 
from these sources is unable to expand to meet the growing demand for HIV treatment. 
Therefore, an alternative option to complement current funding sources will require payment for 
14 
treatment services by the patients either through out-of-pocket payment or through payment of 
health insurance premiums.  
 
Figure 1: Conceptual Framework Adopted from Schieber G, et al, (2006). Financing Health 
System in the 21st Century 
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CHAPTER 2: LITERATURE REVIEW 
Selection of Search Databases 
I employed a systematic approach for the literature search. This ensured that all key and 
relevant literature on willingness of clients to pay for HIV/AIDS treatment were identified through 
the search. I conducted electronic searches in PubMed, Scopus and Global Health databases. I 
selected these three databases because they provide access to millions of citations in multiple 
disciplines including medicine and public health. PubMed provides links to full text articles from 
PubMed central or publisher web sites for close to the last 70 years. Scopus, on the other hand, 
covers scientific, medical, and social sciences and provides citation analysis for relevant articles 
which complemented articles obtained from PubMed. In addition, PubMed allows a larger 
number of key words to be used during the search to enable identification of relevant articles. 
Literature Search Terms 
I conducted an initial advanced search in PubMed using key concepts from the research 
topic “Willingness to pay” and Boolean operator AND with “HIV treatment.” I evaluated the 
resulting articles from the initial search to identify abstracts that were most relevant and related 
to my study. I examined the language in the pre-selected articles to identify words in the initial 
search. Similarly, I identified relevant MeSH terms in each article for possible use for the 
reformulation of the search terms. Synonyms of identified words were considered for possible 
use. The process resulted in the following search terms: 
“Willingness to pay”; “HIV* treatment”; HIV* services; HIV* therapy. These terms were used with 
Boolean operators (AND/ OR). 
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Inclusion and Exclusion Criteria 
I employed specific standardized inclusion and exclusion criteria in selecting studies for 
the review. The criteria for inclusion were:  
1) Relevant literature from peer reviewed research conducted after the year 2003. The 
rationale for this is that donor funding and free treatment for HIV/AIDS treatment 
commenced after 2003. Therefore, issues around payment for HIV/AIDS treatment did 
not arise until that year.  
2) Relevant articles written in the English language. This was to ensure good 
understanding of the study without the need for translation which may have created 
language bias.  
3) Studies which covered research on willingness to pay for HIV/AIDS treatment involving 
both adults and children.  
4) Studies conducted in low- and medium-income countries. This ensures the setting of 
included studies was similar to Nigeria.  
5) Both qualitative and quantitative studies were considered in the literature search. 
Exclusion criteria included:  
(1) Studies involving willingness to pay for HIV screening, prevention services and pre-
exposure prophylaxis (PrEP) 
(2) Studies conducted in high income countries. 
(3) Studies published in the grey literature. 
Search Strategy 
Electronic Database Search 
Beginning with PubMed, I searched each of the three electronic databases. I applied the 
search terms “Willingness to pay” AND “HIV treatment” in each database. I refined the search 
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results by using another Boolean operator “OR” with “HIV services”. I repeated the process 
using same search terms in SCOPUS and Global Health database. 
Copying and Deduplication of Articles 
I imported the articles identified from each of the three electronic databases to 
Covidence for deduplication and review before I imported them into citation manager F1000. 
Title and Abstract Review 
I reviewed the title and abstract sections of each of the identified articles to determine 
the focus and relevance of the articles to my research topic. I retained for full text review those 
articles that were relevant and met the inclusion criteria and eliminated those that did not meet 
the criteria.  
Search for Missed Articles 
There is a possibility that I may have missed some relevant articles due to the use of 
different keywords than those I applied in the electronic search. Therefore, I employed snowball 
sampling to the literature search after the electronic database search. This ensured wider 
search of peer reviewed literature while adhering to the inclusion and exclusion criteria. During 
snowball sampling, I reviewed the reference list of articles that met the inclusion and exclusion 
criteria and I also used the citation analysis provided by SCOPUS to identify and scrutinize 
articles that cited the selected relevant articles. 
For every new article found to be relevant from snowballing, I repeated the sequence of 
preliminary article review, importation into Covidence for deduplication with adherence to the 
inclusion and exclusion criteria before I imported the articles into F1000. I retained or discarded 
these articles in F1000 as applicable after title and abstract review. 
Full Article Review 
I retrieved the full text of all articles found to be relevant from F1000 for a comprehensive 
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review to determine if the articles were truly relevant to the research question.  
Data Extraction Process 
I developed an Excel worksheet to extract key information about the five included 
studies. This enabled a simple presentation of the information from each of the included studies. 
The information extracted included:  
(1) The type of study design utilized  
(2) The method of study (Qualitative or Quantitative) 
(3) The study population and setting 
(4) Sampling method employed 
(5). Sample size of the study 
(6) Type of data used and collection method  
(7) Method applied for the evaluation of willingness to pay 
(8). Data analysis procedure 
(9) Outcomes measured  
(10) Results of study 
 (11) Limitation of study  
(12) Author’s conclusion; and  
(13) Quality rating of the included studies 
Results of Literature Review 
The search strategy produced 195 articles from three electronic database searches. 
When the articles were imported into Covidence for screening, I identified sixty-nine duplicate 
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articles and I removed them from the analysis. The remaining126 articles were screened 
through a review of the abstract and title sections. This resulted in the elimination of ninety-five 
studies as they were not relevant to the research question based on the inclusion and exclusion 
criteria. The thirty-one articles found to be relevant were assessed through a full -text review; 
twenty-eight of these studies were excluded based on the inclusion and exclusion criteria. Three 
articles remained for data extraction.  
The snowballing approach I applied to the reference list of the three articles selected 
resulted in the identification of two more articles that met the inclusion and exclusion criteria. 
This resulted in a total of five articles meeting the requirements for data extraction. Full data 
extraction was conducted on the five remaining articles. 
The PRISMA diagram of the process is as depicted in Figure 2. 
 
Figure 2: PRISMA Diagram of Literature Search Strategy 
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Study Characteristics 
Although the main interest of the included studies was to evaluate the willingness to pay 
for HIV/AIDS treatment, all the studies included respondents’ demographic data, including 
occupation, income earning capacity, and marital status. Collectively, these helped me 
determine the socio-economic status of respondents and how such factors may influence 
willingness to pay for HIV/AIDS treatment. 
The five studies from which data were extracted were conducted in low and middle-
income countries. Three separate studies were conducted in Zimbabwe, Cameroon, and India. 
Two other studies were conducted in the eastern part of Nigeria. The study population in the 
different articles were all individuals living with HIV/AIDS and receiving free HIV/AIDS treatment 
services in public health facilities. The only exception to this was the study by Gupta (2007), 
where data were collected in India. This study included clients who were living with HIV/AIDS 
but who had not started treatment. On average, there were more female (about 65%) than male 
(about 35%) respondents in the selected studies. 
All the studies used similar cross-sectional study designs to evaluate willingness to pay. 
A combination of structured, semi-structured, closed, and open-ended questions were employed 
in the questionnaires. 
All five studies were quantitative studies while four of the studies conducted additional 
informant interviews to elicit supplementary information from the respondents. The sample size 
employed in the included studies ranged from 84 respondents (Muko et al.,2004) to 552 
respondents (Chirundu et al.2017. Four of the studies employed random sampling techniques 
for selection of respondents, while Gupta (2007) utilized a purposive sampling technique. 
One of the studies conducted multivariate analysis and used logistic regression with 
odds ratios (OR) and 95% confidence intervals to describe associations.  
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The following are the major themes from the five reviewed studies.   
1. What Methods Were Applied in the Evaluation of Willingness to Pay for HIV/AIDS 
Treatment? 
All five studies evaluated the willingness to pay for HIV/AIDS treatment using the 
contingent valuation method. This involves hypothetical bidding for the cost which the 
respondents were willing to pay for HIV/AIDS treatment services. Bidding involves using an 
iterative question format with higher amounts offered with each round of questions until the 
highest amount the person is willing to pay is reached (Bateman et al., 1993).  Respondents 
were asked whether they would be willing to pay a given amount (bid). Based on their 
responses, the bid is lowered or raised, and the individual is asked about the new bid until the 
maximum willingness to pay amount is determined (Klose, 1999).  In the study by Gupta (2007), 
a two-bid method was utilized; Nwobi et al., (2017) and Chirundu et al., (2017) utilized three 
bids; Muko et al., (2004) utilized four bids, while Mbachu et al., (2018) utilized five bids to elicit 
the cost respondents were willing to pay for HIV/AIDS treatment services. 
2. Are Clients Willing to Pay for HIV/AIDS Treatment? 
The percentage of respondents willing to pay for HIV/AIDS treatment varied between 
studies. The percentages are shown in Table 1. About 35% of respondents in the studies 
conducted by Mbachu et al., (2018) and Muko et al., (2004) reported willingness to pay for HIV 
treatment services while Chirundu et al., (2017), Nwobi et al., (2017) and Gupta (2007), 
reported willingness to pay for HIV/AIDS treatment by 66.4%, 85.3% and 90% of the 
respondents respectively. The selected studies reported that the number of male respondents 
willing to pay for HIV/AIDS treatment was higher compared to the number of female 
respondents, despite the higher number female respondents in all the selected studies. More 
than 90% of the respondents who were willing to pay for treatment offered to pay a cost that is 
far less in value than the actual cost of treatment. For example, Mbachu et al., (2018) reported 
that the mean amount clients were willing to pay was about US$15 per month while the cost of a 
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monthly drug refill was about US$31 per month (see Table 1). However, the range of HIV 
services provided varied between the various studies. While Chirundu et al., (2004) included 
CD4, viral load, cost of transportation to clinics and cost of antiretroviral in the evaluation of 
willingness to pay for HIV treatment services, Mbachu et al., (2018) included only the cost of 
monthly antiretroviral drugs. 
Table 1: Distribution of Willingness to Pay for HIV Treatment Services and Average Amount 
Offered by Respondents Across the Relevant Studies 
Study % of respondents 
willing to pay for HIV 
services 
Mean Amount Respondents 
offered to pay as a percentage 
of the cost of treatment 
Mbachu et al., (2018) 35% US$15.32 (49%) * 
Muko et al., (2004) 35% N/A 
Chirundu et al., (2017). 66.4% US$11(7.9%) * 
Nwobi et al., (2017) 85.3% US$3.1 (7.1%) 
Gupta (2007) 90% N/A 
*Services classified as HIV services vary between the various studies. 
3. What Were the Determinants of Willingness to Pay for HIV/AIDS Treatment?  
a. Cost of Monthly Antiretroviral (ARV) Medicines Refill:  
The monthly cost of ARV medicines refill is a major determinant of willingness to pay for 
HIV/AIDS treatment. The higher the cost of ARV drug refill, the lower the percentage of clients 
who were willing to pay for treatment. When the cost of monthly refills was doubled, the 
percentage of clients who were willing to pay decreased almost three-fold (Muko et al., 2004). 
b. Socio-Economic Status of Clients:  
Clients’ income level is a major determinant of willingness to pay for HIV/AIDS 
treatment. Clients who lack or have a low level of income were less willing to pay for HIV/AIDS 
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treatment services than clients with a higher income.  For those who are willing to pay, the cost 
they offered to pay was much lower (less than 50% of cost) compared to the actual cost of 
treatment (Table 1). This was linked with the cost of monthly ARV medicines as respondents 
with low or no regular source of income were not able to afford monthly ARV drug refills. These 
clients perceived ARV medicines as being non-affordable (Chirundu et al., 2017). Clients of 
lower socio-economic status were about three times less likely to be willing to pay for HIV/AIDS 
treatment compared to those higher in the socio-economic ladder (Nwobi et al., 2017). 
Respondents who earned a salary or were in paid employment were more willing to pay 
compared to those who were engaged in farming or small-scale trading. 
Clients showed a lower willingness to pay for HIV/AIDS treatment services when they 
incurred additional costs associated with seeking HIV treatment services such as the cost of 
transportation to the clinic. This was also associated with the frequency of clinic visits for 
medicine refills. Clients who visited clinics once in a quarter for drug refills and those who 
travelled less than 40 minutes to clinic were more willing to pay for HIV treatment compared to 
those who visited the clinic monthly or travelled more than 40 minutes to the clinic (Chirundu et 
al., 2017). 
c. Knowledge and Belief in the Efficacy of HIV/AIDS Treatment:  
Respondents who had low or no knowledge about treatment of HIV/AIDS or who did not 
believe in the efficacy of ARV medicines were less willing to pay for treatment (Muko et al., 
2004). In addition, when clients did not have a regular source of income, they depended on 
friends and family for financial and psychosocial support. If such friends and family did not 
believe in the efficacy of ARV medicines, the financial and psychosocial support received by 
such clients was limited. Therefore, a large percentage of such clients were not willing to pay for 
treatment.  
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For clients who were willing to pay, the amount offered by such clients was usually very 
low compared to the cost of care (Nwobi et al., 2017). In communities where there was access 
to loans from friends and community groups which do not accrue interest and could be paid 
back at the receiver’s convenience, such loans could be applied to pay for HIV/AIDS treatment 
with the expectation that they would repay the loan once the beneficiary was back to work. 
However, poor knowledge of the efficacy of ARV medicines by friends and community members 
was a determinant of willingness to pay as such clients were deprived of the opportunity to 
benefit from such loans since it was believed that they could not be cured and would soon die 
from the disease (Chirundu, et al., 2017). 
d. Patient-Provider Relationship:  
There was a positive association between patient satisfaction with the quality of service 
provided and willingness to pay for HIV treatment (OR= 5.05; p=0.03), (Chirundu, et al., 2017). 
When clients were treated with respect and received free refills of ARVs without a history of 
stock out (inability of the healthcare provider to refill the adequate quantity and strength of a 
particular medicine when required by a patient) of medicines, such clients were more willing to 
pay when free treatment was discontinued by donors compared to those who were not treated 
with respect or those who had experienced stock outs of ARV medicines at the clinic at some 
time. 
e. Availability of Psychosocial Support:  
There was a positive association between willingness to pay for HIV/AIDS treatment and 
having a sense of support from community and friends (Muko et al., 2004). Stigmatization of 
people living with HIV/AIDS was a major determinant of willingness to pay for HIV/AIDS 
treatment (Muko et al., 2004). Stigma was one of the factors responsible for difficulty in getting 
money from friends and family as such benefactors may blame the patient and be unwilling to 
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associate with the patient. In situations where HIV status had not been declared to such 
benefactors, the client might be ashamed to reveal or discuss their HIV status while seeking 
support. Chirundu et al., (2017) reported a positive association between disclosure of HIV status 
to family and friends and willingness to pay for HIV treatment. 
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CHAPTER 3: METHODOLOGY 
The literature review revealed a dearth of studies and information on willingness to pay 
for HIV treatment services in low-income countries and approaches to utilize such information to 
improve funding sustainability for HIV treatment services. The few studies identified also lacked 
in-depth understanding of the factors that influence decisions on willingness to pay. In addition, 
there was no information on how willingness to pay could be incorporated into existing funding 
options to improve sustainability.  
This study employed an explanatory mixed method designed to obtain current 
information on the population of patients who are willing to pay for HIV treatment services and 
the factors that influence their willingness to pay in Nigeria. In addition, I conducted key 
informant interviews (KIIs) to obtain the perspectives of patients, senior government officials in 
the ministry of Health, HIV program managers, and representatives of donor agencies and civil 
society organizations on how patients’ willingness to pay for treatment services can be 
incorporated into other funding streams to improve funding sustainability. 
The mixed method approach enabled me to draw from the strengths of both quantitative 
and qualitative methods while also helping to minimize the limitations of both approaches. 
Figure 3 illustrates the logical flow of the aims and methods applied in the dissertation. 
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Figure 3: Logical Flow of the Aims and Research Methods.  
Overview of Methodology 
Table 2 indicates the four aims of this dissertation. The first two aims were achieved 
from the quantitative study component which involved a survey of a sample of people living with 
HIV and receiving free HIV treatment services in Nigeria. The third aim was achieved from the 
findings from key informant interviews while the fourth aim was achieved by the consolidation of 
the findings from the mixed method study to create a plan for change. 
Table 2: Overview of Dissertation Aims 
S/N AIMS 
1 To determine the proportion of people living with HIV who are willing to pay for 
HIV treatment services if free services are no longer available. 
2 To explore and obtain in-depth understanding of the factors that influence the 
willingness of people living with HIV to pay for HIV treatment 
3 To explore alternative methods for structuring funding for HIV treatment 
services in Nigeria. 
4 To develop a plan for change to improve funding sustainability for HIV 




I implemented a cross-sectional interviewer-administered semi structured survey of 
people living with HIV who are currently receiving free HIV treatment services in Nigeria. The 
purpose of the survey was to assess patient’s willingness to pay for such services if current 
funding is no longer available, and to identify the factors which influence one’s decision about 
willingness to pay. It is estimated that about 2 million Nigerians are currently living with HIV 
while about 1 million of them are receiving free HIV treatment (NACA, 2019b). I utilized this 
population size of people living with HIV in Nigeria to conduct a power analysis with a 95% 
confidence level and 5% margin of error. This analysis produced a minimum sample size of 385 
respondents. Eventually, a sample size of 400 was used for this study. 
Table 3: Sample Size Calculation 
  
Population size 2,000,000 
Confidence Interval 95% 
Margin of Error 5% 
Calculated minimum sample size 385 
 
Survey Instrument 
The use of survey instruments in research enables researchers the opportunity to 
administer questions in a standardized format. This study used an interviewer-administered 
semi-structured questionnaire to obtain quantitative and qualitative data from respondents on 
willingness to pay for HIV treatment services. The survey instrument was adapted from previous 
studies on willingness to pay for health commodities or services conducted in Nigeria and 
several other African countries. I modified the survey instrument to meet the purpose of this 
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study by incorporating bidding amounts which align with current estimated cost of obtaining HIV 
treatment services in Nigeria.   
I collected data on the socioeconomic status of respondents, existence of comorbidity, 
history of payment for existing comorbidity, history of payment for HIV treatment services and 
types of treatment services paid for. In addition, the survey instrument asked questions on 
respondents’ perception of the quality of HIV treatment they received, respondents’ knowledge 
of the implications of non-adherence to HIV treatment, awareness of the implication of early 
state of treatment after diagnosis, and their perception of the average cost of HIV treatment 
services (before they are informed of the average cost), type (level) of HIV treatment being 
received, duration of time on treatment and what respondent’s decision would be if free 
treatment services were no longer available. Other questions in the survey included the type of 
healthcare facility preferred by respondents if they have to pay for treatment services, the 
preferred mode of payment, willingness to pay for treatment if respondent’s income increases or 
decreases and the maximum amount respondents are willing to pay. The sample in this study 
included respondents who were currently receiving free HIV treatment; therefore, they were 
informed of the estimated cost of providing treatment services per patient per month. This was 
to ensure that they become aware of the actual cost of treatment and to enable them to make 
informed decision during the bidding process and to set the tone towards the determination of 
how much they were willing to pay for treatment. The bidding method as depicted in Figure 4 
was used to obtain information on willingness of respondents to pay for HIV services and the 
maximum amount respondents were willing to pay. During the bidding, I asked the respondents 
if they were willing to pay the current price of N5,000 ($12.5) per month to access treatment. 
Respondents who answered “Yes” to the question were asked if they were willing to pay for 
treatment if the price of accessing treatment increases to N6,000 ($15). For each “Yes” 
response received, respondents were asked of their willingness to pay if the price increased 
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further until a “No” response was received. However, respondents who answered “No” to any 
price bid were asked if they would be willing to pay for treatment services if the price was lower.  
 
Figure 4: Bidding for Amount Respondents are Willing to Pay for HIV Treatment Services 
 
The maximum amount a respondent was willing to pay was determined from the highest 
price point at which at the respondents provided a “YES” answer to a bid which was followed by 
a “NO” response. 
For purposes of this study, I modified an existing survey instrument which was used for 
several studies on willingness to pay for health services. I requested review and feedback from 
colleagues who had conducted similar studies. In addition, I pre-tested the instrument with 10 
individuals living with HIV who were potential respondents to the survey. This step was critical to 
improve the validity of the instrument and to test the appropriateness of the skip mode 
employed in the questionnaire. The questionnaire was designed to utilize skip logic between the 
questions used for bidding based on responses provided on the amount respondents are willing 
to pay. The review and pre-test processes provided me with feedback on the clarity of terms, 
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and the appropriateness and acceptability of language used. During the final review, I 
incorporated all feedback into the final questionnaire before submission for UNC IRB and 
NHREC approvals. Please see Appendix 1 for sample of the approved questionnaire. 
I sought and received buy-in of gate keepers in each of the selected clinic/health 
facilities before the questionnaire was administered. The survey instrument was administered 
between January 29 and March 22, 2020.  
Sampling Approach and Rationale 
For the survey data collection, I purposely selected two states (Lagos and Enugu) and 
the federal capital territory Abuja. Lagos state and FCT are ranked as state/territory in Nigeria 
with medium level burden of HIV with prevalence rate of 1.3 and 1.5 respectively (NACA 
2019b). Enugu state is ranked as a high HIV burden state with a prevalence of 2.1 (NACA, 
2019b). These three states/territories combined have over 200,000 people living with HIV/AIDS 
(NACA, 2019b). In addition, these settings were selected as they provided a good mix of 
population of different socio-economic status and a mix of urban and rural population. From a 
list of all health facilities providing HIV treatment services in each state/territory, five (5) health 
facilities were randomly selected to give a total of fifteen (15) health facilities. I visited each of 
the 15 selected healthcare facilities to administer the questionnaire. On clinic days of each of 
the 15 facilities, I randomly approached potential participants while waiting for consultation with 
the doctor or for drug refill and adherence counselling at the pharmacy department. The 
respondents were adults who met the inclusion criteria of being over 18 years living with HIV 
and receiving free HIV treatment services in Nigeria.  
Duration of Survey Participation 
The administration of the survey took about 45 – 60 minutes. 
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Data Management and Analysis 
This section describes the scope of the data management and analysis for the cross-
sectional survey. Figure 5 depicts the schematic of the data management and analysis for the 
dissertation. The quantitative data were analyzed, and the key findings addressed aims 1 and 2 
of the study. This was followed with analysis of the qualitative data which provided in depth 
understanding of findings on aim 2 and provided answers to aim 3 of the study. All the findings 
were then synthesized into the development of a plan for change and an implementation plan 
for improved funding sustainability for HIV treatment services in Nigeria. 
 
Figure 5: Sequence of Data Analysis and Output 
Quantitative Data Management and Analysis 
The unit of analysis of the survey was respondents who are known HIV positive 
individuals and receiving free HIV treatment services in Nigeria. The aims of the survey are: 
1. To determine what proportion of people living with HIV are willing to pay for HIV 
treatment services in Nigeria if free services are no longer available. 
2. To identify, explore and obtain in-depth understanding of the factors that influence 
willingness to pay for HIV treatment services. 
I administered a paper-based semi-structured questionnaire between January 28th and 
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constituted the sample for the study.  The initial plan was to use an electronic device for data 
collection to limit the need for data entry from paper. However, feedback during pre-test of the 
electronic based questionnaire indicated that some of the respondents may perceive that the 
device will be used to record both video and audio sessions of the administration, even after 
assurances that this would not be the case. Therefore, I implemented a paper-based 
questionnaire to allay the fears of potential respondents and to ensure transparency in the entire 
process. Furthermore, the fact that no video or audio recordings were conducted helped to 
assure anonymity and likely encouraged honest responses from survey participants. 
I conducted data transfer into an Excel spreadsheet created on a password protected 
computer for data management and analysis. I conducted data entry and verification from paper 
into computer every week as the survey progressed to minimize data entry error which may 
arise due to the need to conduct large data entry after the entire survey would have been 
completed. After all the data from 400 respondents were transferred to Excel spreadsheets, I 
verified the data for accuracy and completeness. I delinked the patient identification number 
from the spread sheet and separated responses that were provided to open ended questions 
which were analyzed separately as qualitative data. 
I imported the data from Excel into an SPSS file for preliminary analysis. I conducted 
preliminary descriptive data analysis to ensure there were no missing data. I administered the 
questionnaire, and this ensured that all required questions were answered, and responses were 
appropriately and completely documented. The final cleaned survey data set had no name or 
any form of patient or clinic identification and had no responses to open ended questions which 
could be used to identify any of the respondents.  
Dependent Variables 
As described below, I identified two key dependent variables (Table 4). The key 
dependent variables included: 
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a. Respondent’s willingness to pay for HIV treatment services if free treatment services are 
no longer available. This variable was obtained from question 19 in the survey 
instrument. This question asked respondents what their action would be if government 
and non-governmental organizations (NGOs) are not able to support free HIV treatment 
services and the clinics require payment for services. The survey participants responded 
to the question with categorical “I will stop receiving treatment”, or “I will try to pay for the 
treatment” or “others” in which respondents were probed to clarify what “others” meant to 
them. I coded all responses with “I will try to pay for the treatment” as “YES” while other 
responses were coded as “NO”. 
b. Maximum amount respondent was willing to pay. This variable was obtained using 
responses from the hypothetical bidding game in which iterative question format from 
question 20 through 20G were asked. Higher amounts were offered with each round of 
questions until the highest amount the respondent was willing to pay was reached 
(Bateman et al, 1993). Respondents were offered a bid (by asking if they are willing to 
pay an amount). Based on the response to the bid, a “YES” response leads to another 
question with a higher bid while a “No” response leads to another question with a lower 
bid. This continued until a maximum amount was reached. The response to the 
maximum amount a respondent was willing to pay was validated by using question 22 
which asked respondents how much they consider HIV treatment services to be too 
expensive, but still worth paying for. 
Data on these two variables were collected using the bidding method explained earlier. 
This was a critical component of the willingness to pay survey and it is usually used to estimate 
the number of individuals who are willing to pay a given price for health commodities or services 
as well as the maximum amount respondents are willing to pay (Foreit &Foreit, 2004). This 
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approach has been used in several studies in Ghana, Guatemala, Philippines, Ecuador, India, 
Nigeria among several other countries. 
Table 4: List of Dependent Variables and Data Type 
 Dependent Variable Type of data 
1 Respondent’s willingness to pay for treatment Categorical (Yes/No) 




Independent variables used in the analysis included socio-demographic characteristics 
of the respondents, level of HIV treatment being received, duration on HIV treatment, preferred 
type of clinic for treatment, preferred mode of payment among other. Table 5 describes the 


















Table 5: List of Independent Variables and Data Type 
 Independent Variable Data collected 
1 Age Continuous (converted to nominal  
2 Sex  Categorial 
3 Marital status Categorical 
4 Highest education completed Categorical 
5 Employment status Categorical 
6 Monthly income Scale/Interval (converted to 
ordinal) 
7 Changes in monthly Income Categorical 
8 Availability of financial support from friends 
and family 
Categorical 
9 Awareness of benefits of early start of 
treatment 
Categorical 
10 Duration respondents have been on HIV 
treatment  
Categorical 
11 Average cost of transportation to clinic Continuous  
12 History of previous payment for HIV 
treatment services 
Categorical 
13 Perception of quality of HIV treatment 
services being received 
Categorical 
14 Frequency of clinic visits by respondents Categorical 
15 Awareness of benefits of adherence to 
treatment 
Categorical 
16 Existence of comorbidity with HIV Categorical 
17 Preferred type of healthcare facility for HIV 
treatment services 
Categorical 
18 Sources of payment for HIV treatment Categorical 
19 Perception of the monthly cost of accessing 
HIV treatment services 
Categorical 
 
• Sex: This is the reported sex of respondents. This is a categorical variable with 
options of male and female. 
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• Age: This measures the age of respondents in years based on the last birthday. I 
collected information on age of respondents as continuous data. This was converted 
into categorical data based on range of 18 – 28 years; 29 – 39 years; 40 – 50 years; 
51— 61 years; and above 62 years. 
• Marital status: A categorical variable, responses were categorized as “Single”, 
“Married”, “Cohabiting”, “Divorced/Separated”, or “Widowed”.  
• Highest education completed: This measured the highest level of education 
completed by respondents. This categorical variable had options of “None” for no 
education at all, “Primary”, “Secondary”, “Vocational”, or “University”. 
• Employment status: This measured if respondent has a regular source of income 
either through employment or being self-employed. This categorical variable has 
options of “Student”, “Unemployed”, “Employed” and “Self-employed”. 
• Monthly income: This measured the average monthly income of respondents. This 
is a categorical variable with options of “No income”, “Less than N10,000 (<$25)”, 
“Between N10,000 – N20,000 ($25- $50)”, “Between N30,000 – N40,000 ($75 - 
$100)”, “Between N50,000 – N100,000 ($125 - $250)”, “Over N100,000 (>$250)” and 
“Would not disclose”. 
• Frequency of visit to clinic: This is a measure of the average number times the 
respondent visits the clinic for HIV treatment services. The categorical variable was 
measured based on options of “Once a month”, “More than once a month”, “Once in 
two months”, ‘Once in three months”. 
• Level of HIV treatment being received: This categorical variable measured the 
level/type of HIV treatment being received by respondents. The available options 
include “First line treatment”, “Second line treatment”, “Third line treatment”. 
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• Duration on HIV treatment: This measured the time in years during which 
respondents have been receiving HIV treatment services. This categorical variable 
was measured based on options of “Less than 1 year”, “Between 1 – 3 years”, and 
“Over 3 years”. 
• Perception of quality of HIV treatment services being received: This is a 
measure of how respondents perceive the quality of free HIV treatment services they 
current receive. This variable is measured as categorical data on a 5-point Likert 
scale of “Excellent”, “Very Good”, “Good” “Poor”, “Very Poor.”   
• Sources of payment for HIV treatment: This variable was measured among 
respondents who expressed willingness to pay for HIV treatment services if free 
treatment services are discontinued. This was used to obtain data on the sources of 
money respondents would use to support their treatment if free treatment is 
discontinued. The was measured as a categorical variable with options of “Personal 
income”, “Family/friends support”, “Combination of personal income and family/friend 
support”. This variable is not applicable to respondents who expressed unwillingness 
to pay for HIV treatment services. 
• Perception of the monthly cost of accessing HIV treatment services: This is a 
measure of how much respondents think it will cost for them to access HIV treatment 
if they were to pay for it. The categorical variable had options of “Less than N5,000 
($12.5)”, “Between N5,000 – N9,999 ($12.5 - $25)”, “Between N10,000 – N14,999 
($25 - $37.5)”, “Between N15,000 – N20,000 ($37.5 - $50)” and “Above N20,000 
(>$50)”. 
• Existence of comorbidity with HIV infection: Respondents were asked if they 
have any chronic disease or condition for which they are receiving treatment. This 
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dichotomous categorical variable was measured by a response of “Yes” or “No” by 
respondents. 
• History of payment for treatment services for comorbidity with HIV infection: 
Participants who responded “Yes” to question on existence of comorbidity were 
asked if they ever paid to access treatment for the disease of comorbidity. This 
dichotomous categorical variable was measured by a response of “Yes” or “No” by 
respondents. 
• History of payment for HIV treatment services: Participants were asked if they 
ever paid for any HIV treatment services. This dichotomous categorical variable was 
measured by a response of “Yes” or “No” by respondents. 
• Amount paid for previous HIV treatment services: Respondents who answered 
“Yes” to the question above were asked to provide information on the amount they 
paid for HIV treatment services. The responses were continuous data of the various 
amounts paid by responders. 
• Type of HIV treatment services paid for in the past: Participants who answered 
“Yes” to the question “Have you ever paid for HIV treatment services” were asked for 
the type of HIV treatment services paid for. This categorical variable was measured 
by a response of “Drug refill”, “Laboratory services” “Physician consultation” or 
“Multiple services”. 
• Preferred type of healthcare facility for HIV treatment services: Respondents 
were asked to select a type of health facility they prefer to receive HIV treatment 
services if they must pay for services. This is a dichotomous categorical variable 
measured as “Public facility” or “Private facility.” 
• Preferred mode of payment for HIV treatment services: Respondents who 
expressed willingness to pay for treatment services were asked for their preferred 
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mode of payment for HIV services. The responses were recorded as categorical 
variable with options of “Payment on clinic day”, “Annual payment to the hospital”, or 
“Payment through National Health Insurance premium”. 
• Perception of the monthly cost of accessing HIV treatment services if 
respondents have to pay for services: Before the bidding for willingness to pay 
and the amount respondents were willing to pay, all respondents were asked for their 
perception of how much it would cost monthly to access treatment if they were to 
pay. Data were collected as a continuous variable based on responses from 
participants. The responses were then classified into dichotomous categories of 
“high cost” and “low cost” based on responses relative to current cost of accessing 
treatment. Responses that were above N5000 (>$12.5) were coded as “high cost” 
while responses below N5000 (<$12.5) were categorized as “low cost” 
Descriptive Analysis 
I conducted a descriptive analysis of all responses to all closed ended survey questions 
using descriptive statistics from SPSS. I summarized the responses for dichotomous and other 
categorical variables by the number and percentages of responses in each mutually exclusive 
category. I also summarized responses for continuous variables by the mean, median, range of 
values and the standard deviation while data on age, which is a continuous variable that was 
converted into ordinal categorical and summarized as the frequency distribution and 
percentages. In addition, I summarized responses on a Likert scale (ordinal categorical) as 
frequency and percentages.  
I regrouped responses to the question on the maximum amount participants were willing 
to pay into two groups. This was guided by the average monthly cost of HIV treatment of N5,000 
($12.5) as estimated by National Agency for the Control of AIDS (NACA, 2018). I included those 
who were willing to pay a maximum amount of less than N5,000 ($12.5) in the first group and 
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the second group included those who were willing to pay a maximum amount of above N5,000 
($12.5).  
The primary research question for this study is “What proportion of people living with HIV 
are willing to pay for HIV treatment services in Nigeria?”. Therefore, during the descriptive 
analysis, I focused on the percentages of respondents who expressed willingness to pay 
through the answer “I will try to pay” which was coded as “Yes” while other responses were 
coded as “No”. The descriptive analysis was also used to determine how the percentages of 
patients who were willing to pay for HIV treatment services would change with changes in cost 
of accessing treatment services as determined from the maximum amount respondents were 
willing to pay. 
I displayed the descriptive statistics for all questions using graphs and data tables (see 
Results section).  
Bivariate Analysis 
Bivariate statistical analysis is usually conducted to identify an association between two 
categorical variables. For this study, I used Pearson Chi-Square statistics as it is appropriate for 
testing relationships between categorical variables (Creswell, 2015). It is useful for the test of 
independence as it is able to assess if there is an association between two variables by 
comparing the observed pattern of response to the pattern that would be expected if the 
variables were truly independent of each other (Stephanie Glen, 2020). In addition, the dataset 
met the two assumptions for the use of the test: 1) the two variables were measured or 
reclassified as categorical data at an ordinal or nominal level, and 2) there were two or more 
independent variables. Before I conducted the bivariate analysis, I ensured all categories of 
each variable had at least five (5) cases by merging some of the categories within a variable. In 
addition, the odds ratio (OR) and confidence interval for each dependent and independent 
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variable were analyzed. Odds ratio is a measure of the degree and direction of association 
between one dependent variable and independent variable.  
I conducted bivariate analysis by testing association between 17 key socioeconomic and 
patient factor variables and willingness to pay (primary dependent variable) on one hand and 
the maximum amount respondents were willing to pay on the other hand (secondary dependent 
variable). All seventeen (17) key independent variables were recoded as dichotomous variables 
before bivariate analysis was conducted for each independent variable with the dependent 
variable. The primary dependent variable was a dichotomous variable comprised of 92% of 
respondents who were willing to pay for HIV treatment services (value 1) and 8% respondents 
who were not willing to pay for treatment services (value 0). The secondary dependent variable 
measured the maximum amount respondents were willing to pay for treatment services. This 
was a continuous variable which was converted into dichotomous variable consisting of 
respondents who were willing to pay a maximum amount higher than N5000 ($12.5) (current 
monthly cost of treatment classified as value 1) and respondents who were willing to pay a 
maximum amount less than N5000 ($12.5) (below current monthly cost of treatment classified 
as value 0).  
I tested a series of hypothesis formulated during the analysis. Two sets of hypotheses 
were formulated to answer the second research question of “What factors influence willingness 
to pay for HIV treatment services by people living with HIV/AIDS in Nigeria?” This helped to 
identify associations between key dependent outcomes and key independent variables. Using a 
Chi- square test, this approach provided an opportunity to identify the existence of association 
between variables as well as quantifies the odds ratio (OR). The OR indicates the magnitude of 
the associations between each independent variable and each of the dependent variables. In 
addition, the value of beta regression analysis was used to interpret the strength of effect of 
each independent variable on the dependent variable. The results of analysis are indicated by 
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the p-value of Chi Square test, Beta value, OR and confidence interval CI) for each analysis. 
The following series of hypothesis were formulated: 
1. H0: Willingness to pay for HIV treatment services is independent of socio-demographic 
and patient characteristics of respondents. 
This null hypothesis was repeated for all 17 key independent variables. I rejected the null 
hypothesis (i.e. Chi square with p-value equal or less than 0.05) if there was an 
association between willingness to pay for HIV treatment services and the particular 
socio-economic and patient variable. I did not reject the null hypothesis if the p-value for 
the chi-square statitistics is greater than 0.05.   
The other independent variables analysed with willingness to pay as the dependent 
variable included the type of treatment being received (1st, 2nd or 3rd line treatment), 
perception of the monthly cost of treatment, perception of the quality of treatment 
currently being received, source of money that would be used to pay for treatment if 
payment is introduced, frequency of visit to clinic for treatment and the durantion for 
which respondent has been on treatment.  
2. H0: Maximum amount patient is willing to pay is independent of socio-demographic and 
patient charateristics of repondents. 
This null hypothesis was repeated for all 17 key independent variables asked about in 
the survey. I rejected the null hypothesis (i.e. Chi square value with p-value of equal or 
less than 0.05) if there was an association between maximum amount respondents were 
willing to pay for HIV treatment services and that particular socio-economic variable. I 
did not reject the null hypothesis (rejected the alternate hypothesis) if the p-value for the 
chi square statistics was greater than 0.05. The other independent variables analysed 
with willingness to pay included the type of treatment being received (1st, 2nd or 3rd line 
treatment), perception of the monthly cost of treatment, perception of the quality of 
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treatment currently being recived, source of money that would be used to pay for 
treatment if payment is introduced, frequency of visit to clinic for treatment and the 
duration the respondent has been on treatment. 
Multivariate Regression Analysis 
Multivariate regression analysis (MRA) enables researchers to explain or predict 
relationship between variables rather than just to establish association (Kumar et al, 2013). I 
conducted multivariate logistics analysis (MLA) to measure the relationship between multiple 
independent variables and one or more dependent variables. Unlike the bivariate association 
analysis conducted above, MLA allows for control of simultaneous effects of the relationships 
between the socio-economic/demographic factors and the willingness to pay for HIV treatment 
services. Multiple logistics regression analysis was selected for this analysis because the 
dependent outcomes are both dichotomous. This enabled the derivation of the best fit and the 
description of the relationship between willingness to pay and a set of predictor variables on one 
hand and maximum amount respondents were willing pay and these predictor variables on the 
other hand. The use of multiple logistics regression was appropriate as it does not assume that 
the measured variables are normally distributed (McDonald, 2014). However, the assumptions 
that the observations are independent, and that the natural logarithm of the odds ratio and the 
measured variables have a linear relationship were considered (McDonald, 2014). The data 
used for this analysis met both assumptions. The results were interpreted in terms of the 
marginal effect of the predictor variables and statistical significance was taken for p-values of 
equal or less than 0.05 in addition to the 95% confidence interval and the regression 






The qualitative component of a mixed method study elaborates on and enhances some 
of the findings from the survey (Creswell & Creswell, 2018). The qualitative component of this 
study provided a transformative perspective of how funding sustainability could be achieved for 
the provision of HIV treatment services for people living with HIV in Nigeria. Therefore, I relied 
on the intuitive and felt knowledge of the key informants as this enabled a great appreciation of 
the nuances and multiple realities on available funding options for HIV treatment services in 
Nigeria. 
Key Informant Interview Guide 
A key informant interview guide was developed to ensure standardization of the 
interviews and to ensure all essential issues were covered during the interview. I developed a 
sample key informant interview guide which was approved by NHREC and UNC IRB (see 
appendix 4 and 5 for approved copy). The sequencing of the questions was such that the first 
part covered questions which sought information about the background of the informant around 
HIV program in Nigeria. This enabled me to develop rapport with the informants and promoted 
free conversation. I ensured that questions which required opinions, perspectives and 
recommendations were asked later during the interview to ensure the informants were fully 
involved in the interview. In addition, this approach probably helped to promote candid 
responses from the informants. Throughout the interviews, I employed transitional comments 
and phrases when switching to a new question area to ensure a smooth conversation. 
The key informant guide has five main components with a total of fifteen questions 
including probing questions to obtain adequate information on all important areas relating to 
financing of HIV program in Nigeria. The five components covered by the guide include: 1) 
Background information on the respondent around HIV program in Nigeria; 2) Respondent’s 
perspectives on the challenges of sustainable funding for HIV treatment services in Nigeria; 3) 
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Respondent’s opinion on the key findings of the survey on willingness to pay for HIV treatment 
services; 4) Respondents opinions on policy and programmatic considerations for sustainability 
of financing of HIV treatment services in Nigeria, and 5) Barriers and facilitators of 
implementation of the recommendations for funding sustainability.  
The questions in the key informant guide were worded in simple English language, so 
they were easy to understand by the informants. They were also worded to elicit detailed 
responses rather than simple affirmation or disagreement. In addition, where terms and 
acronyms were used, they were mentioned in full despite the familiarity of all the informants with 
such terms. 
Selection of Key Informants 
It is important that key informants for a qualitative study be appropriately selected. This 
is because the selection of the right informants will impact the quality of findings. The informants 
must be knowledgeable in the subject area and include representatives of relevant 
stakeholders. In addition, selected informants must be those with divergent perspectives and 
opinions to ensure rich information are obtained.  
For this study, I selected key informants based on purposeful sampling. First, I identified 
the relevant groups from where informants for the research were selected. These are groups/ 
organizations or agencies who are key stakeholders in HIV programming in Nigeria. They 
played a significant role in the funding, policy development, advocacy, implementation, or 
outcome of HIV treatment services in Nigeria. Second, I identified and selected about 4 -10 
informants from each group. In addition, I consulted individuals who were knowledgeable about 
funding for HIV program in Nigeria to guide on other individuals that should be included in the 
study. Some of the informants were identified during the interview with the first set of identified 
informants which snowballed into the identification of other critical informants. I selected thirty 
(30) informants from the following groups of key informants:  
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a. Government officials: This group was selected from the Ministry of Health, the National 
Agency for the Control of AIDS (NACA) and the National Health Insurance Scheme 
(NHIS). Informants from this group provided rich perspectives on policies, 
implementation, and government position on funding sustainability for HIV in Nigeria. 
b. Donor /funding agencies: These agencies have been the primary sources of funding 
for HIV treatment services in Nigeria. Therefore, the perspectives of senior officials of 
such organizations were valuable to the future of HIV program in Nigeria. 
c. HIV program implementing organizations: These are funded organizations who 
implement HIV treatment programs in Nigeria. 
d. Civil societies and representatives of people living with HIV in Nigeria: These 
include Civil Society for HIV in Nigeria and Network of People Living with HIV in Nigeria. 
Duration of Key Informant Interviews 
Each key informant interview took approximately 60 minutes. As expected, during the 
interviews, the issue of how practical a willingness to pay for HIV treatment services compares 
to capacity to pay for such service was discussed. This issue is an important consideration in a 
population with about 50% of people living below $2 per day (World Bank, 2020). However, the 
willingness to pay is a first step and it is hoped that those who are willing to pay will be able to 
seek for support from friends and family even if they lack the capacity to pay from their income. 
Qualitative Data Management and Analysis 
Data analysis is the process of creating order and structure to data collected from one or 
more sources (Walby et al., 2015). The process is more of an iterative rather than a linear or 
successive process. It is often efficient to conduct qualitative data collection and analysis 
simultaneously (Walby et al., 2015). This notion is supported by Creswell, (2013) by stating that 
the qualitative data analysis and interpretation is like a spiral image and the researcher moves 
in analytic circles and not in a fixed linear manner. I utilized the guidance provided by Miles and 
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Huberman (2019) in the analysis of the qualitative data as shown in Figure 6 below.  I initiated 
data analysis immediately after the first round of interviews was conducted. During analysis, I 
classified the initial data obtained and characterized them. I coded the data using various 
categories created. I used a priori code book which was based on the key informant interview 
guide and pre-existing knowledge from literature research. The application of this deductive 
coding method was guided by findings from literature review. However, the codes were modified 
as the information from the collected data was being analyzed. I sought to identify and describe 
patterns and themes from the perspectives of the informants. I attempted to understand and 
explain the themes identified and sought for differences and similarities between themes. I 
repeated this process as data collection continued. 
 
Figure 6: Flow of Qualitative Data Analysis (Adapted from Miles and Huberman (2019) 
I transcribed verbatim, all qualitative data including recordings and notes. I then read the 
transcribed data to get a sense of the whole interviews to enable preliminary reflection on the 
information. I imported the data into MaxQDA software and followed this by thematic content 
analysis of the transcribed data. I coded the data, and identified themes, compared, and 




























from the analysis using a combination of narrative texts, summary tables and quotations. I 
identified themes and sub-themes by looking out for repetitions, transitions and the identification 
of similarities and differences within the obtained data. I followed the process by developing a 
summary of findings on the factors that influence willingness to pay for HIV treatment services 
from the perspectives of patients living with HIV and approaches to improve sustainability of 
funding from the perspectives of key stakeholders (see findings section). 
Reliability and Validity of Qualitative Study 
Unlike a quantitative study in which reliability and validity can be fully assured, it is often 
a challenge with qualitative studies. Validity and reliability help to enhance transparency and 
reduces opportunities for the introduction of biases (Shekhar, 2014). Therefore, I made every 
effort to maximize reliability and validity during the qualitative research. Reliability and validity in 
qualitative studies are usually discussed in terms of transferability credibility, dependability and 
confirmability of the instrument and results of the study (Simon and Goes, 2013). Throughout 
the study, dependability and credibility were assured by the application of strategies such as 
member check and peer review. I provided the transcribed data to about 50% of the key 
informants after the interviews to verify the accuracy of interpretation from data provided.  In 
addition, I ensured external validity by using different types of key informants (explained above). 
Despite my familiarity with the HIV program in Nigeria, I ensured neutrality by not imposing any 
preconceived opinion which could introduce bias during analysis and interpretation of findings. I 
utilized and adhered to the guide suggested by DeCuir-Gunby et al, (2010) during the 
identification and selection of key themes during analysis to avoid bias as some of these 
processes required judgement on my part. 
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Overall Study Management 
I managed all aspects of the study from survey questions administration to the key 
informant interviews and data management under the supervision of my DrPH dissertation 
Chair, Dr. Bruce Fried and guidance of all members of the dissertation committee.  
Ethical Considerations 
All the respondents in the survey were known HIV seropositive individuals as they 
currently receive free HIV treatment services. In addition, they all self-disclosed their HIV status 
before they were recruited into the survey to ensure they met the inclusion criteria. During the 
entire process of data collection and management, I ensured high level of confidentiality and 
adherence to data security plan. Although some of the informants in the key informants’ 
interviews are known HIV seropositive activists and leaders who have been involved in 
advocacy and implementation of HIV program in Nigeria, most of them are program managers 
or senior officials of government or donor agencies who were not required to disclose HIV status 
to be eligible for selection as key informants. Therefore, key informants were able to provide 
perspectives of patients and program managers. 
Throughout the entire study, I maintained the confidentiality of all study participants by 
ensuring that no study data were linked with personal identifiers such as names or designation 
of respondents included in the consent forms. I separated these identifiers from the data to 
ensure anonymity. In addition, all key informant interviews were conducted in private areas at 
preferred locations of the informant while some were conducted online via HIPAA compliant 
Skype or Zoom accounts linked to my school password protected account. The privacy of all 
participants was ensured as there were no third parties during the survey or interviews. I kept all 
copies of the completed survey questionnaire, completed consent forms and recording device 
for the key informant interviews in a cabinet and locked without access to anyone except myself. 
After I completed data upload into excel sheets and download of electronic files from recording 
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device onto the dedicated computer for my dissertation, the computer was password protected 
and kept in a locked cabinet. The electronic and hard copies of all forms and recordings are 
accessible only to me and to the dissertation committee if required. All audio recordings were 
deleted from the recording device immediately data transfer to the computer was completed. All 
data collected will be deleted from the computer and hard copies destroyed after my DrPH 
dissertation defense is completed.  
The findings from both the survey and key informant interviews are presented as 
aggregate data without any link to any respondent. Even when names were mentioned during 
KIIs, these names were excluded during transcription with broad description used in the 
narrative without personal identifiers. 
Informed Consent 
I sought and received consent from all study participants before the survey and key 
informant interviews. I received signed consent forms for all the survey respondents before I 
implemented the questionnaire. For the KIIs, verbal consent was received before a date and 
time was fixed with the interviewees. In addition, permission was sought and received to record 
each interview. The UNC IRB and NHREC had rated this study to have minimal risk and waved 
the need for written consent for the key informant interviews. 
I conducted the survey and KIIs in English language. Before administering the 
questionnaire and interview guide, all the participants were reminded that they could choose not 
to answer any of the questions if it made them uncomfortable or if they were not willing to share 
such information. They were also informed of their right to stop the survey or interview at any 
point if there was any reason to do so. For the survey participants, they were informed that their 
participation was voluntary and the decision to either participate or not to participate and the 
responses provided to the questions would not affect the quality or access to HIV treatment 
services currently being received. I then requested that potential survey participants endorse the 
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consent form before proceeding with the survey. There was no record of any survey respondent 
or key informant who discontinued participation in the survey or interview. 
Institutional Review Board Approval 
Following the successful defense of the proposal for this study, the protocol passed 
through two institutional review boards. These are the Institutional Review Board and Human 
Research Ethics Committee of the University of North Carolina at Chapel Hill and the National 
Health Research Ethics Committee (NHREC) of Federal Ministry of Health in Nigeria.  NHREC 
approval was received on 23rd of December 2019 while UNC-CH IRB expedited review and 
approval was received on 23rd January 2020.  
Delimitations and Boundaries of Study 
This research focused on how funding for HIV treatment services in Nigeria can be 
improved to ensure sustainability. Therefore, it did not cover funding sustainability for other 
components of a comprehensive HIV care such as prevention services and screening for HIV. 
In addition, the study did not cover treatment services for other health conditions such as 
malaria, tuberculosis, sexually transmitted diseases which are equally important but outside the 
scope of this study. 
Also, this research did not focus on the analysis of the actual funding available for HIV 
treatment services in Nigeria but utilized the data on the number of patients currently eligible for 
HIV treatment and the actual number currently on treatment to estimate the gap in funding. 
Timelines 
This study was conducted over a 16-month period. Although it was originally planned for 
12 months, the additional 4 months was because of COVID -19 which delayed data collection. 
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CHAPTER 4: QUANTITATIVE STUDY RESULTS 
Descriptive Statistics 
Survey Sample Size 
The study employed a researcher-administered questionnaire. I obtained responses 
from 400 participants as the minimum sample size required for the study is 385 (Table 6). All the 
participants provided answers to all relevant and applicable questions. The sample of 
respondents employed in the study is more representative of people living in Nigeria compared 
to previous studies (Mbachu et al, 2018) as I had participants from several health facilities in 
three states/territories with the HIV prevalence, socio-economic status, rural and urban settings 
considered compared to previous studies that had respondents from a single health facility in a 
location.  
Table 6: Sample Size Information for Qualitative Survey 
Indicators Values 
Estimated Population of Respondents 2,000,000 
Margin of Error 5% 
Confidence Interval 95% 
Minimum Sample Size required 385 
Sample size used for data collection and analysis 400 
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Data collected from the respondents were entered and cleaned in excel spread sheets before 
they were imported into IBM SSPS statistics 26 software. The data were further reviewed and 
cleaned in SPSS. Descriptive and inferential data analysis were done using the IBM SSPS 
statistics 26. The descriptive statistics was used to describe the socio-demographic 
characteristics, knowledge, and perception of respondents on HIV treatment services and the 
willingness to pay for treatment services. Bivariate logistics regression analysis was conducted 
with chi-square and odd ratio determined for categorical variables to show the relationship 
between the respondent’s socio-demographic and willingness to pay (WTP) for HIV/AIDS 
treatment services and the maximum amount respondents were willing to pay. Statistically 
significant values were taken at p-values of 0.05 and regression coefficient values noted. In 
addition, multivariate logistics regression analysis was conducted to understand the 
demographic, socio economics and patient factors that influence the willingness to pay for HIV 
treatment and maximum amount respondents are willing to pay if free HIV treatment is stopped.  
Socio-demographic Characteristics of Respondents 
a. Age Distribution of Respondents (N=400) 
The ages of the respondents ranged from 18 – 74 years. The mean and median ages 
were 36.1(+/- 10.1) and 34 years, respectively. Most of the respondents (over 90%) fell within 
the age range of 18 – 50 years. This range represents the people mostly affected by HIV/AIDS 
in Nigeria (UNAIDS, 2019). 
b. Sex of respondents (N=400) 
About 53% of the respondents were female while 47% were male. This ratio of 1.1 
female to 1 male is close to nationally representative data of 1.2 females to male for people 
living with HIV/AIDS in Nigeria with 56% being female while 44% being male (UNAIDS, 2019).  
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c. Marital status of respondents (N=400) 
Analysis of marital status of respondents indicates that about 32% of the respondents 
were single, 40% married, 7.2% not married but cohabiting with a partner. Further, 9.8% were 
divorced while 10.5% were widowed. Since respondents were adults who are currently or 
previously sexually active, the recruitment of 70% respondents that were previously or currently 
in sexual relationship is not surprising. 
d. Educational attainment of respondents (N=400) 
About 90% of respondents had at least a primary education while only 10% never 
attended any formal education. Further, 30% had education up to the university level, 38% had 
secondary education, 10% had primary education, while 11% had post-secondary vocational 
education. Compared to previous studies (Mbachu et al, 2018, Chirundu et al, 2017), this study 
employed respondents with proportionally slightly higher post-secondary education. 
e. Employment status of respondents (N=400) 
The employment status of respondents indicates about 10% of respondents were 
students and 11% were not employed. Therefore, 79% had a regular income either through paid 
employment or through informal employment or business. The sample yielded a higher 
percentage of respondents who earn monthly income (79%) compared to prior studies which 
had 75% and 62%) respectively. (Mbachu et al, 2018, Chirundu et al, 2017). 
f. Monthly income of respondents (N=400) 
 The median monthly income of respondents was N28,000 (USD$70). This is slightly 
lower than the monthly minimum wage in Nigeria, which is about N30,000 (USD$75). About 
19% of the respondents (students and unemployed) reported no income, while 2.7% did not 
declare their income. Additionally, 32% earned less than the national monthly minimum wage, 
44% earned above the minimum wage while about 3% who earned income did not disclose the 
value as depicted in Figure 7. 
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g. Travel time from home to health facility (N=400) 
I asked respondents how long it takes to get to health facility from their homes in a bid to 
estimate the distance between respondents’ home and clinic where HIV treatment was being 
received. The mean duration of time was about 50 minutes, with the shortest duration of 5 
minutes and the longest about 120 minutes.  
h. Mode of transportation to health facility (N=400) 
I asked respondents to indicate their mode of transportation to the health facility. An 
overwhelming majority (89%) accessed treatment centres using public transportation services 
provided by buses, motorcycle, or tricycles. Further, 9.8% utilized their personal vehicles, 1% 
walked and 0.5% used bicycle. The mean amount spent on transportation for each clinic visit 
was N700 (USD$1.75) while the median was N600 (USD$1.5). The maximum amount spent 
was N2000 (USD$5) with about 15% spending more than N1000 (USD$2.5) for transportation 
for each clinic visit. 
i. Frequency of clinic visits for HIV treatments services (N=400) 
I asked respondents how frequently they visited the clinic to receive HIV treatment 
services. There were 0.3% of respondents who visited the clinic more than once a month, 22% 
visited once monthly, 19% once every two months and 59% once every three months. 
Observed frequency of visits aligned with differentiated care for patients receiving HIV treatment 
services in Nigeria as patients who were stable on treatment were expected to visit the clinic 
less frequently compared to new and unstable patients. 
j. Duration of time respondents have been on HIV/AIDS treatment (N= 400) 
More than half (58%) of survey respondents had been on HIV treatment for more than 3 
years. In addition, 33% had been on treatment for longer than one year but less than 3 years 
while 9% had been on treatment for less than a year. This indicate that most of the respondents 
57 
involved in the study had experience receiving HIV treatment services. I also ensured input from 
respondents who were recently enrolled into HIV treatment services. 
k. Type of HIV treatment received (N=400) 
About 86% of respondents were on first-line antiretroviral treatment, 14% on second-line 
treatment while none of the respondents was on third line of treatment regimen. The distribution 
of respondents was slightly different compared with the national data of proportion of patients 
receiving HIV treatment services in Nigeria (estimated at 95% on first-line, 4.5% on second line 




Figure 7: Distribution of Monthly Income of Respondents 
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Table 7: Demographic Details of Respondents (N=400) 
Characteristics Categories (n) Percentage (%) 
Age of 
respondents 
   
Mean ±(SD); 
median (IQR) 
36.1(±10.1); 34 (18-74) 
Age group 18-28yrs 91 22.75 
29-39yrs 174 43.00 
40-50yrs 100 25.00 
51-61yrs 27 6.75 
above62yrs 8 2.00 
Sex Female 211 52.72 
Male 189 47.25 
Marital status Cohabiting 32 8.00 
Divorced/Separated 39 9.72 
Married 161 40.25 
Single 126 31.50 




No Education 38 10.00 
Primary 81 21.00 
Secondary 153 38.25 
Post-Secondary 117 29.00 
Others 48 12.00 
Employment 
status 
Salaried 121 30.25 
Self employed 196 49.00 
Students 38 9.50 
Unemployed 45 11.25 
Monthly income No income 76 19.00 
Less than N10,000 (<$25) 10 2.50 




N20,000 - N30,000 
($50 - $75) 
71 17.75 
N30,000 - N40,000 
($75 - $100) 
93 23.25 
N50,000 - N100,000 
($125 - $250) 
67 16.75 
Above N100,000 (>$250) 16 4.00 
Would not disclose 11 2.75 
Transport mode 
to clinic 
Bicycle 2 0.50 
Private car/Taxi 43 10.75 
Public transport 351 87.75 
Walking 4 1.00 
Frequency of visit 
to clinic 
Once a month 86 21.5 
More than once a month 5 1.25 
Once every two months 75 18.75 
once every three months 234 58.50 
Duration on 
treatment 
Less than 1 Year 36 9.00 
Between 1 – 3 Years 132 33.00 
More than 3 years 232 58.00 
Type of HIV 
treatment being 
received 
First Line Treatment 344 86.00 
Second Line Treatment 56 14.00 
 
 
Mean (±SD) Median (IQR) 
Distance of home to clinic (minutes) 50.0 (±16.8) 50 (5-120)  





Knowledge, awareness and perception of HIV treatment services and cost 
Table 8 illustrates the knowledge and awareness of respondents on the importance of prompt 
initiation of treatment, adherence and perception on the cost and quality of HIV treatment 
services being received. 
a. Awareness of Respondents on the Benefits of Prompt Initiation of HIV Treatment 
and the Consequences of Non-Adherence to HIV Treatment (N=400) 
I asked respondents if they were aware of any benefits of promptly initiating HIV 
treatment once diagnosed. Almost all respondents (99%) demonstrated the awareness of the 
importance of initiating early treatment. Similarly, 97% respondents were aware of the 
consequences of non-adherence to HIV treatment or abruptly stopping treatment. This 
observation could be an indication of the quality of counseling received by respondents in 
addition to the fact that most of them have been on treatment for over a year. 
b. Perception of the Quality of Free HIV Treatment Services (N= 400) 
Respondents were asked to rank the quality of free HIV treatment services they currently 
receive on a 5-point Likert scale. About 2% of the respondents rated the current services as 
poor to very poor, but 25% rated it as “good”, 40% rated it “very good”, 33% rated “excellent”. 
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Table 8: Distribution of Level of Awareness of Respondents on HIV Treatment Services 
Variables  Categories Frequency (n) Percentage 
(%) 
Awareness of Benefits of 
early treatment  
No 7 1.75 
Yes 393 98.25 
Awareness of 
consequences of non-
adherence to treatment  
No 14 3.50 
Yes 386 96.50 
Perception of quality of 
services  
Excellent 132 33 
Very Good 160 40 
Good 100 25 
Poor 6 1.5 
Very poor 2 0.5 
Perception of the monthly 
cost of treatment (NGN) 
 
Less than N5000 
(<$12.5) 
77 19.25 
Between N5,000 and 
N9,999 
($12.5 - <$25) 
106 26.50 
Between N10,000 and 
N15,000 
($25 - $37.5) 
164 41.00 
Between N15,001 and 
N20,000 






c. Perception of the Monthly Cost of HIV Treatment Services (N=400) 
Respondents were asked how much they think the monthly cost of access to treatment 
would be based on the current market rate. About 20% of respondents reported that monthly 
cost of treatment is less than N5000 (<USD$12.5), 42% reported that the cost is more than 
N5000 (<USD$14) but less than N10,000 (USD$25), 26% reported more than N10000 
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(USD$25) but less than N15,000 (USD$37.5), 6% reported more than N15000 (USD$37.5) but 
less than N20000 (USD$50) while another 6% reported the cost will be more than N20000 
(USD$50). This indicates that 80% of the respondents think the monthly cost of accessing 
treatment is more expensive than the actual cost of about N5000 (USD$12.5). 
Willingness to Pay for HIV Treatment Services and History of Payment for Health Service 
a. Willingness to Pay for HIV Treatment Services (N=400) 
All respondents were asked if they would be willing to pay for HIV treatment services if 
the free treatment was stopped due to funding challenges. Most (92%) respondents answered 
“Yes” while 8% answered “No”. In addition, they were asked what decision they would take 
about their HIV treatment if payment was required. All those who responded ‘Yes” to the initial 
question indicated that “they would try to look for ways to pay for treatment” – and 8% of those 
reported that they would discontinue their HIV treatment if such situation arose.  
Despite the high willingness to pay for HIV treatment, 68% of the respondents believed it 
was not acceptable for patients to pay for treatment as it was perceived to be the responsibility 
of the government to provide HIV treatment. In addition, about 18% were willing to pay the 
monthly cost of treatment of N5000 (USD$12.5). The mean amount respondents would be 
willing to pay was N3000 (USD$7.5) (range: N500 USD$1.25) – N20000 (USD$50)).  
b. Willingness to Pay for HIV Treatment with Changes in Income (N=362) 
Irrespective of the response on willingness to pay, respondents were asked if their 
willingness to pay would change with increase or decrease in their income. The same 92% who 
were willing to pay would be willing to pay if income increased while only 27.8% would be willing 




Figure 8: Respondents Willingness to Pay for HIV Treatment Services with Changes in Income 
c. Maximum Amount Respondents Are Willing to Pay (N=362) 
During the bidding process, respondents who were willing to pay for treatment services 
were asked for the maximum amount they were willing to pay. Responses ranged from N500 – 
N20000 ($1.25 - $50) with the median amount of N2000 ($4). Figure 9 shows the variation of 
willingness to pay for HIV treatment services at different points for the cost of treatment. About 
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Figure 9: Willingness to Pay at Different Price Points of Treatment Services. 
d. Sources of Funds to Pay for HIV Treatment Services (N=362) 
Respondents who were willing to pay for treatment were asked what the source(s) of the 
funds for payment would be. More than two-thirds (71%) reported the funds would come from a 
combination of personal income and support from family and friends. Further, 20% indicated the 
funds will come solely from personal income while 9% reported the funds will come solely from 
support from family and friends. In addition, 84% of respondents indicated they were sure that 
they could access financial support from family and friends to pay for HIV treatment services if 
such support were required. 
e. Type of Health Facility Preferred for Paid Services 
All respondents in the study received free HIV treatment services at public health care 
facilities at the time of completing the survey. The respondents were asked of their choice of 
service delivery center (public or private) if they must pay for treatment services. About 90% of 
the respondents still prefer a public healthcare facility while about 10% prefer a private health 
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treatment services (drug refill, consultation, and laboratory services) at such locations while 
those who prefer private healthcare facilities cited shorter waiting time and higher level of 
confidentiality at such centres for their choice. 
Table 9: Distribution of Willingness to Pay for HIV Treatment Services (n=400) 
Variables Categories Frequency (n) Percentage (%) 
Willingness to pay for 
treatment If free treatment 
is stopped 
No 38 9.50 
Yes 362 90.50 
Willingness to pay with 
increasing income 
No 29 7.25 
Yes 371 92.75 
Willingness to pay with 
decreasing income 
No 114 28.50 
Yes 286 71.50% 
Sources of payment for 
treatment 
Family/ Friends 33 8.25 




Type of health facility 




Private Hospital 35 9.67 
Preferred mode of payment Annual payment to 
the Hospital 
36 9.94 
Payment on the 








f. Preferred Mode of Payment for HIV Treatment Services (N=400) 
Respondents who were willing to pay for HIV treatment services were asked their 
preferred mode of payment: 75% would prefer to pay on the day of the clinic visit as this would 
limit the burden of payment. In addition, 11% would prefer to make annual payment to the clinic 
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where services were being provided while 14% would prefer payment through the National 
Health Insurance Scheme (NHIS). This finding aligns with a minority of Nigerians currently 
enrolled in health insurance schemes in Nigeria (Uzochukwu et al., 2015). 
g. History of Previous Payment for HIV Treatment Services (N=400) 
Respondents were asked if they ever paid for any component of HIV treatment services 
in the past. Over half (58%) reported they paid for treatment services at least once since they 
were diagnosed with HIV while 42% have never made any form of payment. Among those who 
ever paid (N=232), 83% made the payment in a publicly owned health facility while 17% paid in 
a privately owned health facility.  
Respondents who paid for HIV treatment services in the past were asked the type of 
service they paid for. About 3% of respondents paid for registration for consultation, 56% paid 
for laboratory services only, while 41% paid for multiple services including laboratory tests, 
registration for consultation and drug refill. 
h. Highest Amount Paid for Previous HIV Treatment Services (N=232) 
Respondents who ever paid for HIV treatment services (N=232) were asked the highest 
amount they ever paid for HIV treatment services. The median amount reported by respondents 
was N5000 (USD$12.5) while the reported amount ranged from N1000 to N15000 (USD$2.5 - 
USD$37.5). About 7% of the respondents paid up to N1000 (USD$2.5), 27% paid up to N2000 
(USD$5), 38% paid up to N4000 (USD$10), 18% paid up to N6000 (USD$15) while 10% paid 
over N6000 (USD$15) for previous treatment services. 
Bivariate Analysis 
I conducted Bivariate analysis to determine which of the respondents’ socio-economic 
and patient variables were associated with willingness to pay on one hand and maximum 
amount respondents were willing to pay on the other hand. P-values equal or less than 0.05 
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were taken to be statistically significant and McFadden's R-squared was calculated to examine 
the model fit, where values greater than 0.2 were indicative of models with excellent fit (Louviere 
et al., 2000). Logistic regression analysis was used to quantify the OR, 95% confidence 
intervals and regression coefficient were used to indicate the direction and magnitude of the 
association of the independent variable with the dependent variable considered in the 
interpretation of the result.  
This section provides results of the analysis of the relationship between willingness to 
pay for treatment services if free treatment were stopped as well as associated socio-economic 
and patient variables. 
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Table 10: Output of Bivariate Analysis of Willingness to Pay for HIV Treatment Services and 
Independent Variables  
  Willingness 
to Pay 
   95% CI 
 
 
Variable n Yes (%) B X2 OR Lower Upper P 
value 
Sex 
Male 189 173 (91.5%   1.0   
Female 211 189 (89.6%) -0.23 0.45 0.79 -0.91 0.45 0.505 
Age  
Over 40 years 265 240 (90.6%)   1.0    
Under 40 years 135 122 (90.4%) 0.77 2.50 1.023 0.261 2.070 0.950 
Marital category      
Has a partner 193 180 (93.3%)   1.0    
Has no Partner 207 182 (87.9%) -0.64 3.38 0.53 -1.34 0.06 0.072 
Level of Education Completed        
Below secondary 
school 
119 105 (88.2%)   1.0    
Above secondary 
school  
281 257 (91.5%) 0.02 0.00 1.02 -0.65 0.69 0.948 
Employment status 
Employed 317 299 (94.3%)   1.0    
Unemployed 83 63 (75.9%) -1.66 22.6 0.19 -2.356 -0.97 0.001* 
Monthly Income      
>minimum Wage 187 182 (97.3%)   1.0    
< minimum Wage 213 180 (84.5%) 1.90 14.9 0.15 -2.86 -0.94 0.001* 






 1.0    
Increase in Income 400 371 (92.8%) 2.05 7.79 22.6 1.21 2.90 0.001* 
Availability of Support 
No Support 69 43 (62.3%)   1.0    
Family & friend 
support 
331 318 (96.1%) 2.65 49.17 14.22 1.91 3.40 0.001* 
Sources of money to be used to pay for HIV treatment services 
Personal income + 
support 
284 275 (96.8%)   1.0    
Personal income + 
alone 
73 67 (91.8%) 1.01 3.42 2.74 -0.06 2.07 0.064 
Perception of the monthly cost of HIV treatment services 
Cost is low 183 168 (91.8%)   1.0    
Cost is high 217 194 (89.4%) 0.28 0.66 1.33 -0.40 0.97 0.415 
History of previous payment for HIV treatment services 
No 166 147 (88.6%)   1.0    
Yes 234 215 (91.9%) -0.37 1.24 1.46 -1.29 1.05 0.27 
 
Awareness of benefits if treatment 
No 7 3 (42.9%)   1.0    
Yes 393 359 (91.3%) 2.64 11.36 14.08 1.11 4.18 0.001* 
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Duration the respondents have been on HIV treatment 
Less than 3 years 167 148 (88.6%)   1.0    
Over 3 years 233 214 (91.8%) -0.37 1.17 0.69 -1.04 0.30 0.280 
Preferred location to receive HIV treatment services 
Public hospital 37 35 (95%)   1.0    
Government 
hospital 
327 320 (98%) -0.84 235 2.78 -1.03 3.08 0.329 
Existence of comorbidity with HIV infection 
No comorbidity 346 343 (99.1%)   1.0    
Yes comorbidity 54 19 (35.2%) -0.44 0.91 0.65 -1.70 0.83 0.499 
Frequency of clinic visits by respondents 
More than once a 
quarter 
166 139 (83.7%)   1.0    
Once is a quarter 234 223 (95.2%) 0.64 3.06 1.89 -0.08 1.35 0.80 
Awareness of the benefits of adherence to HIV treatment services 
No 7 3 (42.9%)   1.0    
Yes 393 359 (91.3%) 1.01 2.22 2.74 -0.32 2.33 0.136 
*Statistically significant p-values of 0.05 
Relationship between Socio-Demographic/Socio-Economic Factors and Willingness to 
Pay for HIV Treatment Services 
a. Sex Category and Willingness to Pay for HIV Treatment Services  
The percentage of respondents willing to pay for HIV treatment services was slightly 
higher among males (91.5%) compared to females (89.6%). However, bivariate analysis did not 
show any significant statistical difference based on sex of respondents (p=0.505; χ
2
(1) = 0.45, 
OR: 0.79, CI: -0.91 – 0.45). The McFadden R-squared value calculated for this model was 0.00. 
Since the overall model was not significant, the individual predictors were not examined further.  
b. Age Group and Willingness to Pay for HIV Treatment Services  
About 90.4% of respondents below 40 years were willing to pay for treatment services 
while about 90.6% of those above 40 years were willing to pay. The comparison of willingness 
to pay for HIV treatment services if free treatment services were stopped was not significant 
when those aged 40 years were compared with those aged below 40 years (χ
2
(1) = 2.50, p = 
.950, McFadden R
2
 = 0.01, CI: -0.261, 2.070). The overall model was not significant (p-value 
0.138), suggesting that age did not have a significant effect on the odds of observing willingness 
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to pay for HIV treatment services. The McFadden R-squared value calculated for this model 
was 0.01.  
c. Marital Category and Willingness to Pay for HIV Treatment Services 
Responses observed from participants based on marital status were recoded based on 
presence or absence of a sexual partner. The result indicates about 93.3% of respondents who 
reported having a partner at the time of data collection were willing to pay for HIV treatment 
services while 87.9% of those who reported absence of a partner were willing to pay for HIV 
treatment services if free services were no longer available. The bivariate analysis indicates that 
willingness to pay for HIV treatment services is independent of the absence of a partner (p-
value 0.072; χ
2
(1) = 3.38, OR: 0.53; CI: -1.34 – 0.06). The overall model was not significant 
suggesting that marital status did not have a significant effect on the odds of observing 
willingness to pay for treatment services. The McFadden R-squared value calculated for this 
model was 0.01. Since the overall model was not significant, the predictor was not examined 
further. 
d. Level of Education Completed and Willingness to Pay for HIV Treatment Services  
The responses received based on highest educational level completed was recoded into 
a dichotomous variable of those who completed secondary level education and above and 
respondents who completed below secondary level education. Maximum education completed 
did not have a significant effect on the odds of observing a willingness to pay for HIV treatment 
services (p= 0.948; χ
2
(1) = 0.00, OR: 1.02; CI: -0.65 – 0.69). The McFadden R-squared value 
calculated for this model was 0.00. Since the overall model was not significant, the role of this 
variable was not examined further. Therefore, willingness to pay for HIV treatment services is 
independent of having a post-secondary education.  
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e. Employment Category and Willingness to Pay for HIV Treatment Services 
Observations based on the employment status of responses were reclassified into those 
who were employed and receiving income (self-employed and paid employment) and those who 
were not employed and has no income (students and unemployed). About 94.3% of those who 
were employed were willing to pay for treatment while about 76% of respondents within the 
unemployed category were willing to pay for treatment services. The overall model was 
significant, χ
2
(1) = 21.28, p < .001, CI: -2.35 - -0.97; suggesting that employment status had a 
significant effect on the odds of observing willingness to pay. The McFadden R-squared value 
calculated for this model was 0.08. The regression coefficient for Employment Status of “no 
Income” was significant, B = -1.66, OR = 0.19, p < .001, indicating that for a one unit increase in 
Employment Status (No Income), the odds of observing willingness to pay would decrease by 
approximately 81%. Therefore, willingness to pay for HIV treatment services was dependent on 
the employment status in which income was earned.  
f. Monthly Income Category and Willingness to Pay for HIV Treatment Services 
The reported average monthly income was recoded into dichotomous categories of 
those who earn below the minimum wage (N30,000 ($75)) per month and those who earn 
above the minimum wage. The overall model was significant, χ
2
(1) = 21.41, p < .001, 
suggesting that monthly income had a significant effect on the odds of observing willingness to 
pay. The McFadden R-squared value calculated for this model was 0.09. The regression 
coefficient for monthly income under minimum wage was significant, B = -1.90, OR = 0.15, p < 
.001, indicating that for a unit increase in monthly income below minimum wage, the odds of 
observing willingness to pay would decrease by approximately 85%. Therefore, respondents 
who earned above the minimum wage were more likely to be willing to pay for HIV treatment 
services. In addition, the willingness to pay increased with increasing income above the 
minimum wage of respondents.  
72 
g. Changes in Monthly Income and Willingness to Pay for HIV Treatment Services 
The overall model was significant, χ
2
(1) = 7.79, p < .001, suggesting that increase in 
respondent’s income had a significant effect on the odds of observing willingness to pay for HIV 
treatment services. The McFadden R-squared value calculated for this model was 0.08. The 
regression coefficient for willingness to pay with increasing Income was significant, B = 2.05, 
OR = 22.6, p < .001, CI: (1.91 – 3.40) indicating that for a one unit increase in income, the odds 
of observing willingness to pay would increase by approximately 2160%. 
h. Availability of Support from Family and Friends and Willingness to Pay for HIV 
Treatment Services  
The overall model was significant, χ
2
(1) = 51.87, p < .001, suggesting that support from 
family and friends had a significant effect on the odds of observing “Yes” for willingness to pay 
for HIV treatment services. The McFadden R-squared value calculated for this model was 0.21. 
The regression coefficient for availability of family and friends support was significant, B = 2.65, 
OR = 14.22, p < .001, indicating that for a one unit increase in availability of family and friends 
support, the odds of observing “Yes” category of willingness to pay would increase by 
approximately 1322%.   
i. Awareness of Benefits of Prompt Initiation of HIV Treatment and Willingness to 
Pay for HIV Treatment Services 
The overall model was significant, χ
2
(1) = 10.21, p = .001, suggesting that awareness of 
the benefits of initiating HIV treatment early had a significant effect on the odds of observing the 
“Yes” category of willingness to pay. The McFadden R-squared value calculated for this model 
was 0.04. The regression coefficient for benefits of starting HIV treatment services was 
significant, B = 2.64, OR = 14.08, p < .001, indicating that for a one unit increase in 
benefitearlytxAwareness1, the odds of observing the “Yes” category of willingness to pay would 
increase by approximately 1308%. The wide value of 95% CI: 1.11 – 4.18 indicates that this 
finding should be interpreted with caution due to the wide margin.  
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j. Other Independent Variables with Willingness to Pay for HIV Treatment Services  
Bivariate analysis of the relationship of each of the remaining independent variables with 
willingness to pay for HIV treatment services was conducted. These independent variables 
included: duration the respondents have been on HIV treatment; average cost of transportation 
to clinic; history of previous payment for HIV treatment services, perception of the monthly cost 
of HIV treatment services, frequency of clinic visits, awareness of the benefits of adherence to 
HIV treatment services, existence of comorbidity with HIV infection, preferred location to receive 
HIV treatment services and sources of money to be used to pay for HIV treatment services. 
None of these independent variables showed statistically significant association with willingness 
to pay for HIV treatment services. Table 12 shows the summary of outputs of analysis for the 
other independent variables. 
Summary of Bivariate Analysis of Independent Variables with Willingness to Pay for HIV 
Treatment Services. 
Five (5) out of the 17 independent variables investigated were observed to have 
statistically significant association with willingness to pay for HIV treatment services. The p-
values for the variables were less than 0.05, thereby rejecting the null hypothesis that 
willingness to pay for HIV treatment services is independent of each of these factors. The rank 
order of the statistically significant independent variables based on their Beta weights relative to 
the dependent outcome (willingness to pay for treatment) is as follows: 
A. Availability of Financial Support from Friends and Family: With an absolute 
regression coefficient of 2.65 (B=2.65, OR of 14.22), the availability of family and friends 
who can provide financial support was determined to be the highest ranked independent 
variable which had an association with willingness to pay for HIV treatment services. 
Respondents who had access to financial support from family and friends have a higher 
willingness to pay for HIV treatment services compared to those who lacked such 
support. Patients who had access to such to financial support from family and friends 
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were about 14 times more likely to be willing to pay for treatment compared to those 
without such support if free treatment services were no longer available. 
B. Awareness of Benefits of Early HIV Treatment Initiation: This was determined as the 
second highest ranked independent variable with correlation to willingness to pay for HIV 
treatment services. With an absolute regression coefficient of 2.64 (B = 2.64, OR = 
14.08, p < .001), indicating that for a one unit increase in awareness of the benefits of 
early HIV treatment initiation, the odds of observing a positive response to willingness to 
pay would increase by approximately 1308%. 
C. Change in Monthly Income: With an absolute regression coefficient of 2.05 (B = 2.05, 
OR = 22.6, p < .001), change in monthly income was the third ranked independent 
variable which was associated with willingness to pay for HIV treatment services. The 
regression coefficient for willingness to pay for HIV treatment services, indicates that for 
a one unit increase in income, the odds of observing a ‘Yes” willingness to pay category 
would increase by approximately 2160%. 
D. Level of Monthly Income: With an absolute regression coefficient of 1.90 (B = -1.90, 
OR = 0.15, p < .001), the level of monthly income was the fourth ranked independent 
variable which was associated with willingness to pay for HIV treatment services. 
Respondents who earned monthly income below the national minimum wage of N30,000 
($75) per month were about 85% less willing to pay for HIV treatment services. This 
indicated that for a unit increase in monthly income below minimum wage, the odds of 
observing willingness to pay would decrease by approximately 85%. Therefore, 
respondents who earned above the minimum wage were more likely to be willing to pay 
for HIV treatment services. In addition, the willingness to pay increases with increasing 
income above the minimum wage of respondents. 
E. Employment Category: With an absolute regression coefficient of 1.66 (B = -1.66, OR 
= 0.19, p < .001), employment was the fifth ranked independent variable which was 
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significantly associated with willingness to pay. Respondents who were unemployed 
were about 81% less willing to pay for HIV treatment services compared to those who 
have an income.  
Four of the five (5) variables which showed statistically significant relationship with 
willingness to pay were related to the socio-economic factors of respondents while the fifth was 
associated respondents’ knowledge of the importance of early treatment initiation once an HIV 
diagnosis was confirmed. Respondents who belonged to a higher socio-economic stratum of the 
society by virtue of their employment status and income and those who had friends and family 
who can support them financially had a higher willingness to pay for treatment services. 
The variables that did not show statistically significant association with willingness to pay 
for HIV treatment services included sex, age, education level completed, marital status, duration 
respondents have been on treatment, history of previous payment for HIV treatment services, 
frequency of clinic visits, existence of comorbidity with HIV infection, and preferred location to 
pay for treatment. Although, there were variations within these factors among respondents, it 








Table 11: Summary of Relationship of Independent Variables with Willingness to Pay 
 Variables that are dependent on 
willingness to pay for HIV 
treatment services 
Variables that are independent of 
willingness to pay for HIV treatment 
services 
1 Employment status Age of respondents 
2 Monthly income Sex of respondents 
3 Change in monthly income Marital category of respondent 
4 Availability of financial support from 
family & friends 
Education level completed by respondents 
5 Awareness of benefits of early start 
of treatment 
Duration the respondents have been on 
HIV treatment 
6  History of previous payment for HIV 
treatment services 
7  Perception of the monthly cost of HIV 
treatment services 
8  Frequency of clinic visits 
9  Awareness of the benefits of adherence to 
HIV treatment services 
10  Existence of comorbidity with HIV infection 
11  Preferred location to receive HIV treatment 
services 
 
Relationship between Socio-Demographic/Socio-Economic Factors and Maximum 
Amount Respondents Were Willing to Pay for HIV Treatment Services 
All the respondents who expressed willingness to pay for HIV treatment services were 
asked about the maximum amount they would be willing to pay to access HIV treatment 
services if free treatment services were no longer available. The current cost of providing HIV 
treatment services has been estimated to be about N5000 ($12.5) per month. Therefore, data 
collected on the maximum amount that respondents were willing to pay was recoded into a 
dichotomous variable of below N5000 (< $12.5) and N5000 and above (>=$12.5). This section 
describes the findings from the bivariate analysis of how this dependent variable is predicted by 
the demographic and socio-economic factors of the respondents. 
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Table 12: Output of Bivariate Analysis of Independent Variables with Maximum Amount 
Respondents are Willing to Pay for Treatment 




   95% CI  
Variable n >N5000 B X2 OR Lower Upper P 
value 
Sex         
Male 189 27(14.3%)   1.0    
Female 211 20(9.5%) -0.37 1.38 0.69 -0.98  0.25 0.238 
Age 
Over 40 years 135 20(14.8%)   1.0    
Under 40 years 265 27(10.2%) 0.38 0.37 1.46 -0.84 1.60 0.543 
Marital category         
Has a partner 193 31 (16.1%)   1.0    
Has no partner 207 16 (7.7%) -16.1 1.06 1.5 0.86 2.52 0.154 
Education completed  
Below secondary 
school 
119 23 (19.3%)   1.0    
Secondary school & 
above 
281 24 (8.5%) 0.83 6.33 2.30 0.18 1.48 0.012* 
Employment status 
Employed 317 39(12.3%)   1.0    
Not employed 83 8(9.6%) -0.65 2.0 0.52 -1.54 0.25 0.157 
Monthly income 
> minimum wage 187 36(19.3%)   1.0    
< minimum wage 213 11(5.2%) -0.59 3.45 0.56 -1.21 0.03 0.001* 
Change in Income 
Decrease in income 361 137(38%)   1.0    
Increase in Income 361 116(32%) 15.64 0.02 6.17 -0.74 0.60 0.983 
Availability of support 
Family & friend 
support 
332 37(11.1%)   1.0    
No support 68 10(14.7%) 1.61 23.67 0.20 -2.25 0.96 0.001* 
Sources of money to be used to pay for HIV treatment services 
Personal income 
alone 
357 39(10.9%)   1.0    
Personal income + 
support 
43 8(18.6%) -0.63 2.93 2.74 -0.06 2.07 0.064 
Perception of the monthly cost of HIV treatment services 
Cost is low 350 41(11.7%)   1.0    
Cost is high 50 7(14%) 0.35 1.13 1.33 -0.40 0.97 0.415 
 
History of previous payment for HIV treatment services 
No 166 26(15.7%)   1.0    
Yes 234 21(9%) -0.15 0.22 1.46 -1.29 1.05 0.27 
Other Factors 
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Awareness of benefits of treatment 
No 7 0(0%)   1.0    
Yes 393 47(12%) 14.57 0.01 1.77 0.010 0.028 0.987 
Duration the respondents have been on HIV treatment 
Less than 3 years 167 11(6.6%)   1.0    
Over 3 years 233 36(15.5%) 0.049 1.02 0.69 -0.04 0.34 0.333 
Preferred location to receive HIV treatment services 
Public hospital 37 1(2.7%)   1.0    
Government 
hospital 
327 46(14.1%) 1.3 1.05 2.78  3.08 0.329 
Existence of comorbidity with HIV infection 
No 378 40(10.6%)   1.0    
Yes 22 7(31.8%) 0.55 0.91 0.65 -1.70 0.83 0.499 
Frequency of clinic visits by respondents 
More than once a 
quarter 
166 11(6.6%)   1.0    
Once in a quarter 234 36(15.4%) 0.54 0.59 1.89 -0.08 1.35 0.80 
Awareness of the benefits of adherence to HIV treatment services 
No 7 0   1.0    
Yes 393 47(12%) 1.16 3.58 2.74 -0.32 2.33 0.136 
 
a. Sex Category and Maximum Amount Respondents Were willing to Pay (N=400) 
The overall model for the bivariate regression analysis of sex with maximum amount 
respondents were willing to pay for treatment was not significant based on an alpha of 0.05, 
χ
2
(1) = 1.39, p = .238, suggesting that sex did not have a significant effect on the odds of 
observing willingness to pay a maximum amount which was greater than current cost of N5000 
($12.5) per month. The McFadden R-squared value calculated for this model was 0.00. Since 
the overall model was not significant, the relationship was not examined further. The alternate 
hypothesis that the maximum amount respondents were willing to pay was dependent of sex of 
respondents was rejected. 
b. Age Category and Maximum Amount Respondents Were Willing to Pay (N=400) 
The proportion of respondents above 40 years of age who were willing to pay N5,000 
($12.5) and above per month for HIV treatment was about 14.8% and was slightly higher than the 
proportion of respondents below 40 years (10.2%) who were willing to pay N5000 ($12.5) and 
above per month. The overall model was not significant based on an alpha (p value) of 0.05, χ
2
(1) 
= 0.37, p = .543, suggesting that age did not have a statistically significant effect on the odds of 
79 
observing payment above N5000. The McFadden R-squared value calculated for this model was 
0.00. Since the overall model was not significant, the variable was not examined further. 
Therefore, age was not associated with the maximum amount respondents were willing to pay for 
HIV treatment services. The alternate hypothesis that maximum amount respondents were willing 
to pay is dependent on age of respondents was rejected. 
c. Marital Category and Maximum Amount Respondents Were Willing to Pay 
Comparing the percentage of respondents who were living with their partners (16.1%) with 
the respondents who were not with partner (7.7.0%) and who were willing to pay the maximum 
amount of five thousand naira (N5000) and above for their treatment did not show a statistically 
significant difference. Therefore, no association was observed with the maximum amount 
respondents were willing to pay if free treatment stopped (P-value: 0.154; OR: 1.475, 95 per cent 
CI: 0.863- 2.522). The alternate hypothesis that the maximum amount respondents were willing 
to pay was dependent on marital status of respondents was rejected.  Hence marital status was 
not one of the determinant factors for the maximum amount respondents were willing to pay if 
free treatment stopped. 
d. Level of Education Category and Maximum Amount Respondents Were Willing to 
Pay 
The model was evaluated based on an alpha of 0.05. The overall model was significant, 
χ
2
(1) = 6.33, p = .012, suggesting that the maximum education completed had a significant 
effect on the odds of observing the more than N5000 category of the maximum amount 
respondents were willing to pay. McFadden's R-squared was calculated to examine the model 
fit, where values greater than 0.2 were indicative of models with excellent fit (Louviere et al., 
2000). The regression coefficient for maximum education completed (secondary school and 
above) was significant, B = 0.83, OR = 2.30, p = 0.012, indicating that for a one unit increase in 
education completed above secondary school, the odds of observing the willingness to pay an 
amount above the current price of N5000 would increase by approximately 130%. The null 
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hypothesis that maximum amount respondents were willing to pay was independent of level of 
education completed by respondents was rejected. 
e. Employment Category and Maximum Amount Respondents Were Willing to Pay 
Higher percentages of employed (12.3%) respondents were willing to pay maximum 
amount above five thousand naira (N5000) for treatment compared to 9.6% of unemployed and 
student respondents. Although the analysis showed some association (OR=0.52) between the 
unemployed and the maximum amount respondents were willing to pay but with the p-value of 
0.157 and the 95 percent CI of -1.54 - 0.25 was not statistically significant and the association 
may likely have been due to chance. The alternate hypothesis that the maximum amount 
respondents were willing to pay was dependent on employment status of respondents was 
rejected. 
f. Monthly Income and Maximum Amount Respondents Were Willing to Pay 
The proportion of respondents in the income category of above minimum wage of 
N30,000 (Thirty thousand naira) willing to pay a maximum amount of five thousand naira and 
above was 19.3%. While the proportion of respondents in the income category of below 
minimum wage of N30,000 (thirty thousand naira) that were willing to pay the maximum amount 
of five thousand naira and above for HIV treatment services was 5.2%. The overall model was 
statistically significant based on an alpha of 0.05, χ
2
(1) = 3.452, p = .01, CI: -1.21 -0.03 
suggesting that monthly income had a significant effect on the odds of observing a willingness 
to pay a maximum amount above N5000 ($12.5). The odds of paying a maximum amount 
above N5,000 was reduced by about 44% for one unit increase in income below the minimum 
wage of respondents. This showed that the higher the number of respondents in higher income, 
the higher the number of respondents willing to pay the higher maximum amount. The null 
hypothesis that the maximum amount respondents were willing to pay was independent of 
monthly income of patients receiving free treatment service was rejected. 
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g. Changes in Income and Maximum Amount Respondents Were willing to Pay 
(N=362) 
The model was evaluated based on an alpha of 0.05. The overall model was not 
significant, χ
2
 = 7.55, p = 0.983, B = 15.64, OR = 6.17 × 10
6
, p = .983). The McFadden R-
squared value calculated for this model was 0.00. Since the overall model was not significant, 
the individual predictors were not examined further. This suggests that change in income had no 
statistically significant effect on the odds of observing a willingness to pay a maximum amount 
higher than the current cost of treatment (N5000). The alternate hypothesis that the maximum 
amount respondents were willing to pay was dependent on change in income of respondents 
was rejected.  Hence change in income was not one of the determinant factors for the maximum 
amount respondents were willing to pay if free treatment stopped. 
h. Availability of Family and Friends Support and Maximum Amount Respondents 
Were Willing to Pay 
The model was evaluated based on a p-value of 0.05. The overall model was significant, 
χ
2
 = 22.63, p < .001, suggesting that the lack of availability of financial support from friends and 
family to pay for treatment had a significant effect on the odds of observing the willingness to 
pay a maximum amount that was less than N5000 for treatment. The regression coefficient for 
non-availability of financial support from friends and family to pay for treatment was B = -1.61, 
OR = 0.20, p < .001, indicating that for a one unit increase in lack of financial support, the odds 
of observing willingness to pay a maximum amount above N5000 would decrease by 
approximately 80%. The null hypothesis that the maximum amount respondents were willing to 
pay was independent of availability of financial support from friends and family was rejected. 
i. Awareness of Benefits of Prompt HIV Treatment Initiation and Maximum Amount 
Respondents Were Willing to Pay (N=400) 
The overall model was not significant based on an alpha of 0.05, χ
2
 = 1.77, p = .184, 
suggesting that awareness of benefit of early HIV treatment initiation did not have a statistically 
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significant effect on the odds of observing a willingness to pay a maximum amount greater than 
N5000. Since the overall model was not significant, the individual predictor was not examined 
further.  
j. Other Independent Variables and Maximum Amount Respondents Were Willing to 
Pay  
Bivariate analysis of the relationship of each of the remaining independent variables with 
the maximum amount respondents were willing to pay based on dichotomous variable of less 
than N5000 and greater than N5000 was conducted. These independent variables included: 
duration the respondents have been on HIV treatment; average cost of transportation to clinic; 
history of previous payment for HIV treatment services, perception of the monthly cost of HIV 
treatment services, frequency of clinic visits, awareness of the benefits of adherence to HIV 
treatment services, existence of comorbidity with HIV infection, preferred location to receive HIV 
treatment services and sources of money to be used to pay for HIV treatment services. None of 
these independent variables showed statistically significant association with maximum amount 
respondents were willing to pay for HIV treatment services. The alternate hypothesis that the 
maximum amount respondents were willing to pay was dependent on these variables was 
rejected. 
Summary of Bivariate Analysis of Independent Variables with Maximum Amount 
Respondents Were Willing to Pay for HIV Treatment Services 
Three (3) out of the 17 independent variables investigated were observed to have 
statistically significant correlation with the maximum amount respondents were willingness to 
pay for HIV treatment services. The p-values for the variables were less than 0.05, thereby 
rejecting the null hypothesis that willingness to pay for HIV treatment services was independent 
of these factors. The rank order of the statistically significant independent variables based on 
their Beta weights relative to the dependent outcome (maximum amount respondents were 
willingness to pay for treatment) was as follows: 
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A. Availability of Financial Support from Friends and Family: Respondents who did not 
have access to financial support from family and friends had a lower willingness to pay 
an amount above N5000 per month for HIV treatment services compared to those who 
had such support. With an absolute beta regression coefficient of 1.61, this variable had 
the highest effect on the maximum amount respondents were willing to pay. An OR of 
0.20 indicated that for a one unit increase in lack of financial support, the odds of 
observing willingness to pay a maximum amount above N5000 would decrease by 
approximately 80%. 
B. Level of Education Completed: Bivariate logistics regression analysis of the 
association between the maximum amount respondents were willing to pay and the 
maximum education completed (secondary school and above) was statistically 
significant. With absolute beta regression value of 0.83, the level of education completed 
was the second ranked independent variable associated with maximum amount 
respondents were willing to pay. The OR of 2.30 indicated that for a one unit increase in 
education completed above secondary school, the odds of observing a willingness to 
pay an amount above the current price of N5000 would increase by approximately 
130%. 
C. Income Level: Income level of respondents was the third ranked independent variable 
that was statistically correlated with the maximum amount respondents were willing to 
pay based on the absolute beta regression value of 0.59. Specifically, with odds ratio of 
0.56, respondents who earned lower than the minimum wage were about 46% less likely 
to be willing to pay a maximum amount greater than N5000 ($12.5) compared to those 
who earned above the minimum wage.  
All three variables which showed a statistically significant relationship with maximum 
amount respondents were willing to pay were related to the socio-economic factors of 
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respondents. Respondents who belonged to a higher socio-economic stratum of the society by 
virtue of their income, educational level completed and those who had friends and family who 
could support them financially had a higher willingness to pay for HIV treatment services. 
Although the level of education completed indicated a relationship with willingness to pay, this 
independent variable did not have a statistically significant relationship with willingness to pay a 
maximum amount greater than N5000 ($12.5). Similarly, the employment status of respondents 
was determined to be statistically associated with willingness to pay for HIV treatment services 
but was not found to be statistically significant with the willingness to pay an amount greater 
than N5000.  
The variables that did not show statistically significant association with the maximum 
amount respondents were willing to pay for HIV treatment services included: sex, age, marital 
status, duration respondents have been on treatment, history of previous payment for HIV 
treatment services, perception of monthly cost of accessing HIV treatment services, frequency 
of clinic visits, existence of comorbidity with HIV infection, preferred location to pay for 





Table 13: Summary of Relationship of Independent Variables with Maximum Amount Patients 
Were Willing to Pay 
 Variables that were dependent on 
maximum amount respondents 
were willing to pay 
Variables that were independent of 
maximum amount respondents were willing 
to pay 
1 Level of education completed Age 
2 Income Level Sex 
3 Availability of friends and family 
support 
Marital Status 
4  Employment status 
5  Change in monthly income 
6  Frequency of visits to clinic 
7  Duration the respondents have been on HIV 
treatment 
8  Awareness of importance of prompt start of 
treatment 
9  History of previous payment for HIV treatment 
services 
10  Perception of the monthly cost of HIV 
treatment services 
11  Existence of comorbidity with HIV infection 
12  Preferred location to receive HIV treatment 
services 
13  Sources of money to be used to pay for HIV 
treatment services 
 
Multivariate Logistics Regression 
Multivariate logistics regression analysis (MLA) was conducted to measure the 
relationship between multiple independent variables and willingness to pay for HIV treatment 
services as a dependent variable. Unlike the bivariate association analysis conducted, MLA 
allowed for control for simultaneous effects of the relationships between the socio-
economic/demographic factors and the willingness to pay for HIV treatment services. The 
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approach enabled the derivation of the fittings and best fit model to describe the relationship 
between willingness to pay for HIV treatment services and the 17 independent variables. The 
result of the analysis helped to provide answers to research question 2 on the factors which 
influenced willingness of respondents to pay for HIV treatment services. 
Willingness to pay for HIV Treatment Services and Independent Variables  
The result of the multivariate logistics regression analysis showed an overall model that 
was statistically significant at a 95% confidence interval (p=0.000). Looking at the individual 
predictor factors, employment, changes in income and availability of financial support from 
families and friends were statistically significant with p-values of less than 0.05. Compared to 
the bivariate analysis of the variables with willingness to pay for HIV treatment services, income 
level and awareness of benefits of early HIV treatment initiation were not statistically significant 
during multivariate logistics analysis. However, these variables were observed to have positive 
regression coefficients. The R-squared value of the regression analysis (0.217) as shown in 
Table 14 indicates that about 22% of the variance in the respondent’s willingness to pay for HIV 










Table 14: Multivariate Regression Analysis of Willingness to Pay and Independent Variables 
Model Unstandardized 
coefficients 
OR 95.0% Confidence 
interval for B 
P values 





(Constant) 0.477 4.622 0.274 0.680 0.000 
Age category -0.029 0.934 -0.091 0.032 0.351 
Marital category -0.004 0.130 -0.060 0.052 0.897 
Educational category -0.010 0.355 -0.064 0.044 0.723 
Employment category 0.109 0.190 0.015 0.202 0.023* 
Income 0.011 2.389 -0.046 0.069 0.697 
Sex -0.035 0.288 -0.089 0.019 0.199 
Level of treatment -0.024 0.770 -0.086 0.038 0.442 
Duration on treatment 0.027 1.274 -0.015 0.070 0.204 
Co-morbidity with HIV 0.007 0.119 -0.110 0.124 0.905 
Change in income 0.116 2.015 0.003 0.229 0.045* 
Availability of financial 
support 
0.218 14.209 0.151 0.285 0.000* 
Sources of money to be 
used to pay for HIV 
treatment services 
0.216 0.548 1.523 20.24 0.802 
Perception of the monthly 
cost of HIV treatment 
services 
0.034 1.493 0.398 2.273 0.892 
Awareness of 
consequences of non-
adherence to HIV 
treatment 
0.703 1.856 2.753 10.274 0.136 
Awareness of starting 
treatment as soon as 
diagnosis is completed 
0.316 0.998 3.02 65.57 0.075 
History of previous 
payment for HIV 
treatment services 
0.278 0.576 0.443 32.74 0.144 
Frequency of clinic visits -0.037 2.457 0.122 0.523 0.784 
# Observation=400; Prob>F=0.000; R-square= 0.217; Root MSE = 0. 263 
Maximum Amount Respondents were Willing to Pay and Independent Variables 
The result of the multivariate logistics regression analysis of the maximum amount 
respondents were willing to pay for HIV treatment and all 17 independent variables indicated that 
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the overall model was statistically significant at p value of 0.05. Availability of financial support 
from family and friends, monthly income and change in monthly income were statistically 
significant at p-value less than 0.05 while other independent variables considered were not 
statistically significant. However, positive regression coefficients were observed for most factors 
except age, level of treatment, and sex of respondents. Hence improvement or upward change in 
socio-economic factors was important in influencing maximum amount respondents were willing 
to pay for their treatment if the free treatment is stopped. The R-square value in Table 15 shows 
that about 19.70% of the variances in the maximum amount respondents were willing to pay if 
free treatment were stopped could be attributed to the respondent’s socio-economic status. 
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Table 15: Multivariate Regression Analysis of Maximum Amount Respondents Were Willing to 











Bound Upper Bound 
(Constant) -91.280 2.156 -1242.161 1059.601 0.876 
Age category -231.946 1.003 -581.887 117.994 0.193 
Marital category 112.728 0.699 -204.520 429.975 0.485 
Educational category 123.887 0.797 -181.817 429.592 0.426 
Employment category 314.738 1.168 -215.269 844.746 0.244 
Awareness of early 
start of treatment 
124.786 0.646 -254.997 504.569 0.519 
Sex -147.272 0.948 -452.638 158.094 0.344 
Income 410.965 2.476 84.698 737.233 0.014* 
Change in income 1863.984 4.332 1222.577 2505.391 0.000* 
Comorbidity with HIV 276.263 0.821 -385.006 937.531 0.412 
Availability of financial 
support 
-327.347 1.092 -567.603 -87.090 0.008* 
Level of treatment -68.269 0.383 -418.816 282.278 0.702 
Sources of funds -356.545 1.072 0.053 3.071 0.387 
Perception of cost of 
HIV treatment 
services 






123.763 1.175 -432.34 123.345 
0.673 
Frequency of clinic 
visits 
-89.324 0.881 0.072 10.804 
0.921 
Duration on treatment 45.657 0.457 1.325 7.824 0.732 
#Observation=400; Prob>F=0.000; R square= 0.197; Root MSE=1503.9 
Summary of Findings from Multivariate Logistics Regression Analysis 
➢ Availability of financial support had the strongest correlation with willingness to pay 
followed by change in income (specifically increase in income) and employment status, 
respectively. All three independent variables were statistically significant with willingness 
to pay for treatment services from the multivariate logistics regression. This consistency 
is an indication of the robustness of the analysis.  
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➢ However, increase in monthly income had the strongest correlation with maximum 
amount respondents were willing to pay followed by income level and availability of 
financial support from friends and family. 
➢ Respondents who had access to financial support from friends and family had a higher 
willingness to pay for HIV treatment services. Compared to those who lacked such 
support, the former had about 1320% higher likelihood to be willing to pay for HIV 
treatment services. 
➢ Similarly, availability of financial support from family and friends was associated with 
maximum amount respondents were willing to pay for HIV treatment services. Access to 
financial support increased the likelihood of being willing to pay an amount greater than 
N5000($12.5) compared to those who did not have access to such support. The 
likelihood in willingness to pay increased by about 9% if such financial support existed. 
➢ Being unemployed has a negative correlation with willingness to pay. Being without 
employment resulted in about 81% reduction in willingness to pay for HIV services 
compared to those who were employed. Although bivariate analysis indicated an 
association between willingness to pay and income, multivariate regress did not show 
such correlation. It is likely that the association observed during bivariate analysis was 
influenced by the employment status and not the income on its own. 
➢ Income level was correlated with the maximum amount respondents were willing to pay 
for HIV treatment services. When income level was above the minimum wage, the 
likelihood of being willing to pay a maximum amount above N5000 ($12.5) (cost of 
treatment) was increased by about 150% compared to those who earned below the 
minimum wage. 
➢ Change in income (specifically increase in income) had a positive correlation with 
willingness to pay. When income level increased, willingness to pay for treatment 
increased by about 220% compared to when income reduced.  
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➢ Similarly, change in income (increase) had positive association with the maximum 
amount respondents would be willing to pay for HIV treatment services. An increase in 
income increased the likelihood of being willing to pay a maximum amount greater than 
N5000 ($12.5) by about 330% compared to when there was a decrease in income. 
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CHAPTER 5: QUALITATIVE STUDY RESULTS 
This section describes the results from the key informant interviews and responses to 
the semi- structured questions from the cross-sectional survey of patients on their willingness to 
pay for HIV services if free treatment services were no longer available in Nigeria and the 
factors influencing their willingness.  
I began this chapter by providing a summary of current challenges encountered in HIV 
treatment programming in Nigeria. I then delved into the specific challenges around 
sustainability of funding for the program and possible solutions to these funding challenges. 
Finally, I explored how the expressed willingness to pay for treatment services by a significant 
portion of patients who currently receive free services could be incorporated into other funding 
streams to improve sustainability of program funding. Although I identified certain factors which 
could facilitate or hinder effective implementation of identified solutions, as well as information 
on policy and programmatic considerations to bring about the required change for improved 
funding for the program, these factors and considerations are highlighted later under the 
discussion section to avoid repetition.   
Characteristics of Key Informants Interviewed 
As depicted in Table 16, a total of thirty (30) key informants were interviewed between 
August and October 2020.  
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Table 16: Characteristics of Key Informants Interviewed 
Type of key informant Number 
HIV Program Managers 
✓ HIV implementing organizations 
n=4 
Leaders of Civil Society Organizations 
✓ Civil Society for HIV/AIDS in Nigeria (CISHAN) 




✓ United States Agency for International Development (USAID) 
✓ US Presidents Emergency Plan for AIDS Relief (PEPFAR) 
✓ Global Fund for AIDS Tuberculosis Malaria/Country 
Coordination Mechanism (GFATM/CCM) 
n=6 
Representatives of People Living With HIV/AIDS (PLWH) n=5 
Representatives of Government Agencies 
• National Health Insurance Scheme (NHIS) 
• Federal Ministry of Health/National AIDS and Sexually 
Transmitted Infection Control Program (FMOH/NASCP) 




Current Challenges Being Encountered in HIV Treatment Programming in Nigeria  
All the informants interviewed agreed that the HIV program at the national level has 
always been blessed with knowledgeable and competent leadership. However, the program is 
constrained by a lack of stability of the leadership of the government agencies 
responsible for coordination and policy direction for the program. The lack of continuity in 
leadership was highlighted particularly by informants from donor agencies and civil society 
groups. Despite the existence of a national strategy for the implementation of the program in 
Nigeria, each government appointee come with different ideas on how the strategy is to be 
implemented. When such leaders retire from public service or are replaced, traction is often lost 
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because the new appointee comes up with different priority areas or approaches to 
implementation of the strategy. According to one of the civil society informants:   
“The leadership of government agencies saddled with coordination of 
stakeholders involved in HIV program in Nigeria usually have very short tenure to 
bring about sustainable change even if they come with great ideas. They are often 
replaced before such ideas see the light of the day and then we start the cycle all 
over again.” – Civil Society KI (#06). 
This lack of stability in the leadership of government agencies responsible for HIV 
program implementation in Nigeria affects effective coordination and timely implementation of 
policies. 
Weak healthcare delivery system was also identified as a challenge of the HIV 
treatment program in Nigeria. As a component of the healthcare delivery system, the HIV 
treatment program is affected by the challenges faced by the entire healthcare delivery system. 
While a lack of stability of leadership highlighted above is among the weaknesses of the 
healthcare delivery services in Nigeria, key informants identified additional weaknesses in the 
system. These include poor funding, which results in lack of adequate infrastructural support 
such as use of applicable modern technology that can help to improve service delivery. Other 
weaknesses include high out-of-pocket spending on healthcare, poor data management and 
poor supply management of healthcare commodities. Nigeria lacks accurate and reliable data to 
guide decisions by government and key players. This makes program implementation very 
difficult and costly as new systems had to be put in place for the HIV program using donor 
funds. Key informants highlighted that health system weaknesses are responsible for the 
dependence of a large proportion of Nigerians on the poorly regulated private sector health 
system despite there being more public sector healthcare facilities than private facilities. A key 
informant from a donor agency reiterated that that these weakness in the healthcare system 
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were responsible for the need to create a vertical system for the HIV program in order to quickly 
arrest the growing incidence of HIV in Nigeria as the existing healthcare system could not 
address the challenge.  
“At the time the donors started supporting HIV activities in Nigeria, it would have 
been very difficult to strengthen the healthcare system in Nigeria to a level where 
quality HIV programming would be delivered. No one had the time and financial 
resources to achieve strengthening of the entire health system at that time. Look 
at things now, despite huge investments, the healthcare system is not where it 
should be. For example, the system does not have in place an electronic system 
to trace, monitor patients and the performance of the program. These are 
required to demonstrate performance to the donor, and we had to establish this 
vertical system to create visibility into how donor funds are spent” – Donor 
Agency KI (#11) 
The healthcare system in Nigeria is incapable of delivering a sustainable and cost-
effective HIV program. The identified weaknesses will always be a justification for a vertically 
implemented HIV treatment program, an approach that has been identified to be unsustainable.  
All key informants converged on the opinion that the limited role by government at the 
state and local government levels is another challenge of the HIV program in Nigeria. Health 
care services, including HIV treatment services, are the responsibility of government at the 
federal, state, and local government levels. This means governments at all levels have roles to 
plan in funding and implementing of HIV treatment services. While government at the federal 
level plays a huge role in funding, policy development and implementation, not so much is being 
done by the governments of the 36 states and Federal Capital Territory (FCT) as well as the 
774 local government areas (LGAs). Some respondents clarified that some state governments 
are doing better than the others, and that lower-level governments need to do more. According 
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to an HIV program Manager, KI#7) while all the states have the State Agency for the Control of 
AIDS (SACA) with the responsibility of overseeing the implementation of HIV activities at the 
state level, many of these agencies play only a limited role in HIV treatment services, leaving a 
substantial role the federal government and development partners.  
“It may interest you to know that those state agencies for the control of AIDS, 
they may appear on paper that they have been established but they are not 
supported with funding so most of their budgets or their work plans remain 
unimplemented across the states and the same thing happens at the local 
government” – HIV Program Manager (KI #7) 
Governments at lower levels often focus on HIV prevention activities, such as testing 
and counselling to identify new cases of HIV infection; however, they may lack a plan to initiate 
and keep patients on treatment. In other states, there is rivalry between the SACA and the State 
Ministry of Health (SMOH). This cold war often limits collaboration for effective HIV program 
implementation among government agencies at the state level. In states where such cold war 
does not exist, the state government agencies are poorly funded and are therefore unable to 
bring improvements to the program. 
“Until a few months ago, local government did not have any autonomy in the 
management of their resources, how do you expect such level of government to 
play a role in provision of HIV treatment program if they do not have access to 
funds” – Government Agency (KI #3). 
This lack of funding and active participation by governments at the state and local 
government levels create huge limitations in the effective implementation of HIV treatment 
programs in Nigeria. The program is not sustainable through reliance solely on the federal 
government while lower levels of government remain passive. 
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While key informants agreed that government at different levels are not doing enough, a 
key reason suggested by several of the informants was the problem of poor communication of 
the burden and needs of the HIV program to political leaders. The country has several 
challenges, including infrastructural needs, high level of poverty, security, unemployment, 
dwindling national income among several others. Political leaders at various levels of 
government are not receiving appropriate and consistent information on the challenges of the 
program including required policy changes to achieve desired results. In addition, there are very 
few lobbyists and champions of the HIV program in Nigeria and their voices are often not loud 
enough. According to a key informant from the donor agencies: 
“The information and messaging are not coming out very clearly to key decision 
makers at the highest level of government such as the president and state 
governors. We need to do more to get their attention” – Donor Agency (KI #4) 
This poor communication of the challenges of HIV treatment program in Nigeria does not 
allow government at all levels to appreciate the enormity of the problem and are therefore not 
giving the program the needed attention. 
Another key informant involved in implementation of the HIV program (KI#18) noted that 
even when information reaches decisionmakers, such information is often not presented in a 
form to enable leaders to appreciate the urgency and the need to act. Therefore, they often 
make commitments but are slow to fulfil such commitments or are never fulfilled. In situations 
where they act promptly, it is usually inadequate to bring a meaningful change. 
Stigmatization and discrimination of people living with HIV is still a challenge to HIV 
treatment services in Nigeria. Despite huge efforts by donors and other key stakeholders to 
create awareness and correct myths and misconceptions around HIV, stigma and discrimination 
are still widespread globally, including in Nigeria. People living with HIV experience stigma in 
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the community, workplace and at healthcare delivery service points. These judgmental attitudes 
affect the health seeking behaviors of patients including seeking for treatment for HIV. 
According to two key informants from the network of people living with HIV: 
 “[W]e still experience stigma from healthcare providers and some of the 
community and political leaders. These people believe that HIV infection is a 
punishment for immoral behaviors and such people should not be support in any 
way” – Patient KI (#12) 
“[A]part from stigma that HIV is for people who are promiscuous and Nigerian 
claims to be a religious country; everybody in Nigeria belongs to one of the two 
religions and so you can understand why the stigma index is very high and why 
that makes those in power more judgmental towards allocating resources to the 
program and that might be responsible for why money is not being allocated to it, 
because people feel that it's a judgment, it's God's judgment on those infected” – 
Patient KI (#9) 
Patients who receive treatment for HIV continue to experience stigma and discrimination 
especially at healthcare delivery points.  This discourages current and future patients from 
seeking treatment at public healthcare facilities, which in turn motivates the need for vertical 
programs separate from existing healthcare facilities to address the needs of HIV patients.  
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Table 17: Key Findings on Current Challenges of HIV Treatment Services in Nigeria 
Key findings  
• Lack of stability of leadership of government agencies 
• Weak healthcare delivery system 
o Poor funding 
o Inadequate infrastructure 
o High out of pocket expenditure 
o Poor data management 
o Poor supply management of health commodities 
• Limited roles of government below federal level 
• Poor communication of the burden of HIV to political leaders 
• Persistent stigma and discrimination of patients 
 
Challenges and Possible Solutions to Sustainability of Funding for HIV Treatment 
Services in Nigeria 
According to the majority of key informants, one of the key challenges of sustaining 
financing for HIV treatment in Nigeria is over-dependence on donor funding for the program. 
While all the informants agreed that donor funding has significantly improved access to HIV 
treatment services in the country, current and past governments have left a large proportion of 
the funding to be provided by foreign donors. With dwindling donor funding for healthcare 
services, key informants agreed that this is the time for government of Nigeria to take up the 
responsibility of leading the provision of program funding. Unlike patient informants who think 
that Nigeria is a rich oil exporting nation and should be able to fund free HIV treatment services 
for all Nigerians who require the service, most of the key informants including policy makers and 
program managers highlighted the constraints of government to fund universal free HIV 
treatment in Nigeria. However, all the key informants agreed that government should utilize 
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existing opportunities to gradually increase its share of funding for the program. According to 
one of the informants from the HIV implementing organizations, this will require interventions 
such as increasing budget allocation for the program, in addition to prompt release of the funds 
for program implementation. In addition, government needs to ensure all other funding and non-
funding commitments to the program are fulfilled. This will help empower the program to begin 
to wean itself of donor funding and to reject unfavorable conditions sometimes imposed by 
foreign donors. 
Patient respondents, on the other hand, believe that apathy on the part of government 
for HIV treatment services is responsible for the dependence on donor funding for the 
program. According to one patient informant:  
“[T]he government is not willing to look after its people, and this is the reason 
why the donors have to do virtually everything around HIV funding in Nigeria. 
Government has not seen HIV treatment services as priority as the pollical will is 
lacking.” – Patient Network (KI #22). 
This perception of a lack of strong political will and commitment to HIV treatment 
services by the government of Nigeria is a major challenge to overcoming over reliance on 
donor funding for the program. 
Another challenge to sustainability of funding is that the HIV program has always been 
considered as a “special program.” This unhelpful status and segregation of the program 
often leads to high cost of program implementation. While informants agreed that the quality of 
service delivery for the program is high and continues to improve, a position confirmed by 
patients during the survey, non-patient key informants noted that having the HIV program 
implemented as a vertical program rather than as part of an integrated healthcare delivery 
services creates unnecessary costs, waste and exaggerated patient expectations.  This 
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includes requests for free treatment services for all patients. Most program managers and policy 
makers interviewed cited examples of the creation of separate laboratory units, pharmacy and 
consulting units for people living with HIV. They confirmed that these separate units often 
require additional personnel to manage rather than having HIV treatment services integrated as 
part of other services provided by the clinic or hospital.  
“At a point, government and donors were building or renovating buildings solely 
for the provision of HIV treatment services rather than expanding existing 
structure to accommodate HIV treatment services and to have overall high -
quality healthcare services irrespective of the condition being treated” –HIV 
Program Manager (KI #18).   
A program manager (KI #7) further highlighted that aside making HIV treatment services 
less cost effective due to its “special status,” it also leads to inadvertently stigmatizing patients 
as additional costs are expended by the program. 
“So much mystery and special status is put around the HIV program and these 
make the program complicated. This results in higher cost of providing similar 
services in the HIV clinic compared to other clinics within the same hospital. We 
need to demystify HIV treatment service delivery as part of efforts to make it 
sustainable ... if we continue to treat HIV as a separate program, sustaining the 
funding will continue to be a challenge” – HIV Program Manager (KI #7). 
“Sentimental or emotional attachment that often goes with HIV program in which some 
people will continue to “blackmail” government into sticking to status quo even when there 
are possible things that can be done to improve the system, so when these emotional 
things are attached to decision making, government in a bid to be responsive to the needs 
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of the populace, often is hesitant to make some of these pronouncements and make some 
of these difficult changes.” – Government Agency (KI # 1) 
While HIV treatment services in Nigeria require adequate attention, ascribing a special 
status to the program creates bigger challenges rather than addressing existing ones. 
Until recently, the private sector was left out of activities around HIV treatment in 
Nigeria. While private hospitals and clinics provide HIV treatment services just as they do for 
other health conditions, private sector activities are poorly regulated. In addition, there are huge 
funding opportunities within the private sector which remained untapped. Like the public sector, 
the private sector has advantages in providing HIV treatment services. However, weak 
collaboration with the public sector has resulted in the inability of the country to maximize the 
comparative advantage of the private sector around the provision of HIV treatment services. 
The Nigerian Business Coalition Against AIDS (NIBUCCA) was created to galvanize private 
sector resources and technical expertise towards addressing HIV challenges in Nigeria. 
However, this has not yielded expected results due to weak partnership within the private sector 
and with the public sector. The private sector remains fragmented with limited impact on the HIV 
program in Nigeria. One HIV program manager cited the example of the education trust funds to 
which the private sector contributes financially for the development of the education sector.  
This individual highlighted that such a trust fund is not available for HIV or the entire health 
sector. Another key informant from the network of people living with HIV cited examples of lack 
of engagement of not-for-profit organizations and foundations which can help with funding and 
advocacy to key political leaders to bring issues of HIV to the forefront of discussions. 
“[T]he not-for-profits, the foundations, they've not actually pulled their weight. We 
have not gotten the right incentives to get them engaged as they should be. 
We've got NEBUCAA but this is just an association of blue-chip companies that 
have been enlightened to initiate HIV response in their own place, but they are 
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yet to look outward into the national response and make endearing 
contributions.” – Patient (KI #27) 
The lack of partnership and active participation of the private sector in HIV programming 
in Nigeria is a major challenge. The public sector cannot solve all the problems alone. There are 
huge human and financial resources that can be tapped from the private sector for 
strengthening the program in Nigeria, however this is not being fully utilized at this time.  
Out of pocket expenditure by patients has remained a challenge around funding for 
HIV treatment services in Nigeria. Despite funding from donors and the government of Nigeria 
at designated healthcare facilities across the states of Nigeria, patients are still required to pay 
out of pocket for various HIV related services due to lack of adequate resources. Therefore, it 
would be difficult for the donors and government to completely stop out of pocket payment for 
some components of HIV treatment services if gaps in funding to cover some operational costs 
incurred by the healthcare facilities are not met through other funding mechanisms. According to 
civil society key informants: 
 “Health facilities need to seek ways to cover these operational costs if user fees 
are eliminated, if not filled, the quality of service provided at the health facilities 
will be impacted”. – Civil Society (KI# 28) 
“Although some of the out-of-pocket payments are allowable fees, others are 
informal, but they pose significant financial burden on a lot of patients, yet these 
healthcare facilities cannot do without these payments as the quality of HIV 
treatment services will drop.” – Civil Society (KI#16) 
The inadequate funding for certain operational costs of healthcare delivery facilities has 
been the reason for out-of-pocket payments required from patients receiving free HIV treatment 
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services. Such payments need to be eliminated as some hospitals and healthcare workers hide 
under this guise to charge other informal fees which put additional burden on the patients. 
The challenge of out-of-pocket expenditures is complicated by the absence of an 
effective health insurance scheme in the country. Apart from low level of enrolment, there is 
reluctance among existing public and private health insurance schemes to cover HIV treatment 
services. In addition, recent data from the government of Nigeria indicate that about 76% of 
people living with HIV are employees in the informal sector of the economy in Nigeria. The 
informal sector comprises less than 1% out of the 5% of the population with health insurance 
coverage in Nigeria. Therefore, the inability to expand access to health insurance coverage to a 
significant proportion of people in the informal sector will not be in the interest of people living 
with HIV, even if HIV treatment services are included in the package of benefits of health 
services covered. 
“Health insurance has not been able to pick up more than five percent of 
Nigerians population and a country wide study that was done by Health Policy 
plus Project is saying that seventy six percent of people who are living with HIV 
and AIDS are actually from the informal sector (poorly documented small scale 
business owners); so if we pretend that we have even put them on the health 
insurance package, they are secluded by the fact that they are not in the formal 
sector.” – Government Agency (KII #2) 
Poor health insurance coverage of Nigerians and absence of comprehensive HIV 
treatment services under benefits of health insurance packages in Nigeria is a major challenge 
to the sustainability of the HIV treatment program in Nigeria. This challenge creates health 
inequities among patients and increases the financial burden on government.  
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Table 18: Key Findings of Challenges of Sustainability of Funding for HIV Treatment Services in 
Nigeria 
Key findings 
✓ Overdependence on donor funding for the program 
✓ “Specialized” status attributed to HIV treatment services and vertical implementation. 
✓ Government apathy towards the HIV program  
✓ Weak participation by the private sector 
✓ High level out of pocket expenditure by patients 
✓ Poor implementation of the National Health Insurance scheme 
 
How can Expressed Willingness to Pay for Treatment Services by Patients and Other 
Approaches Can Be Used to Improve Funding Sustainability 
Inclusion of HIV treatment services into health insurance schemes in Nigeria is 
one of the options available to Nigeria to improve the sustainability of funding for HIV treatment 
services. There is growing interest and advocacy for the expansion of the number of Nigerians 
covered by the national health insurance scheme as a way of improving financial protection for 
the population. If HIV treatment services are included in the insurance scheme, the HIV can l 
benefit significantly. In addition to the national health insurance scheme, state governments in 
Nigeria are now setting up similar schemes at the state level as part of efforts to increase 
coverage, especially for vulnerable population groups. An effective and functional health 
insurance scheme will reduce out-of- pocket expenditures for health and would be a significant 
reform that would improve financing for HIV treatment services through premiums or 
contributions. This will also help improve the quality and efficiency of the health system. 
According to a government agency key informant: 
 “HIV treatment services should be listed under the benefit of package for 
national and state health insurance schemes, as this will provide a pool of funds 
that the HIV program can benefit from.” – Government Agency (KI #26) 
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Key informants agreed that premiums or contributions alone might not be adequate to 
sustain such a scheme. Rather, a combination of funding sources including government and 
donors subsidizing premiums for the poor should be considered for the health insurance 
scheme to become viable. 
Creation of targeted funding initiatives such as Trust funds. This approach has 
been used in the past by the government of Nigeria based on the identification of the need to 
improve funding for sectors of the country such as education and infrastructure development. 
Key informants suggested that the government should consider creating a national health trust 
fund with part of the funds allocated to the treatment of HIV. The trust fund should have similar 
modalities as the Education Trust Funds (ETF) and the Tertiary Education Trust Funds 
(TETFUND), but with the new initiative to focus on the health sector. Such a trust fund will 
address gaps in infrastructure for health as well as commodities used in HIV treatment services. 
Although one of the key informants from the government agencies (#2) pointed out that the 
creation of a trust fund could be a duplication as the National Health Act of 2014 which already 
allocates 1% of government’s consolidated revenue to fund primary health care services, the 
health insurance scheme, and vaccine provision. This informant suggested that there is no need 
for a new trust fund for health. However, proponents of the establishment of trust funds 
highlighted that the fund provided by the National Health Act is currently facing operational 
challenges, and that while HIV screening is covered, HIV treatment services are not covered.   
“For the past two and half years, stakeholders have been deliberating on how to 
launch a trust fund that would benefit HIV treatment services in Nigeria using a 
private sector initiative aside contribution from government. The HIV program can 
reach out to wealthy Nigerians and the private sector to advocate for support for 
the program. With proper management, the funds can be put in low-risk 
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investments with proceeds used to support HIV treatment services in the 
country.”– Civil Society (KI #6). 
The lack of a dedicated trust fund to support HIV treatment services in Nigeria is a 
missed opportunity to leverage domestic funding for the program. This has been explored 
successfully for education, infrastructure, and the police force. Therefore, this option should be 
considered for supporting the health system, including HIV treatment services.   
Improvement of the cost effectiveness of the HIV treatment program will free up 
resources to do more for less. Rather than implementing a vertical system of HIV treatment 
service, integrating services into the existing healthcare delivery system will reduce the overall 
program cost, and minimize waste and duplication. Key informants from government agencies 
(#1, #3 and #26) and HIV program managers (#7, #13 and #18) suggested that the 
decentralization of HIV treatment services will improve service acceptability, and referral, and 
ensure overall lowering of cost of providing services.  
“There are existing structures in the health system, what we need to do is to 
strengthen these structures and let them work in an integrated manner and this 
will not require much of the new funding unlike if we maintain a vertical system 
for HIV.” – Government Agency (KI #26) 
In addition, key informants listed above believe that decentralization would provide the 
opportunity to share infrastructure and personnel involved in service monitoring, information 
sharing, record keeping, supply chain management system, and maintenance of network of 
laboratories.  
However, key informants from NEPWAN opposed this approach. The opposition stems 
from their claim that such integration could increase stigmatization and discrimination of people 
living with HIV. 
108 
“There could be accidental disclosure of the HIV status of patients” – Network of 
patients (KI #22).  
Therefore, efforts must be put in place to strengthen the capacity of all healthcare 
providers to enhance privacy and confidentiality of patient information before such integration 
could benefit HIV patients.  
Another way to improve funding for HIV treatment services in Nigeria is through the 
encouragement of patients to contribute towards their treatment. While most of the key 
informants were surprised that I found in my study that there is a large proportion of patients 
(90%) who expressed willingness to pay for HIV treatment services in Nigeria, they expressed 
caution in planning based on the findings because willingness to pay for services may not be 
the same as capacity to pay. Key informants suggested that some of the ways to encourage 
patients to contribute to program funding include health insurance premiums (as stated earlier), 
so that patients’ overall healthcare needs could be met without creating a financial burden to the 
patients. In addition, the quality of services must be very high and the premium or contribution 
must be affordable and equitable. The argument in support of the need to encourage patients to 
contribute to HIV treatment services is that, if other patients pay for other health conditions 
including treatment of other infectious diseases, HIV treatment services should not be an 
exception. 
“It is an HIV patient that suffers from malaria, they can seek treatment and buy 
their malaria medicines so why can't they buy HIV medicines? It's the same HIV 
patients that are hypertensive, they can go and buy the antihypertensive 
medicines, why can't they do the same for HIV? So, encouraging patients to pay 
for some of these services would go a long way in mobilizing additional financial 
resources especially from those that can afford to pay for them.” – Government 
Agency (KI #1) 
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While not all the patients will be able to pay for HIV treatment services, it is important 
that the program identifies patients who are genuinely unable to pay for treatment and provided 
with access to treatment while others should be encouraged to either pay a subsidized or full 
cost of HIV treatment services.  
“So, when a patient can afford the cost of treatment, we should make it clear that 
it's no longer free; there is no free lunch in Freetown, people should be able to 
contribute, no matter how little to their care. We should engage them and carry 
them along with the decision, look, somebody is providing drugs, test kits are 
available, these laboratory tests we cannot go beyond this and this. Can you pay 
for this? While somebody pays for this for you… So that there would be co-
payment and that will alleviate the cost borne by the clients or the patient who 
are on ARVs.” – Government Agency (KI #20) 
An HIV Program Manager key informant (#13) highlighted that a likely challenge to the 
segmentation of patients based on willingness/capacity to pay for HIV treatment services is 
the lack of reliable data to guide this process. The informant also suggested that there is a need 
for effective engagement of patients to ensure they understand the reasons for this approach 
and the importance of sustainable funding for the program.  
“Rather than free treatment for HIV, I prefer that the government and donors 
support people living with HIV with income generating activities that would 
empower us to earn good income to pay for required treatment services and to 
live a comfortable life.” - Patient survey respondent (#234) 
Another government agency key informant (#3) highlighted that once patients are 
encouraged to contribute to the cost of their treatment for HIV, aside the increased funding, this 
approach would likely improve effective utilization of services through diminished “frivolous” 
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service consumption and helps limit the practice where patients access HIV treatment services 
at multiple locations during the same period. However, to prevent inequitable payment for 
services and depriving the very poor from getting treatment, the program must determine how to 
achieve desired results.  
Promotion of local manufacture of antiretroviral drugs and other commodities 
used in HIV treatment will benefit the HIV treatment program. Antiretroviral (ARV) drugs and 
diagnostics form a significant component of the cost of providing HIV treatment services. ARVs 
and diagnostics that are provided free of charge to patients in Nigeria are purchased by donors 
through centralized negotiations and pooled procurement from international manufacturers 
(WHO 2020). Considering that about 1.4 million patients are currently receiving free treatment 
services every month in Nigeria, most key informants advocated for local manufacture of these 
commodities rather than relying on procurement from foreign manufacturers. The argument for 
this is that considering the large volume of commodities that are used monthly, the unit cost of 
producing these commodities locally will be lower than the unit cost of procuring the 
commodities from foreign markets. Although there were no data cited by key informants to 
support this cost analysis aside information they received from their previous engagements with 
local manufacturers of pharmaceuticals in Nigeria, most of the key informants agreed that this is   
a suitable approach for Nigeria. Key informants highlighted that about 11 pharmaceutical 
companies are already manufacturing ARVs in Nigeria. However, the volume being produced is 
still very low and s cost will remain high due to the low volume. Despite the low volume 
produced annually, low patronage of these companies results in the risk of expiry of the 
commodities. 
Another argument in support of the feasibility of this approach was provided by one key 
informant who highlighted that locally manufactured ARVs and other commodities would have a 
significant market in other West African neighbor countries, as other pharmaceuticals produced 
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in Nigeria are already being sold in these countries. This potentially added boost in income to 
the sector will benefit the economy of the country.  
“We have a robust manufacturing system that that can help with local production 
of some of these HIV medicines. As far back as fifteen years ago HIV medicines 
were already being manufactured in Nigeria by some local companies so this can 
help reduce the cost of treatment.” – Civil Society (KI #28) 
“[W]e must make sure that we manufacture ARVs in Nigeria because we cannot 
continue to use scarce resources to buy at a very expensive price outside of the 
country. If we are able to get that patient trust fund up and running and we have 
say $1 million dollars there, we can on our own start the conversation with 
manufacturers and say we have these funds, we are ready to buy your drugs, 
come and manufacture here in Nigeria we cannot use our own resources to be 
buying at a very expensive price outside.” – Government Agency KI #20) 
A key informant from one of the donor agencies (#17) cited the inability of local 
manufacturers to meet WHO guidelines for the manufacture of ARVs as the main reason donors 
are not willing to buy locally produced ARVs in Nigeria. According to this informant, once these 
guidelines are followed and the manufacturers are pre-qualified, donors will buy health 
commodities from local sources. This argument was opposed by other key informants (#2, #3, 
#26) who suggested that the stringent guidelines were deliberately put in place to discourage 
the local manufacturers from benefiting from the potentially huge market. Irrespective of the side 
of the divide, all the key informants agreed that the government of Nigeria should provide 
support to those local manufacturers who meet and adhere to the WHO criteria and guidelines. 
These informants are of the opinion that such support should not come only from government 
but also from the donors and other sources of funding highlighted earlier. 
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Table 19: Funding Options for Improved Sustainability of HIV Treatment Services 
 Identified funding options 
1 Increased funding from government at all levels 
✓ Increased allocation to HIV program 
✓ Tax from consumption of high-volume services/commodities 
2 Donor funding for integrated health system strengthening. 
✓ US President’s Emergency Plan for AIDS Relief (PEPFAR) 
✓ Global Fund for AIDS Tuberculosis and Malaria (GFATM) 
✓ Bill and Melinda Gates Foundation (BMGF) 
✓ Others 
3 Health Insurance premium/contributions 
✓ Formal sector 
✓ Informal sector 
4 HIV/AIDS Trust funds and other private sector contributions 
✓ Philanthropy 
✓ Contributions from private foundations 
✓ Contributions by multinational companies and business 
community 
5 Support for local manufacture of ARVs and other HIV related 
commodities 
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CHAPTER 6: DISCUSSION 
This section reviews the results from the mixed method study and relates the findings to 
the research questions and aims of the dissertation. The main objective of the research was to 
help inform the development of a sustainable financing approach to increase access to HIV 
treatment services in Nigeria. The study gathered opinions of people living with HIV, policy 
makers, HIV program managers and senior officials from the Ministry of Health, HIV Control 
Program, donor organizations, HIV intervention implementing organizations and civil society 
groups on how funding for HIV treatment services could be made more sustainable using a 
combination of funding mechanisms. 
The mixed method study design helped to better understand the funding situation for 
HIV treatment services in Nigeria, existing challenges, and opportunities for the country to 
achieve sustainable funding for the program. In addition, the mixed method approach helped 
explain and deepen the meaning of some of the findings from the cross-sectional survey. This 
research sought to answer three questions: 1) What proportion of people living with HIV are 
willing to pay for HIV treatment services in Nigeria. 2) What factors influence willingness to pay 
for HIV treatment services by people living with HIV/AIDS in Nigeria. 3) How can patients’ 
willingness to pay for HIV treatment services and other sources of funding be used to improve 
sustainability of funding for HIV treatment services in Nigeria? The first aim of the research was 
to determine the proportion of people with HIV infection who currently receive free HIV 
treatment who would be willing to pay for such services. The second aim was to obtain in-depth 
understanding of the factors that influence willingness of people living with HIV to pay for HIV 
treatment services. The third aim was to explore alternative methods of structuring funding for 
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HIV treatment program in Nigeria to inform a plan for change to improve funding 
sustainability for the program in Nigeria.   
In this chapter, the results of the mixed study are considered collectively and discussed 
in relation to each of the aims stated above and in consideration to existing literature. 
Description of Key Findings in Relation to Research Questions and Aims 
Aim 1: To Determine the Proportion of People Who Currently Receive Free HIV Treatment 
Services Who Would Be Willing to Pay for Such Services.  
Overall, 92% of patients expressed they would be willing to pay for HIV treatment 
services if free services were no longer available. The observed high proportion of patients is 
very surprising for a service that has been provided free to patients in Nigeria for over a decade. 
However, wide disparity in the amount that patients were willing to pay did not come as a 
surprise. Considering that almost all the patients reported that they were aware of the 
consequences of interrupting treatment for HIV/AIDS due either to non-adherence to ARVs or 
lack of clinical monitoring through laboratory investigations, such awareness could have 
influenced their willingness to contribute to funding their treatment. Adherence to HIV treatment 
has been identified to be very critical in optimizing patients’ response to therapy (HIV.gov. 
2020). Although long-term adherence to ART is perceived as a compromise between conflicting 
demands of everyday work (Adam, B.D, et al, 2003), almost all patients appreciated and valued 
the importance of adherence to their treatment and thus, their willingness to pay. 
The proportion of patients who were willing to pay for HIV treatment services obtained 
from this study is one of the highest ever recorded in any study conducted in Africa. Compared 
to Mbachu et al, (2018) in which about 67% of patients were willing to pay for HIV treatment 
services, findings by Nwobi et al, (2017) were similar to my findings with about 91% of patients 
willing to pay for HIV treatment services. A study conducted in Cameroun by Muko et al, (2012) 
115 
report just about 30% of patients were willing to pay for HIV treatment services just as Chirundu 
et al, (2017) reported a 66% willingness to pay for HIV treatment services in Zimbabwe.  
Despite the high proportion of patients who expressed willingness to pay for HIV 
treatment services, the amount expressed by patients varied significantly. Despite the 
willingness to pay, most patients indicated that HIV treatment should be provided free of charge 
by the government and if such provision could not be made by government of Nigeria, this 
amounts to failure of governance.  
Cunningham & Smith (2004) suggests that patients would be willing to pay a higher 
amount than the actual cost of the service if they value such health service. This may not be 
true if patients do not possess the financial capacity to pay for service even if the health service 
is perceived to be important. Despite most patients rating the quality of HIV treatment services 
to be very good, the maximum amount patients were willing to pay reduced with increasing cost 
of the service during the bidding game. Only about 20% of patients were willing to pay the 
current cost of monthly ARV services at N5000 ($12.5). With over 1.2 million patients currently 
on HIV treatment, the expression of willingness to pay the current cost of treatment by a fraction 
of the patients will potentially increase funding for HIV treatment services by a minimum of 14 
billion naira ($36 million) annually. However, as highlighted during the key informant interviews, 
an expression of willingness to pay for a health service does not necessarily translate to a 
capacity to pay. Some of the patients may not have thought through the long-term implications 
of paying to access health services for a chronic health condition. Even if expressed willingness 
to pay for the services translates to a capacity to pay, some patients may default in payments 
due to competing financial demands. Therefore, such a funding source may be unreliable due to 
inconsistency of payment by patients. A way forward to improve the reliability of this source of 
funding would be to have payments paid via insurance premium which can help pool resources 
from both healthy and sick populations with different levels of income rather than out-of-pocket 
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payment by the patients. Such a payment method will likely protect patients from financial 
hardship and ruin due to ill health (Folland S. et al, 2017). Unfortunately, over two thirds of the 
patients who expressed willingness to pay for treatment preferred payment out of pocket at the 
point of care rather than through a health insurance premium. The reason ascribed by the 
patients for this preference is their perception of a lack of transparency in the health insurance 
program in Nigeria as well as challenges of information asymmetry and poor quality of services 
experienced by those who currently have health insurance. These failures of the health 
insurance market in addition to cream skimming by health insurance providers due to their 
reluctance to cover preexisting health condition such as HIV/AIDS, limit people living with HIV in 
purchasing health insurance in Nigeria (Okpani & Abimbola, 2015). This is why out of pocket 
expenditure as a percentage of total healthcare cost in Nigeria has remained above 70% for the 
last decade (World Bank, 2020). This preference for out-of-pocket payment could also be due to 
the fact that some patients feel more comfortable with monthly payments of a lower amount to 
access HIV treatment services rather than a higher annual payment as the former limits the 
financial burden. This opinion was buttressed by the findings of this study that about 20% of 
patients who expressed willingness to pay for treatment will source the funds solely from their 
personal income while about 70% will source funds from a combination of personal income and 
support from family and friends. This finding could also be an indication of the low socio-
economic status of most patients. 
Although a significant number of patients expressed willingness to pay for HIV treatment, 
a significant proportion of these patients offered to pay an amount that was far less than the 
current cost of services. Their main reason for this decision was because they perceive the 
provision of free HIV treatment services as a social responsibility of the government of Nigeria 
and patients should never need to pay for HIV treatment. This perception is often supported by 
the argument that the failure to provide free access to HIV treatment services will negatively 
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affect patients, the caregiver, and the economy and therefore, the services must be free. This is 
because there is a loss of output and income by both the patients and caregivers as well as the 
cost of frequent hospital visits, in patient care as well as death and burial costs (Binswangner, 
H. 2003). This school of thought further argues that being HIV positive comes with stigma and 
discrimination and patients do pay more especially for transportation to get to healthcare 
centres.  Unlike patients who suffer from other chronic health conditions, most HIV patients 
choose to seek care at health facilities that are far away from where they live or work, in their 
effort to avoid stigma and discrimination. A counter argument to this is that people who suffer 
from other chronic health conditions which will require long term treatment throughout the life of 
the patient do not receive free treatment for these conditions. People with this school of thought 
argue that since other patients pay for managing these chronic diseases without reliance on free 
services, the same approach should be applied to HIV treatment services. Their position is that 
making HIV treatment services “special” is bad for the patients as this contributes to stigma.   
This issue came out strongly during the key informant interviews as respondents felt that 
handling HIV treatment services differently from other chronic diseases is responsible for the 
sense of entitlement to free treatment services (irrespective of capacity to pay) often expressed 
by people living with HIV concerning who should pay for their treatment.  
Aim 2: To Explore and Obtain In-Depth Understanding of the Factors that Influence the 
Willingness of People Living with HIV to Pay for HIV Treatment. 
This study evaluated the effects of 17 key independent variables on willingness of 
patients to pay for HIV treatment services. Employment status, changes in income and 
availability of financial support from family and friends were the key factors with statistical 
association with willingness to pay for HIV treatment services.  
The bivariate analysis indicated that five factors were strongly associated with 
willingness of patients to pay for HIV treatment services. Availability of financial support from 
family and friends had the strongest association with willingness to pay, followed by the level of 
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awareness of the benefits of early initiation of treatment by patients, increase in income, current 
income level and the employment status of the patient. These findings did not come as a 
surprise considering that four of the five identified factors are related to patients’ socio-economic 
status. These findings are consistent with findings from various studies which found that socio-
economic factors are associated with the willingness of patients to pay for healthcare services. 
Healthcare is considered a social good and the willingness to pay for such social goods are 
influenced largely by the financial capacity of patients. However, there is variation among the 
specific socio-economic factors that were associated with willingness to pay for HIV treatment 
from this study and the other studies from literature. While a number of studies (Bertozzi et al, 
2006; Onwujekwe et al, 2010; Onwujekwe et al, 2013, Guimaraes et al, 2009) have previously 
revealed that willingness to pay for healthcare services was associated with level of education, 
marital status, distance from home to clinic and area where the patient lives, findings from this 
study did not identify any statistically significant association with these factors. Rather, this study 
found patients who had education above secondary school level were more likely to be willing to 
pay a higher amount for HIV treatment compared to those who had education below secondary 
school level, but this was not statistically significant. A possible reason for this observation could 
be the ability of individuals who had post-secondary school education to attract higher paying 
jobs. This could also be due to the higher literacy level of such individuals which results in 
greater understanding of the funding challenges of the HIV program. 
Family and friends play a significant role in providing psychological, emotional, and 
financial support to patients undergoing long term treatment (Bellou & Gerogiani, 2020). This is 
a very common phenomenon in Nigeria and most African countries where people live communal 
life and rely on family and friends for support. Support from family and friends could be in terms 
of actual payment for healthcare services, economic empowerment in terms of providing job 
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opportunities. In all, such support helps improve the economic status of patients temporarily or 
permanently and probably leads to increased willingness to pay for HIV treatment services. 
The role of employment status, level of income, changes in income and availability of 
financial support in the willingness and capacity of an individual to pay for healthcare services 
cannot be over-emphasized. This is because there are competing needs for limited financial 
resources and an individual would have to sacrifice payment for these competing needs to pay 
for treatment for HIV. Although about 80% of patients indicated having a source of income, the 
median income was about N28,000 ($70) per month. This value is below the national minimum 
wage in Nigeria and far less than the average monthly income of a working Nigerian which 
stands at about N85,000 ($213) (Salary explorer, 2020). This low level of income among 
patients limits the willingness of patients to pay about N5000 ($12.5) per month as this will take 
up more than 25% of the monthly income of an average patient. 
Employment status and monthly income play critical role in socio-economic status of 
patients as would be more willing to pay a higher amount for HIV treatment if they were gainfully 
employed or if they had a stable source of income. 
Therefore, the government of Nigeria and donor agencies should consider incorporating 
income generating interventions into the HIV program as part of efforts to empower patients to 
pay for HIV treatment. 
Patients with a higher level of awareness of the benefits of early initiation of treatment for 
HIV after diagnosis expressed higher willingness to pay for such treatment services. This could 
be because having access to information on the importance of prompt initiation on treatment 
helps adherence to treatment as this has been found to be critical to maintaining viral 
suppression in patients. Therefore, patients with higher levels of awareness are more likely to 
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explore all opportunities to ensure they initiate and remain on treatment even if the services are 
no longer be provided free of charge. 
The perception of the cost of a service or product is likely to be one of the determinants 
of the willingness to pay for such service or product. A decision on willingness to pay is likely 
easier if the potential payer is aware of the actual cost. Findings from this study indicated that 
about 80% of patients perceive the cost of treatment to be higher than what the actual estimated 
cost is in the public healthcare facilities. Their perception of the cost was highly exaggerated. 
This wrong perception is not unexpected as the cost of ARVs and laboratory tests provided 
outside of public hospitals are significantly higher than in the public sector. This is because HIV 
commodities used in the public sector are pooled procured directly from manufacturers thereby 
lowering the cost. In addition, the services are not for profit and the personnel cost for the 
services providers are not usually included in the estimation of cost of treatment in the public 
sector. Unlike in the public sector where services are provided for profit, the cost in the public 
sector is estimated just for cost recovery. 
While it would be correct to say willingness to pay for HIV treatment would likely 
increase if the current cost of treatment is reduced, this study did not find any association 
between patients’ perception of the cost of treatment and willingness to pay for HIV treatment. 
This finding contradicts Muko et al, (2012) which identified the cost of ARVs as a major driver of 
willingness to pay for HIV treatment services. A possible reason for this difference is that 
compared to about eight years ago when the Muko et al. study was conducted, the cost of 
ARVs has reduced significantly in the last fifteen years with as much as a 60% reduction in cost 
of generic first line ARVs (R4D.org 2019). Therefore, the cost of ARVs may no longer be a 
major driver of willingness to pay. However, I believe that patients would continue to benefit 
from further reduction in cost of ARVs. 
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Aim 3: To Explore Alternative Methods for Structuring Funding for HIV Treatment 
Services in Nigeria. 
As shown in Figure 10, key informants identified four broad types of funding sources 
that should be explored in structuring funding for HIV treatment services to enhance 
sustainability in Nigeria. 
 
Figure 10: Possible Funding Options for HIV treatment services 
Facilitators and Barriers to Effective Implementation of Identified Solutions  
During key informant interviews, some factors were identified as potential facilitators and 
barriers to the implementation of the solutions proffered by key stakeholders. Some of the 
factors include: 
Avoid Sentiments Attached to Provision of HIV Treatment Services 
There is a need for key stakeholders and decision makers to overcome the sentiments 
that promote resistance to desired change within the HIV program in Nigeria. There is no doubt 
that there is a need for changes in the design, funding, and implementation of HIV treatment 
services in Nigeria. However, these changes could be overshadowed by these sentiments and 
emotional attachments by key stakeholders. There is a wide gap between what is feasible and 
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what is desired by stakeholders around HIV treatment services as the political and economic 
environment of the program plays a significant role in these decisions. For example, there is the 
tendency by certain key stakeholders to insist that government should maintain the status quo 
of universal free HIV treatment services in Nigeria even if the donor funding and government 
income are dwindling. The current economic realities indicate that this is not sustainable. About 
four years ago, the current donors to the HIV treatment services decided to discontinue funding 
for certain laboratory tests (e.g., chemistry and hematology tests) provided as part of the 
package of free HIV treatment services. This was an economic decision guided by research 
findings to improve cost-effectiveness and reduce waste in the program. Decisions such as this 
would need to be taken to ensure the program becomes more sustainable. 
Explore Willingness of Patients to Contribute to HIV Treatment Services 
Findings from this study and several other studies (Mbachu et al., (2018); Muko et al., 
(2004); Chirundu et al., (2017), Nwobi et al., (2017) and Gupta (2007) indicated a proportion of 
patients are willing to contribute to the cost of their treatment. While it has been established that 
willingness to pay for treatment is not the same as the capacity to pay, these findings provide an 
opportunity for the HIV program in Nigeria to look into the opportunities provided by such 
willingness to improve funding for the program. Some patients are already paying for HIV 
treatment services in the private sector; therefore, adequate systems should be put in place to 
optimize such willingness through proper engagement with patients and key stakeholders to 
ensure their commitment to sustainability of funding and to eliminate exploitation by the private 
sector service delivery providers. In addition, efforts to improve the socio-economic status of the 
population will enhance willingness and capacity to fulfil such commitments.  
Studies have shown that payment of user fees could be a financial barrier to people 
seeking or remaining on treatment for HIV (Roberts et al, 2018, Onwujekwe et al. (2016)). 
These fees can potentially impact health seeking behavior of people living with HIV. Such 
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inequitable out of pocket payment for HIV treatment services will have greater impact on 
socioeconomically vulnerable patients. This could be in terms of missed appointments or poor 
adherence to medication. Although donors and federal government agencies have always 
opposed user fees, there is evidence that health facilities continue to charge these fees to fill 
existing gaps in funding to provide services to patients (Onwujekwe et al. 2016). There is a need 
for the creation of an effective system that will eliminate or minimize informal out-of-pocket costs 
incurred by patients while receiving HIV treatment.  
Extend Anti-Corruption Drive of Government to HIV Treatment Program to Minimize 
Fraud 
Current funding for the HIV program in Nigeria from outside of government is managed 
by third party organizations called implementing nonprofit organizations. The use of these 
organizations rather than government agencies is due to the lack of transparency in government 
systems and documented cases of fraud committed from previous programs managed by 
government agencies. However, this desired accountability and transparency by donor agencies 
comes at a higher cost of implementation and administration of the program. Fraud in 
healthcare is very difficult to eliminate as studies suggest that about 6% health expenditure is 
lost to fraud globally (WHO 2016), yet one of the cardinal goals of the current federal 
government of Nigeria is to significantly reduce corruption in all spheres of the government and 
improve financial accountability. This agenda provides an opportunity for government 
anticorruption agencies to shed the spotlight on the agencies involved in the coordination of HIV 
treatment services as well as the entire health system. Such in-house “cleaning” will build 
confidence of international and local donor agencies and individuals to trust government 
agencies with their funds. In addition, effective monitoring of program implementation and 
ensuring transparency with the application of information technological systems as much as 
possible will help maximize the use of funds with improved outcomes. 
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Explore Opportunities from Dwindling Donor Funding 
The dwindling funds from international donors for developmental purposes is often seen 
as a challenge to the effectiveness and sustainability of the program, especially in high donor-
dependent countries (Arhin, 2016). However, this situation also provides an opportunity to 
reverse high donor dependence by looking inwards to mobilize alternative or complementary 
domestic funding. The identification and documentation of such alternative/complementary 
funding sources is one of the aims of this dissertation. Key informant interviews highlighted 
some of these sources as captured in the Results section (Increased allocation from 
government, introduction of consumption tax; Health insurance premium/contribution, and 
introduction of trust funds to be contributed by domestic private individuals and corporations to 
complement existing donor funding). It is inevitable that donor funding for the HIV program in 
Nigeria and several other countries will eventually end, and the onus will be on the government 
of Nigeria to fill the funding gap to preserve the gains made in HIV viral suppression rates in the 
past few decades. Therefore, the government should seize the opportunity to act on the early 
warning signs through innovative thinking and intensify efforts to harness potential alternative 
funding sources such as a strengthened health insurance system, increased government 
funding, securing funding from corporate organizations and private individuals in Nigeria. There 
is the need to commence the implementation of the existing regulatory framework and provision 
of financial incentives to drive domestic resource mobilization and cost reduction measures 
highlighted by key informants. 
In addition, dwindling donor funding presents great opportunities for the HIV program 
under domestic funding to integrate the program into the existing healthcare delivery system. 
This proposal from key informants is supported by Price et al, (2009), which suggests that such 
integration will improve staff capacity as a result of in-service training opportunities beyond HIV 
and a creation of a mutually beneficial interaction between HIV and non-HIV care services. 
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Explore Current Momentum Around Health Insurance Schemes in Nigeria 
As part of efforts to bridge the gap in health insurance coverage, about 20 states in 
Nigeria are at different levels of implementing a state health insurance scheme. The state 
governments have committed to dedicate a percentage of the state consolidated revenue to 
fund the premium for the poor and vulnerable in the state. In addition, these states have defined 
the benefits packages for the scheme, and these vary between states. Although most states still 
do not cover comprehensive HIV treatment services due to the assumption that this is already 
covered by donor funding under the national HIV program, and the fact that HIV infection as a 
pre-existing condition will increase the financial burden on the scheme. The current momentum 
around health insurance in Nigeria provides an opportunity for engagements to ensure all the 
benefit packages being developed cover HIV treatment services. In addition, the usual 
challenge of failure to release the full committed funds by government should be avoided. In 
states where some components of HIV treatment services are already covered by the benefit 
package, actions should be taken to work with the donors and the implementing organizations 
to avoid duplication of services. Instead, the possibility of using such donor funds to broaden the 
funding available for the scheme should be considered.  
While this approach may be a feasible option to fund HIV treatment services in Nigeria, 
the implementation of such a social health insurance program may be difficult in a country with a 
stagnant economy and very large proportion of people who work in the informal sector 
(Ogundeyi et al, 2019). This could be due to difficulty in collecting contributions from the 
informal sector which in turn could lead to insufficient funds (Santana V, 2015). Therefore, the 
design and implementation of the insurance scheme must be considered critically to avoid 
failure of the scheme. 
The effective administration of the insurance scheme should also be a priority of the 
government at all levels. The administrative cost should be as low as possible with funding 
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allocated for healthcare service delivery taking a significant portion of the revenues.  This 
optimal resource allocation is critical for the success and efficiency of the scheme. In addition, 
effective monitoring system should be put in place to ensure quality of service delivery and to 
prevent abuse of the scheme by beneficiaries and healthcare service providers. 
Policy and Programmatic Considerations to Achieve Desired Change of Improved 
Funding for HIV Treatment Services  
In the last four decades, Nigeria has developed various health policies aimed at 
improving the health system in the country. The first comprehensive national health policy was 
developed in 1988, and these policies have resulted in some progress in the performance of the 
system, especially around key indicators for maternal, child and major communicable diseases 
including HIV/AIDS (FMOH, 2016). Some of the policies highlighted by key informants included: 
National Policy on Health (2016), National Health Act (2014), National Strategic Health Plan II 
(2018-2022), National Policy on HIV/AIDS (2009), National HIV and AIDS Strategic Framework 
(2019- 2021). These policies were formulated, and the implementation coordinated at the 
national level by the Federal Ministry of Health (FMOH) under the National AIDS and Sexually 
Transmitted Infections Control Program (NASCP) and the National Agency for Control of AIDS 
(NACA) and domesticated by the 36 states in Nigeria and the Federal Capital Territory, (FCT). 
Therefore, key informants were unanimous that while there is a need to review some of the 
existing policies around the health system including those around HIV treatment services in 
Nigeria, the major challenge is the poor implementation of existing policies. As shown in Table 
20, key informants highlighted some of the questions that must be addressed before the journey 




Table 20: Key Questions to Guide Policy and Implementation Direction 
 Program and policy questions to improve funding sustainability of HIV 
treatment services in Nigeria 
1. How can we improve the contributions of government at the federal, state and 
local government levels to support coordination and funding of HIV treatment 
services in Nigeria? 
2. What policies contribute to the current challenges in sustaining the funding for HIV 
treatment services in Nigeria? 
3. What would be required to improve the number of people covered by health 
insurance in Nigeria? 
4. What would be required to ensure HIV treatment services are covered by health 
insurance policies in Nigeria? 
5. What does the country need to do to promote the integration of HIV care and 
treatment into the health sector? 
6. How can the private sector participation in HIV treatment services be improved? 
7. What support is required to promote local manufacture of HIV commodities? 
8. What income generating activities can be implemented for economic 
empowerment of people living with HIV? 
 
The answers to these questions will be provided in the plan for change to avoid redundancies. 
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CHAPTER 7: PLAN FOR CHANGE 
The findings from this study highlighted key challenges and potential solutions and 
opportunities that could be utilized to improve sustainability of funding for HIV treatment 
services in Nigeria. A key requirement for sustainability is for the health system to transition to 
increased domestic funding for the HIV treatment program. Therefore, key approaches will 
require a reversal of the huge donor dependence on funding for the program. Multiple questions 
were raised during the study as well as potential solutions.  If well implemented, these solutions 
could facilitate sustainability of HIV treatment services in Nigeria. The questions included: 
1. How can Nigeria improve the contributions of government at federal, state, and local 
government levels to support coordination and funding of HIV treatment services in 
Nigeria? 
2. What policies contribute to the current challenges in sustaining funding for HIV treatment 
services in Nigeria and need to be changed? 
3. What would be required to increase the number of people covered by health insurance 
schemes in Nigeria? 
4. What would be required to ensure comprehensive HIV treatment services are covered 
by health insurance policies in Nigeria? 
5. What does the country need to do to promote the integration of HIV care and treatment 
into other healthcare delivery services? 
6. How can Nigeria improve private sector participation in and funding for HIV treatment 
services? 
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7. What support is required to promote local manufacture of quality and affordable HIV 
commodities in Nigeria? 
8.  What income generating activities can be implemented to promote economic 
empowerment of people living with HIV? 
Employing the two approaches below, this plan for change attempts to provide answers 
to these questions based on findings from this study. 
a. A leadership model to bring about the desired change. 
b. Lewin’s change management model, to be used to provide actionable recommendations 
to achieve desired changes. 
A. Leadership Model 
Considering the size, complexity and the large number of key stakeholders involved in 
the HIV program in Nigeria, great efforts must be put into consensus building among 
stakeholders at all levels of government as well as non-government stakeholders. In addition, 
the leadership of government agencies at the federal level alone may not be able to drive the 
desired change. There is a need for shared leadership through effective distribution of leading 
and learning opportunities (ACSA, 2020) among change implementation team members. This 
will require the leadership of relevant government agencies to harness talents within and 
outside of government agencies to build a strong coalition for change implementation. 
According to Kotter (1997), one of the general lessons from successfully executed change in 
large organizations is that the change process occurs in phases and usually requires a 
considerable length of time. The leadership and the implementation team that will drive such 
change must have the following characteristics: 
• The team must envision a future where HIV treatment services in Nigeria become 
sustainable. This dissertation has identified steps the program must take to achieve 
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desired changes. The team must demonstrate the capacity to identify the need for the 
modification of strategy when the need arises. 
• Effective communication is required to achieve change. This starts from conception 
of the change and creating vision and providing justification for the change. It is also 
important to secure buy-in and to build a coalition for the change process. The 
importance of effective communication will be highlighted further in this chapter. 
• Change usually requires champions to drive the process and bring the discussion 
to the front burner of discussions. However, these champions must have behind 
them, a strong coalition to jointly overcome resistance and change the status quo. The 
coalition must include individuals and organizations that can wield power, have interest 
in the outcome of planned change, and can influence actions. In addition to having foot 
soldiers with the appropriate mix of skills on the implementation team, the coalition must 
include senior officials of key organizations with the capacity to make decisions on 
behalf of the organizations when necessary. 
• Great understanding of key internal and external stakeholders, their interests, 
level of influence and power: A stakeholder mapping and analysis should be 
conducted to identify where each stakeholder currently stands in relation to the planned 
change (e.g., advocates, opponents, supporters, or neutral stakeholders). In addition, 
the leadership working with the change implementation team must identify in specific 
terms, the expectations in terms of contributions of each stakeholder and a ranking of 
these expectations or required support in relation to the level of importance in achieving 
desired change. This analysis will create a template for effective engagement with 
stakeholders. 
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B. Change Management Model 
Kurt Lewin’s change management model (Lewin, 1947), shown in Figure 11, was 
developed following his research into group dynamics and organizational development. The 
change model is comprised of three main stages:  unfreeze, change, and refreeze. The HIV 
treatment program needs to go through these stages of change to achieve funding 
sustainability. Each stage is described below. 
 
Figure 11: Lewin's Change Management Model 
Unfreeze Stage 
This is the first stage where the current approaches to the HIV treatment program in 
Nigeria need to be reviewed and the need for change identified. Some of the actions to be taken 
at this stage include: 
1. Determination of What Needs to Change: 
Findings from this study identified major approaches, systems and processes that need 
to change. The key issue is the need for a reversal of over-dependence on donor funding for 
HIV treatment services through: 
• Determine what 
needs to change
• Secure support of 
senior management
• Create the need for 
change








• Involve people in 
the process
Change • Anchor changes into 
the culture
• Develop ways to 
sustain change





o Increased investment and funding for HIV treatment services by the government 
of Nigeria at the federal, state, and local government levels: The Federal 
government of Nigeria should significantly increase investments and funding for HIV 
treatment services. Due to the dwindling income of government, there is a need for the 
introduction of a special tax on high volume services such as telecommunication. For 
example, introduction of an annual tax about N100 ($0.25) on every mobile telephone 
user in Nigeria would result in about N19 billion (US$47 million) to support the program 
in Nigeria. Considering the modest size of this tax, is not likely to be a burden on mobile 
phone users. The large number of mobile telephone users would provide a boost in 
funding for the program. 
o In addition, the government at the state and local government levels must increase 
budgetary allocation to support HIV treatment services. To estimate funding needs for 
HIV treatment services, each state ministry of health should work with the relevant 
federal government agencies, including the National HIV/AIDS and STI Control program 
(NASCP), the National Agency for Control of AIDS (NACA), HIV implementing partners, 
the civil society for HIV in Nigeria, and networks of people living with HIV. This analysis 
should include an estimate of the funding gap and identification of potential domestic 
sources for filling these gaps.  While donor funding would still be required for several 
years, a funding sustainability plan should be developed that gradual weans the program 
off external donor funding and increases domestic funding. The section on funding 
sustainability for HIV program in the national strategic plan for HIV in Nigeria should be 
updated with comprehensive information which captures the output from the analysis of 
each of the 36 states and federal capital territory. This would be used as a blueprint to 
attract and/or generate the required domestic funding.   
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o Increase the drive for domestic funding outside of the government through 
contributions from private individuals and organizations: Effective and sustainable 
HIV treatment services require a coordinated response across all sectors. Although 
there is an existing platform for coordination and partnership between the public and 
private sectors in Nigeria through NIBUCCA, this coordination and partnership needs to 
be improved. Such improved engagement and partnership should be geared towards 
accessing resources and technical skills that are available in the private sector. The 
strengthening of the process must be driven by the public sector in collaboration with key 
private sector stakeholders. This will require expanding the membership and scope of 
activities of NIBUCCA to cover all stakeholders within the private sector. The existing 
country level coordination and implementation strategy for resource mobilization should 
be strengthened for improved performance. This should start with a mapping of 
individuals and organizations with resources that can be approached to support program 
funding. A communication and engagement strategy should be developed to guide every 
step in the interaction with the mapped individuals and organizations. Poor messaging 
during communication with decision makers and influential individuals was identified as a 
key challenge of the program; therefore, the strategy to be developed should contain 
appropriate messaging which will help highlight the burden of HIV in Nigeria and funding 
challenges. Such appropriate messaging could also help put an end to the silence and 
myths around HIV which will enable open discussion on HIV with individuals and 
organizations with the financial capacity to support the program but may be unwilling due 
to perceptions of HIV as a disease which arise from “sexual sins” and immoral 
behaviors. Once the business community and philanthropic individuals are convinced, 
they should be used to reach top level government officials, members of the upper and 
lower legislature and state legislature to bring issues around HIV treatment services to 
the front burner of discussions for actions.   
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o Utilize technical support available in the private sector: The private sector can also 
support the national HIV treatment program to operationalize affordable HIV treatment 
services outside of the public sector. There are private healthcare facilities that provide 
free HIV treatment services through support from donor agencies. While this is a good 
approach to expand access to services, all existing patients on HIV treatment services 
should be segmented based on their socio-economic status and encouraged to pay for 
services based on willingness and capacity to pay rather than universal free treatment 
services as it is currently being implemented. This total market approach to HIV 
treatment services in Nigeria will ensure a departure from universal free treatment 
services to an equitable approach that would promote sustainability. In addition, the 
private sector has comparative advantage around supply management of commodities 
due to availability of a wide distribution network. This advantage should be explored by 
the HIV program by leveraging existing distribution channels of fast-moving consumer 
goods to save huge costs currently incurred in the distribution of HIV commodities to a 
network of about 3000 health facilities in Nigeria. However, effective mechanisms must 
be put in place to maintain the integrity and storage requirements of HIV commodities. 
o Expansion of the population covered by social and private health insurance 
schemes: The study strongly supported the need to expand the population of Nigerians 
covered by health insurance as well as ensuring that comprehensive HIV treatment 
services are included in the benefits packages of health insurance plans. Expanding the 
number of Nigerians covered by health insurance can be achieved by ensuring there are 
adequate incentives for Nigerians to embrace health insurance and by protecting health 
insurance administrators from the risk of having a disproportionate number of people in 
the pool of insured with preexisting health conditions, thereby threatening companies’ 
financial viability. Health insurance providers believe there will be a need for higher 
premiums to avoid the risk of the scheme’s failure if comprehensive HIV treatment 
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services are covered. The priority at this point should be a review of the health insurance 
act to make enrolment mandatory rather than optional. There should be a repeal of the 
National Health insurance Act of 2004 and a reenactment of the new policy being 
considered by the legislature. Such combination of enabling policy and incentives for 
providers and buyers, should improve coverage of health insurance in Nigeria. 
o Inclusion of comprehensive HIV treatment services in the benefits of packages of 
health insurance in Nigeria: It is acknowledged that the premium for packages that 
cover HIV treatment services would be higher than the premium for people without pre-
existing health conditions. To address this the HIV program should work with 
stakeholders at the national and state levels to develop a workable framework to 
accommodate HIV treatment services within social and private health insurance 
schemes in Nigeria. The framework to be developed should clearly state the eligibility 
criteria, clauses to ensure privacy and confidentiality of patients are maintained, and 
procedures be established to determine and review premiums to be paid, among other 
critical issues. Wealthy individuals and organizations discussed under private sector 
participation above could be approached to adopt and pay premiums for patients who 
are unable to pay. This is currently being done successfully in some states in Nigeria 
around non-HIV related care. This support could be full or partial payment of the 
premium on behalf of patients based on the willingness and capacity of patients to pay 
the determined premium.  
o Promotion of local manufacture of ARVs and other HIV treatment-related 
commodities: Local manufacture of quality and appropriately priced ARVs and other 
HIV commodities has been identified as a potential solution to sustainability of funding 
for HIV treatment services in Nigeria. Although this comes with complexities, it is 
achievable as observed in some low- and middle-income countries. The large number of 
people living with HIV in Nigeria (about 2 million) and the implementation of the “test and 
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treat” strategy of WHO provides a great market incentive for the manufacture of ARVs in 
Nigeria, whereby companies take advantage of economies of scale. In addition, local 
production of ARVs is not new in Nigeria as a few pharmaceutical companies have been 
involved in the production of generic ARVs. This needs to be scaled up to meet the need 
of all patients receiving treatment. The government of Nigeria should recognize the 
benefit of local manufacturing of ARVs beyond attempts to ensure sustainability of HIV 
program. This should be an opportunity to increase local manufacture of goods which 
could reduce dependence on imported products, improve knowledge and technology 
transfer, and increase opportunities for research and improved economic development. 
Rather than attempt to manufacture all HIV treatment-related commodities from the 
onset, the priority of local production should be in a selected number of fixed dose 
combination ARVs used as first line regimen in the management of HIV infection. 
Because over 90% of HIV patients in Nigeria are on first line treatment, this will help 
ensure that economies of scale are maximized, resulting in favorable pricing. To ensure 
the produced commodities are of very high quality and cost effective and acceptable by 
all stakeholders, certain changes must be put in place. First, there must be a strong 
commitment by the government of Nigeria to achieve local production. Under the 
leadership and coordination of the government of Nigeria, a clear description of policy 
priorities must be developed to guide the local manufacture of ARVs in Nigeria. This 
policy should outline potential sources of financial incentives, subsidies, tax waivers, or 
low interest loans to stimulate the interest of local manufacturers of pharmaceuticals. 
This will require a multi-agency plan involving very senior officials from the Ministry of 
Health, Finance, Budget and Planning, Trade, and Industry. Second, the government 
must lead a high-level engagement with international partners and donors to fast-track 
current efforts to support WHO pre-qualification of manufacturers of pharmaceuticals in 
Nigeria. This will help ensure all systems are put in place to make locally produced 
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pharmaceuticals acceptable globally, and most importantly by current program donors. 
In addition, the government of Nigeria should establish partnerships with other West 
African countries to support local manufacturing of HIV treatment-related commodities 
by utilizing platforms offered by the Economic Commission of West African Countries 
(ECOWAS), African Union (AU) and Africa Development Bank (ADB), among others, to 
rally political and financial support as well as explore existing trade and other 
agreements with member countries. Third, the manufacture of quality HIV treatment-
related commodities requires a strong and competent regulatory agency. Nigeria already 
has the National Agency for Food Drug Administration and Control (NAFDAC), saddled 
with this responsibility. This agency needs to be provided with improved financial and 
technical support to ensure optimal regulatory control and quality assurance of all 
produced pharmaceuticals. These regulatory activities should cover factory inspection, 
registration of products, ensuring Good Manufacturing Practice (GMP), laboratory 
evaluations, quality control and assurance, and testing for bioequivalence and post-
market surveillance. The price of the final product is a major factor in ensuring 
competitiveness of locally manufactured ARVs with those manufactured outside of the 
country. Therefore, options that could lead to the manufacture of cost-effective products 
should be considered. The source of the active pharmaceutical ingredient (API) in ARV 
manufacture is a key consideration in the selection of options. This is because the cost 
of API is a major driver of the cost of producing the final products (WHO 2010). 
Stakeholders should consider either importation of API from low-cost countries such as 
India and China or local manufacture of both API and final products. Irrespective of 
choice, there must be incentives from the government to subsidize the cost of 
production, and to ensure appropriate and competitive pricing of produced ARVs. 
Another option is for the government to seek technical and financial support from 
countries that have achieved local manufacture of generic ARVs. This could be in the 
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form of requests to put in place technology required to meet GMP and Good Laboratory 
Practice (GLP) and bioequivalence testing, as stated above. 
o Reduction of the cost of implementing HIV treatment services through integration 
of vertical HIV treatment services into other healthcare services: The leadership of 
the HIV program working with stakeholders must agree on the issue of integration of HIV 
program into the healthcare system rather than maintain it as a vertical program. This 
decision must be guided by a critical evaluation of the program with inputs from key 
stakeholders. Most of the participants in this study – except for people living with HIV – 
suggested that integration is the way to go. Therefore, if the program goes with the 
option of integration, concerns around stigma and discrimination at service delivery 
points highlighted by people living with HIV and their networks should be addressed 
through appropriate training of healthcare workers. Rather than immediate integration of 
all components of treatment services, a phased approach should be employed. This can 
be facilitated by increasing the number of private sector pharmacies that are involved in 
the ongoing pilot of ARVs refill to reduce waiting time at public healthcare facilities. 
Lessons learned from such a phased approach could provide information to guide scale 
up until all components of treatment services are integrated.  
o Provision of income-generating interventions to empower people living with HIV: 
Most patient respondents and key informants pointed to the role of economic 
empowerment in improving willingness and capacity of patients to pay and contribute to 
funding for HIV treatment services in Nigeria. Therefore, it is important to mainstream 
income generating and personal and economic empowerment interventions into HIV 
programming as part of efforts to improve the financial sustainability of the HIV program 
in Nigeria. The literature suggests that the relationship between poverty and risk of HIV 
is complex, and poverty interacts with factors such as mobility and socio-economic 
inequality among patients (Kim et al, 2008). Findings from the survey conducted during 
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this study found a strong association between patients’ socio-economic status and 
willingness to pay, and the maximum amount patients were willing to pay for HIV 
treatment services. Most of the current interventions aimed at improving economic 
empowerment of patients around the HIV program are often targeted at orphans and 
vulnerable children and in reducing the risk of contracting HIV among women and key 
population groups. However, there are a few examples of economic empowerment 
approaches directed at patients receiving HIV treatment services in countries such as 
China, India, Vietnam, and Thailand. The HIV program in Nigeria can learn from such 
approaches to support PLWHA to enable them to make informed decisions about 
economic opportunities, education, and employment. Such support should be in terms of 
capacity building that will help patients access information and other resources which will 
help them pursue an education and a career. The government of Nigeria, in partnership 
with stakeholders, should provide financial resources such as credit, employment, and 
training to utilize and manage these resources. These include training in business 
planning, management and marketing, and communication. Other potential supports for 
PLWHA include social capital development and promotion of social interaction to 
minimize isolation and overcome stigma in the community and the workplace. These 
frameworks for empowering PLWHA should be employed using a multi-sectoral 
approach and could be implemented through existing support groups of PLWHA or 
creating new groups at the community level. Evidence from the literature shows that 
interventions which involve local partnerships with community development associations 
and active participation of the beneficiaries from the design stage are more sustainable 
than interventions without these characteristics (Upadhya, 2017). Rather than 
implementing a single approach across all settings, the program should consider pilots 
of different approaches available in the literature and should have proper documentation 
of activities, processes, and results to enable comparison of effectiveness and 
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challenges before scaling up. It is critical to have a clear definition of objectives of 
implementation and indicators of progress and achievements.  
2. Secure Support of Key Stakeholders 
The desired change to improve sustainability of funding for HIV treatment services in 
Nigeria requires the support of key stakeholders. The leadership of the HIV program in Nigeria 
should engage with key stakeholders to obtain required support. There are political and 
economic interests and considerations involved in the desired change. A mapping of 
stakeholders should be conducted to determine the interests, power, and influence of each 
stakeholder. Therefore, the program should frame the drive for funding sustainability in a way 
that would highlight the benefits of the change to key stakeholders and the HIV program. This 
would require the application of some of the approaches highlighted above under stakeholder 
analysis and engagement. Of highest priority is the necessity of securing the buy-in of the 
federal government of Nigeria at the highest level before making attempts to convince the 
external stakeholders. The desired change will require a bigger funding commitment from the 
government, and there must be a genuine willingness to fulfil its own side of the bargain before 
engaging with external stakeholders. 
3. Create Need for Change 
Effective communication is critical in creating the need for change among key 
stakeholders. The change implementation team should develop compelling messages to 
address each stakeholder’s need. The messages should be used to market the important 
reasons why current implementation approaches should change towards promoting 
sustainability. Specific benefits of the desired change for Nigeria, the HIV program, the 
beneficiaries, and other key stakeholders should be highlighted at every opportunity. The long-
term vision of the HIV program around funding sustainability should be highlighted. In creating 
the need for change, effective leadership must be demonstrated at all levels. The importance of 
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leadership in bringing about change is further highlighted below under the leadership model 
required for change. 
4. Manage and Understand Doubts and Concerns. 
While trying to unfreeze the status quo, stakeholders may develop doubts and concerns 
around the proposed change. The implementation team must be prepared to listen and address 
such concerns and doubts. The conversation at this point must be honest and genuine. 
Answers provided to concerns and doubts must be convincing to stakeholders and should get 
them thinking and open for further conversation leading to full buy-in. 
Change 
Once the resistance to the planned change has been overcome and buy-in of 
stakeholders received, it is time to design and implement change. Effective leadership and 
adequate flow of information are key drivers of change implementation. These are required in 
solving problems which may arise because of change and to promote visibility and sharing of 
real time information across various levels of stakeholders. It should be noted that change is not 
likely to be a linear process; effective leadership is required to implement an iterative 
mechanism that would provide an opportunity for learning with adequate reinforcement put in 
place to sustain change. Aside from a well-defined and clear vision, there must be well thought 
out strategies to transform the vision into reality. In addition, this requires individuals and 
organizations (stakeholders) with appropriate skills and commitment selected as members of 
the change implementation team. During the change process, the following must be considered. 
a. Communicate often with stakeholders: Communication is critical at every stage of 
design and change implementation. Communication should be geared towards 
educating, supporting, and incentivizing change. During this stage, communication 
should be timely, accurate, factual, and consistent. This is important for transparency, to 
enhance trust among stakeholders, and provide opportunities for feedback.  
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b. Dispel rumors: As part of communication with stakeholders, answers must be provided 
to questions raised by stakeholders. Where misunderstandings exist, these must be 
clarified and rumors on the goals and objectives of desired change must be dispelled. 
There should not be an opportunity for inaccurate perception to fester about the change 
being implemented.  
c. Empower action: Key stakeholders must be empowered and supported to be part of the 
change. All obstacles to the achievement of change objectives must be identified, 
studied, and eliminated. These obstacles could be around policies, regulations, funding, 
and capacity. In addition, the way key stakeholders would function under the new 
approach would be different from current practices. For example, the role of donors, HIV 
implementing organizations and government at all levels will be different from the current 
practices. Therefore, all stakeholders must understand their roles in the new 
dispensation and how they contribute to the success or otherwise of HIV funding 
sustainability in Nigeria. This new way of doing things may not be easily achieved. 
Therefore, deliberate efforts should be put into reorientation and provision of support to 
drive change. 
d. Involve people in the process: The National Agency for Control of AIDS (NACA) and 
the National AIDS and STI Control Program (NASCP) are agencies of government 
responsible for the regulation, implementation, and creation of policy direction for the 
HIV program in Nigeria and should be at the driver’s seat of this change. However, these 
agencies should ensure active involvement of key stakeholders in the planning, and 
implementation of change towards sustainability. This is important to avoid disruption of 
service delivery and to promote high quality change (Vroom and Yetton, 1973). This 
approach will promote rich contributions from stakeholders during planning and change 
implementation as well as promote their commitment to the cause. 
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Refreeze 
a. Anchor changes into the culture: The new approach to sustainable funding for HIV 
treatment program to be established in Nigeria must be well rooted in the culture of the 
program. It is important that the link between changes introduced and improved funding 
sustainability for HIV treatment services be highlighted continuously for stakeholders to 
see, rather than waiting for them to make the connections on their own. This is another 
area where effective communication from the implementation team is very critical. Every 
platform, such as the HIV/AIDS technical working group meetings, strategy development 
meetings, trainings and program performance reviews, should be used to highlight 
successes of the introduced change. In addition, every stakeholder involved in HIV 
treatment program as well as the leadership of government agencies must be supported 
to personalize the new approach to programming. When new agency heads or 
personnel who hold strategic positions are appointed, efforts should go into ensuring 
these individuals are committed and supportive of the drive for sustainability rather than 
individuals who may disrupt or derail the proposed change.  
b. Develop ways to sustain change: It is equally important that the new approach to 
implementing HIV treatment programs in Nigeria sinks into the culture of governance 
and HIV programming to sustain the change. This will require consistent funding support 
and political will from the government of Nigeria at all levels. This will also require 
consistent support from the private sector, civil society groups, and people living with 
HIV, who are the beneficiaries of the proposed change. Sustaining a change require the 
change implementation team to avoid declaring victory too soon (Kotter, 1997). The 
implementation team must create a system for receiving and providing feedback on all 
activities while also ensuring stakeholders who have remained committed and 
supportive of the change process are appropriately identified and rewarded. The drive 
for sustainable funding for HIV has become an issue which requires urgent attention, 
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particularly due to the impact of COVID -19. With the onset of the pandemic, it is likely 
that donor funding for HIV and other development assistance would be reduced due to 
diversion of such funds towards COVID- 19 interventions, including development and 
provision of access to safe and effective vaccines. The shock to the global economy due 
to the pandemic has resulted in about a US$15 billion deficit in Nigeria’s year 2020 
budget (Agbakwuru, 2020), therefore, these challenges as well as disruptions to global 
supply chain systems may exacerbate HIV treatment funding gaps and would be used 
as pointers to need for change in the way HIV treatment services are implemented in 
Nigeria. 
c. Celebrate success: As the new indicators of success of the introduced change emerge, 
it is important to showcase and celebrate these successes. This will encourage 
stakeholders to keep supporting the process. 
My Support for Implementing Plan for Change 
The majority of the challenges around sustainability of funding for HIV treatment services 
highlighted in this study are not entirely newly identified. Rather, this study confirms that 
challenges remain with the program and there is a need for deliberate efforts to address them 
holistically. The earlier part of the plan for change section provided recommendations and 
approaches to be led by government working with stakeholders to bring about change towards 
funding sustainability. I have identified five ways through which I can contribute to the 
successful implementation of the plan for change. These include:  
1. Support the conduct of stakeholder analysis and development of appropriate 
messaging and communication strategy for engaging the stakeholders: Receiving 
the buy-in and approval of stakeholders is usually considered as the most important step 
in achieving organizational change. In the last 3 years, I have led a project which 
supported the government of Nigeria to map and analyze stakeholders involved in HIV 
145 
prevention program in Nigeria. I plan to work with a few stakeholders to conduct a similar 
activity for the HIV treatment program by using a power interest grid. I hope to consider 
the opinion of each stakeholder on the proposed change towards improved funding 
sustainability. The mapping and analysis would also involve the identification of 
individuals and organizations who can help influence the opinion of key stakeholders to 
support the change. The draft report of the analysis will be reviewed and finalized by a 
wider stakeholder group. In addition, I hope to participate actively in the development of 
a communication strategy to be employed in engaging with stakeholders to create the 
urgency and to seek buy-in for change. I would consider supporting the HIV program in 
developing a communication plan with detailed information about the target audience, 
purpose, frequency, and media to be used for communication and engagement.  
2. Dissemination of the findings of the dissertation: I plan to share key findings from 
this dissertation with key informants and participants who contributed to the study. I 
would also like to present my findings at local and international conferences, workshops, 
journals and technical meetings on health service research, policy, and health program 
implementation around HIV. I plan to work with members of my DrPH committee to 
summarize the key findings into manuscripts and abstracts for submission on various 
topics. Possible topics will include1) willingness of patients to pay for HIV treatment 
services in Nigeria and factors which influence their decision, 2) funding of HIV treatment 
services in Nigeria and sustainability can be improved, 3) the role of leadership in driving 
Nigeria’s quest for funding sustainability for HIV treatment services. 
In addition, I plan to disseminate the findings to key stakeholders at the national and 
state HIV technical working group meetings as well as meetings of the national HIV task 
team meetings. 
3. Support the engagement of stakeholders for creating the urgency for change: 
Although most of the key informants arrived at a consensus on the importance of 
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achieving HIV program funding sustainability, some were of the opinion that the final 
decision rests with government and current donors. These key decision makers must 
demonstrate genuine desire to pursue this change. I plan to engage with the leadership 
of NACA and NASCP to develop a strategy to collaboratively create urgency for change. 
In the last three years, I have led a team of public health specialists to work with other 
stakeholders in implementing interventions aimed at improving sustainability of HIV 
prevention programming in Nigeria. I hope to use my current practice network with 
stakeholders to advocate and encourage members to prioritize issues of funding 
sustainability for HIV treatment services. I would focus my engagement activities in 
pushing improved alignment of goals and priorities of stakeholders towards sustainability 
and building of a culture of trust. 
4. Participate in policy dialogues and support advocacy groups around funding 
sustainability for the HIV program: Members from the civil society for HIV/AIDS in 
Nigeria participated as key informants during the research and have been involved in 
advocacy efforts with government and local and international donors on funding 
sustainability of the program. I plan to support these advocacy efforts by making my 
findings available to supporters of funding sustainability.   
5. Continue to contribute to improvement of potential strategies/ solutions identified 
from this study: If used properly, results from this research have the potential to 
transform the HIV program in Nigeria to a path of funding sustainability. I hope to work 
with the agencies of government and stakeholders who support the urgent need for 
change by identifying specific, measurable, attainable, relevant, and time-bound 
(SMART) indicators to monitor progress.  In addition, I hope to collaborate with the 
stakeholders to identify sources of data to monitor progress and to volunteer to support 
the collation of the data from these sources.  Results of the monitoring will be presented 
at the quarterly HIV technical working group meetings and the Task Team meetings. 
147 
These meetings involve all stakeholders within and outside of government. The platform 
would hopefully be used to provide feedback on the status of change implementation 
and to support review of highlighted strategies. I hope to add my voice to the 
performance monitoring and review as well as provide lessons from previously 
implementing strategies to improve sustainability of HIV prevention program. 
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CHAPTER 8: CONCLUSION 
“The fight against HIV/AIDS requires leadership from all parts of government - and it needs to 
go right to the top. AIDS is far more than a health crisis. It is a threat to development itself.” 
             -- Kofi Annan 
You never change things by fighting the existing reality. To change something, build a new 
model that makes the existing model obsolete. 
 -- Buckminster Fuller  
This dissertation provided answers to the questions, “what proportion of patients are 
willing to pay for HIV treatment services in Nigeria, and how can funding sustainability of HIV 
treatment services be improved?” The mixed method design used for the research provided 
answers to these questions through a survey of patients living with HIV and interviews with key 
informants associated with the HIV program in Nigeria. A significant proportion of the survey 
respondents expressed willingness to pay for HIV treatment; the maximum amount they were 
willing to pay varied widely among the patients. Key informants provided rich information that 
can be used to improve funding sustainability of the program. These answers guided the 
development of a plan for change which emphasized the role of effective leadership, 
partnerships, communication and the importance of strong political will and domestic resource 
mobilization to achieve the desired change. Experience has shown this form of change is not 
achieved within a short period of time; however, the HIV program must begin a gradual 
movement in the right direction with regular monitoring of achievements over time. There are 
opportunities for Nigeria to reverse the foreign donor dependency of the HIV program. Not only 
can the program become sustainable, but it can also empower people living with HIV and 
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contribute to the economic development of the country through increased job creation 
from local manufacture of HIV related commodities. 
In the last decade, issues around funding sustainability for the HIV program has 
remained a topic of discussion globally. It is important to move the issue beyond mere 
discussion to actual strategy development and implementation. Advocacy will continue to play 
critical role in achieving this transition. The emergence of COVID 19 and its impact on the global 
economy and foreign donor funding for health and international development provide another 
wake-up call to begin to do things differently. As this study showed, some patients are willing 
and capable of paying for HIV treatment services; equitable access to services should be 
prioritized over universal free treatment services as the latter puts a significant burden on 
funding for the program. Existing data from the National Social Safety Nets Coordinating Office 
(NASSCO) in Nigeria currently has information on about 21 million poor and vulnerable citizens 
of Nigeria. This could be used to identify PLWHA in the database who must be provided with 
free HIV treatment services. This further highlights the need for multi-agency/sectoral 
collaboration in solving HIV related challenges rather than solely a health sector response. 
As public health experts/practitioners, we must continue to prioritize cost-effective and 
sustainable health interventions. This requires building concrete and time bound sustainability 
plans into the design and implementation of foreign donor funded interventions. This will ensure 
that the gains of such interventions are not lost when foreign donor funding stops. 
My vision of change would be an HIV treatment program which prioritizes sustainability 
of its funding through increased local mobilization of funds. I am hopeful that this will translate 
into equitable access to HIV treatment services for all patients. Whatever approaches 
stakeholders take towards proposed change, the interests of the patients must be prioritized to 
ensure treatment services are not disrupted due to unanticipated consequences of change. 
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Stakeholders must exhibit flexibility and the willingness to trade off some of the current 
personal/organizational benefits for the good of PLWHA. 
I am aware that my sphere of influence on the implementation of the recommendations 
of this study may be limited because the key decisions related to these issues lie primarily with 
the government of Nigeria and the current foreign donors. I hope that the findings from the 
research and the plan for change has helped to articulate the direction, approaches, and 
requirements for improved funding for the HIV program in Nigeria. With practical experience 
from leading the implementation of interventions aimed at improved sustainability of HIV 
prevention programming and the completion of my DrPH, I hope to become a champion for 
research and implementation of strategies aimed at improved sustainability of health programs 
currently funded by foreign donors. I have acquired skills and competencies during the program 
which have made me better prepared as a leader, a change agent, and advocate for 
sustainability of health programs.  
This DrPH journey at the Gillings School of Public Health, UNC at Chapel hill has been 
tremendous. I was able to contribute to learning by members of cohort ’13 (C13) and the 
program prepared me to become a well-rounded public health leader. With enhanced skills in 
leadership, program design, implementation, and monitoring, it has been a wonderful learning 
experience. I am very grateful for the privilege to benefit from this program. 





APPENDIX 1: SAMPLE SURVEY INSTRUMENT (APPROVED BY UNC IRB AND NHREC) 
 
Draft Survey Instrument for Dissertation  
Title: Funding for HIV/AIDS treatment services in Nigeria: How can sustainability be improved? 
 
How can sustainability of HIV treatment services be improved? Your Opinion Matters 
 
There are about one million people living with HIV/AIDS who need treatment but are unable to 
access required treatment. The lack of access is primarily due to the inability of government of 
Nigeria and donor agencies to provide free HIV treatment for everyone who requires it. In 
addition, the foreign donors contribute over 90% of the funding towards free treatment in 
Nigeria. It is known that they may not be able to continue to provide these funds to Nigeria. I 
would like to find out your perspectives on how treatment can be made available to everyone 
and to know if you will be willing to pay if the donors no longer support free HIV treatment 
services in Nigeria. Your answers to these questions will be kept strictly confidential.  
 
You are eligible to complete this survey if you: 
• Are at least 18 years of age. 
• Are living with HIV and receiving treatment for the condition. 
• Are willing to give your opinion on how to sustain the funding for HIV/AIDS in Nigeria 
• Are willing to provide information on your willingness to pay for HIV treatment services. 
• Live in Nigeria  
 
We are interested to find out about:  
• Your knowledge of the importance of adherence to HIV treatment 
• How willing you would be to pay for HIV treatment services. 
• The factors that influence your willingness or lack of willingness to pay for HIV treatment 
services. 
• How funding for HIV treatment services can be made sustainable 
 
What we intend to achieve from the research 
The findings generated from this study will be used to help develop a sustainable funding 
mechanism for HIV treatment services in Nigeria. There are still about 1 million people who 
need HIV treatment, but they are unable to access it due to inadequate funding by government 
and donor agencies, the findings from this research will help to increase access to treatment for 
all those who need HIV treatment.  
 
Time to Complete 
This survey will take from 45 minutes to complete. 
 
Thank You and Questions  
Thank you in advance for your participation and support. If you have any questions about this 







Patient Demographics  
Read Out loud. First, I would like to ask you a few questions about yourself 
1 How old were you at your last 
birthday? 
Age in Years______________ 
















3 What is the highest level of 






























5 Monthly Income No income 
Less than 10,000 Naira 
10,000 – 20,000 Naira 
20,000 – 30000 Naira 
30,000 – 40,000 Naira 
50,000 – 100,000 Naira 
Over 100,000 









6 Approximately how many minutes 
does it take FROM YOUR HOUSE 
to where you receive HIV/AIDS 
treatment services? 
Write answer _______________________ 
7 What means of transport do you 
usually use to get to where you 














8 If you pay for transport above, 
how much does it cost for a trip to 
the clinic and back home? 
Write answer__________________________ 
9 On average, how often do you 
come to the clinic for drug refill? 
Once a month 




Once every two months 
Once every three months 
3. 
4. 
Knowledge on importance of treatment and adherence to treatment 
10 What level of HIV treatment are 
you on?  
First line treatment 
Second line treatment 




11 For how long have you been on 
HIV treatment? 
Less than one year 
1 -3 years 




12 Do you think there are benefits in 
starting HIV treatment as soon as 





13 Are you aware of the 
consequences of non-adherence 





History of payment for Healthcare Services 
14 Have you ever paid for HIV 






14b If yes to question 14, where did 






15 What services did you pay for? 









15b How much did you pay in total? Less than N1,000 
N1,000 but less than N2,000 
N2,000 but less than N4,000 
N4,000 but less than N6,000 






16 Do you have any other chronic 
health condition aside HIV/AIDS 





16b If yes above, what is the 
condition? If No, move to 17 
Write condition_________________ 
16c Have you ever paid to receive 





17 What is the maximum amount you 
pay monthly for the treatment 
Write amount________________________ 
 Willingness to pay for HIV treatment services 
18 Do you know how much HIV 
treatment would cost you monthly 





18b How much? (Ask all participants 
this question irrespective of their 
answer to Q18) 
Write amount___________ 
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NOW TELL RSPONDENT THE AVERAGE 
COST OF ACCESSING TREATMENT PER 
MONTH 
 
19 Please imagine government and 
NGO are not able to support free 
HIV treatment services and this 
hospital stops free HIV treatment 
services.  
what would you do?  
1. Stop my treatment 
2. Try to pay for treatment 




19b Why do you say so?  
19c If you will pay for treatment, which 




19d Probe: What are the reasons for 
your option? 
Probe: If you come to the hospital 
once in 3 months instead of every 
month, do you think this will 
improve your willingness to pay for 
treatment? 
 
20 If [source from where you usually 
receive free treatment services 
are no longer available would you 
be willing to pay N5000 Naira per 
month for your treatment? 
Yes 
No 
If NO, move to Question 
20E 
If Yes move to Question 
20A 
20A If Yes to 20: Would you be willing 
to pay (N6,000) monthly?  
Yes 
No 
If NO move to 20G 
If Yes move to 20B 
20B If Yes to 20A: Would you be 
willing to pay (N7,000) monthly?  
Yes 
No 
If NO move to 20G 
If Yes move to 20C 
20C If Yes to 20B: Would you be 
willing to pay (N8,000) monthly? 
Yes 
No 
If NO move to 20G 
If Yes move to 20D 
20D If Yes to 20C: Would you be 




Move Question 20G 
20E If No to Question 20: Would you 




IF YES move to question 
20G 
IF NO MOVE TO 
Question 20F 
20F If No to 20E: Would you be willing 
to pay (N3,000) monthly?  
Yes 
No 
Move to 20G 
20G What’s the maximum amount you 
will be willing to pay? 
Write figure 
Factors which influence willingness to pay 
21 How much will you consider too 
high for monthly HIV/AIDS 
treatment services 
Write down amount 
22 Now can you tell me at what price 
you would consider HIV treatment 
services expensive, but still worth 
paying for? 
Write down amount 
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23 At what price would you consider 
HIV treatment services so 
expensive that you would not 
consider paying it monthly? 
Write down amount 
24 And at what price would you 
consider HIV treatment services to 
be so cheap that you would 
question the quality of services? 
Write down amount 
25 If you are willing to pay for 
services, what will be the source 





26 On a scale of 1 to 5 with 5 being 
the highest, please rate the quality 
of HIV treatment services you 






27 Will you be willing to pay for 
treatment services in this clinic if 
your income improves? 
Yes 
No 
28 Will you still be willing to pay for 
treatment services in this clinic 
even if your income declines? 
Yes 
No 
29 If you cannot afford to pay for HIV 
treatment services, will you be 
able to approach your family 
members to support you to pay? 
Yes 
No 
30 If you cannot afford to pay for HIV 
treatment services, will you be 
able to approach your friends to 
support you to pay? 
Yes 
No 
Preferred mode of payment (For those who are willing to pay any amount) 
31 What mode of payment do you 
prefer? 
1. Payment on the day you come to hospital 
2. Annual payment to the hospital 
3. Payment through Health Insurance 
premium 
Knowledge of sources of Funding for HIV Treatment in Nigeria 
 What would you say are the 
greatest challenges in accessing 
HIV treatment services by people 
living with HIV? 
Probe: Do you think it is 
acceptable for patients to pay for 
HIV treatment services? 
Probe: Why for yes and for No 
responses 
 
 As government and the 
international agencies are finding 
it difficult to provide free treatment 
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services, what do you think can be 
done to ensure people continue to 
be treated for HIV/AIDS? 
 What recommendations do you 
have to share that we have not 
discussed but you think will help to 
ensure everyone who needs 




Thank you very much for taking the time to complete this questionnaire. Your assistance is very 
much appreciated. If you have any questions or concerns, please contact Olawale Durosinmi-
Etti (olawale@live.unc.edu)  
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APPENDIX 2: ADULT CONSENT FORM (APPROVED BY UNC IRB AND NHREC) 
 
University of North Carolina at Chapel Hill  
Consent to Participate in a Research Study 
Adult Participants [People Living with HIV] 
 
Consent Form Version Date: ____15th January 2020__________ 
IRB Study # 18-2723 
Title of Study: Funding for HIV/AIDS Treatment Services in Nigeria: How can sustainability be 
improved? 
Principal Investigator: Olawale Durosinmi-Etti 
Principal Investigator Department: Health Policy and Management Operations 
Principal Investigator Phone number: 234 8023015240 
Principal Investigator Email Address: olawale@live.unc.edu  
Faculty Advisor: Bruce Fried 
Faculty Advisor Contact Information: (919) 966-7355 
 
 NHREC Protocol Number NHREC/01/01/2007-15/11/2019 
NHREC Approval Number NHREC/01/01/2007-23/12/2019 
 
What are some general things you should know about research studies? 
You are being asked to take part in a research study.  To join the study is voluntary. 
You may choose not to participate, or you may withdraw your consent to be in the study, for any 
reason, without penalty. 
Research studies are designed to obtain new knowledge. This new information may help people 
in the future.   You may not receive any direct benefit from being in the research study. There 
also may be risks to being in research studies.  
 
Details about this study are discussed below.  It is important that you understand this 
information so that you can make an informed choice about being in this research study.  
CONCISE SUMMARY 
This is a research study to find out if people living with HIV are willing to pay for HIV 
treatment services in Nigeria and the factors that influence their decision to pay or otherwise. 
If you decide to participate in this study, you will be required to provide responses to a 
questionnaire on your socio-economic status and willingness to pay for HIV treatment 
services. The questions will take about 60 minutes to be completed and there are no direct 
risks involved if you wish to participate. There are no direct benefits to your participation in 
this study. 





You will be given a copy of this consent form.  You should ask the researchers named above, or 
staff members who may assist them, any questions you have about this study at any time. 
What is the purpose of this study? 
The overall purpose of the research is to help inform the development of a sustainable financing 
approach to increase access to HIV treatment services in Nigeria by exploring patients’ 
willingness to pay for HIV treatment services and the factors that influence their willingness to 
pay. The study will gather opinions of people living with HIV, policy makers, HIV program 
managers and senior officials from the Ministry of Health, HIV Control Program, donor 
organizations and HIV intervention implementing organizations on how funding for HIV 
treatment services can be made more sustainable using a combination of funding mechanisms. 
You are being asked to be in the study because you are living with HIV and you are accessing 
free treatment services in this clinic. 
Are there any reasons you should not be in this study? 
You should not be in this study if you are not living with HIV and are below 18 years 
How many people will take part in this study? 
Approximately 500 people randomly selected from two states plus FCT (Lagos, Enugu and 
FCT) will take part in this study. 
How long will your part in this study last? 
The questionnaire will take from 45 minutes to 1 hour to complete. There is no follow-up needed  
What will happen if you take part in the study? 
Overall design: You will be asked questions using a questionnaire. The questionnaire contains 
about 35 questions and you will be expected to provide information on your socio-economic 
status and your willingness to pay for HIV treatment services. The bidding approach will be used 
to determine your willingness to pay for HIV treatment services and how much you are willing to 
pay. You may choose to not answer a question or withdraw from the interview without any 
reason.  
What are the possible benefits from being in this study? 
Research is designed to benefit society by gaining new knowledge.  You will not benefit 
personally from being in this research study. 
What are the possible risks or discomforts involved from being in this study? 
There are no direct risks to you if you choose to participate in this study. However, as with all 
studies, there is a risk of loss of privacy and a breach of confidentiality. 
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How will information about you be protected? 
All information collected in this study will be given code numbers. Names and signature will 
appear only in the consent forms and will not be linked to you or data collected in anyway. The 
device for recording would be securely kept in a safe where only the researcher has access to 
it. The tapes would be kept safe for 2 years after which it would be destroyed accordingly. All 
data pertaining to this study would be securely kept in a pass-worded laptop.  
Participants will not be identified in any report or publication about this study.  We may use de-
identified data and/or specimens from this study in future research without additional consent. 
Although every effort will be made to keep research records private, there may be times when 
federal or state law requires the disclosure of such records, including personal information.  This 
is very unlikely, but if disclosure is ever required, UNC-Chapel Hill will take steps allowable by 
law to protect the privacy of personal information.  In some cases, your information in this 
research study could be reviewed by representatives of the University, research sponsors, or 
government agencies (for example, the FDA) for purposes such as quality control or safety. 
What if you want to stop before your part in the study is complete? 
You can withdraw from this study at any time, without penalty.  The investigators also have the 
right to stop your participation at any time. This could be because you have failed to follow 
instructions, or because the entire study has been stopped. 
If you withdraw or are withdrawn from this study all data collected up until the point of 
withdrawal will be retained, however no additional information will be collected unless you 
provide additional written permission for further data collection at the time of your withdrawal  
Will you receive anything for being in this study? 
You will not receive anything for taking part in this study. 
Will it cost you anything to be in this study? 
It will not cost you anything to be in this study.  
What if you have questions about this study? 
You have the right to ask, any questions you may have about this research. If you have 
questions about the study, complaints, concerns, or if a research-related injury occurs, you 
should contact the researchers listed on the first page of this form. 
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What if you have questions about your rights as a research participant? 
All research on human volunteers is reviewed by a committee that works to protect your rights 
and welfare.  If you have questions or concerns about your rights as a research subject, or if 
you would like to obtain information or offer input, you may contact the Institutional Review 
Board at 919-966-3113 or by email to IRB_subjects@unc.edu. 
Participant’s Agreement: 
I have read the information provided above.  I have asked all the questions I have at this time.  I 
voluntarily agree to participate in this research study. 
 ______________________________________________________ 


















Signature of Witness if applicable; e.g. literacy issues, 
visually impaired, physically unable to sign, witness/interpreter for 
















APPENDIX 3: SAMPLE KEY INFORMANT INTERVIEW EMBEDED WITH CONSENT FORM 
(APPROVED BY UNC IRB AND NHERC) 
University of North Carolina at Chapel Hill 
Consent to Participate in a Research Study 
Adult Participants [Key informants on implementation of HIV program in Nigeria] 
Consent Form Version Date: ____22nd January 2020__________ 
IRB Study # 18-2723 
Title of Study: Funding for HIV/AIDS Treatment Services in Nigeria: How can sustainability be 
improved? 
Principal Investigator: Olawale Durosinmi-Etti 
Principal Investigator Department: Health Policy and Management Operations 
Principal Investigator Phone number: 234 8023015240 
Principal Investigator Email Address: olawale@live.unc.edu  
Faculty Advisor: Bruce Fried 
Faculty Advisor Contact Information: (919) 966-7355 
 
What are some general things you should know about research studies? 
You are being asked to take part in a research study.  To join the study is voluntary. 
You may choose not to participate, or you may withdraw your consent to be in the study, for any 
reason, without penalty. 
 
Research studies are designed to obtain new knowledge. This new information may help people 
in the future. You may not receive any direct benefit from being in the research study. There 
also may be risks to being in research studies.  
 
Details about this study are discussed below.  It is important that you understand this 
information so that you can make an informed choice about being in this research study.  
 
You will be given a copy of this consent form.  You should ask the researchers named above, or 
staff members who may assist them, any questions you have about this study at any time. 
 
What is the purpose of this study? 
The overall purpose of the research is to help inform the development of a sustainable financing 
approach to improve access to HIV treatment services in Nigeria. The first part of this study 
explored willingness of PLHIV to pay for HIV treatment services and the factors that influence 
CONCISE SUMMARY 
This is a research study to find out how provision of HIV treatment services in Nigeria can be 
made sustainable and how willingness to pay for HIV treatment services by people living with 
HIV can be applied to achieve funding sustainability. If you decide to participate in this study, 
you will be required to provide responses to questions on your perspectives on the key 
findings of the survey conducted among people living with HIV and how a sustainable funding 
for HIV treatment services can be designed and implemented in Nigeria. The questions will 
take about 60 minutes to be completed and there are no direct risks involved if you wish to 
participate. There are direct benefits to your participation in this study. 





their willingness to pay. This second part will gather opinions of policy makers, HIV program 
managers and senior officials from the Ministry of Health, HIV Control Program, donor 
organizations and HIV intervention implementing organizations on the findings from the first part 
of the study and how funding for HIV treatment services can be made more sustainable using a 
combination of funding mechanisms. 
You are being asked to be in the study because you are a policy maker, HIV program manager 
or senior official from Ministry of Health, HIV Control Program, donor organizations or HIV 
implementing organization with opinions that are critical success of the HIV program in Nigeria. 
 
Are there any reasons you should not be in this study? 
You should not be in this study if you are not a policy maker, HIV program manager or senior 
official from Ministry of Health, HIV Control Program, donor organizations or HIV intervention 
implementing organization.  
 
How many people will take part in this study? 
Approximately 25 people randomly selected from Ministry of Health, HIV Control Program, 
donor organizations and HIV intervention implementing organizations in Nigeria will take part in 
this study. 
 
How long will your part in this study last? 
The interview will take about 60 minutes to complete. There is no follow-up needed.  
What will happen if you take part in the study? 
Overall design: You will be asked questions using a guide. You will be expected to provide 
information on your roles in provision of HIV treatment services and your perspectives on key 
findings of the survey conducted among people living with HIV. You would also be required to 
provide information on how sustainable funding for HIV treatment services can be achieved in 
Nigeria including policy changes that need to take place. The interview guide contains about 15 
questions and the interview would be audio recorded. You may choose to not answer a question 
or withdraw from the interview without any reason and at no penalty.  
What are the possible benefits from being in this study? 
Research is designed to benefit society by gaining new knowledge.  You will not benefit 
personally from being in this research study. 
  
What are the possible risks or discomforts involved from being in this study? 
There are no direct risks to you if you choose to participate in this study. However, as with all 
studies, there is a risk of loss of privacy and a breach of confidentiality. 
How will information about you be protected? 
All information collected in this study will be given code numbers. Names and signature will 
appear only in the consent forms and will not be linked to you or data collected in anyway. The 
device for recording would be securely kept in a safe where only the researcher has access to 
it. The tapes would be kept safe for 2 years after which it would be destroyed accordingly. All 
data pertaining to this study would be securely kept in a pass-worded laptop.  
I will report only summaries of the aggregated data.  This means that your responses will be 
combined with all the other responses received and will not be able to be identified as yours. 
Respondents will not be identified in any report or publication about this study.  We may use de-
identified data and/or specimens from this study in future research without additional consent. 
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Although every effort will be made to keep research records private, there may be times when 
federal or state law requires the disclosure of such records, including personal information.  This 
is very unlikely, but if disclosure is ever required, UNC-Chapel Hill will take steps allowable by 
law to protect the privacy of personal information.  In some cases, your information in this 
research study could be reviewed by representatives of the University, research sponsors, or 
government agencies (for example, the FDA) for purposes such as quality control or safety. 
 
What if you want to stop before your part in the study is complete? 
You can withdraw from this study at any time, without penalty.  The investigators also have the 
right to stop your participation at any time. This could be because you have failed to follow 
instructions, or because the entire study has been stopped. 
 
If you withdraw or are withdrawn from this study all data collected up until the point of 
withdrawal will be retained, however no additional information will be collected unless you 
provide additional written permission for further data collection at the time of your withdrawal  
 
Will you receive anything for being in this study? 
You will not receive anything for taking part in this study. 
 
Will it cost you anything to be in this study? 
It will not cost you anything to be in this study.  
 
What if you have questions about this study? 
You have the right to ask, any questions you may have about this research. If you have 
questions about the study, complaints, concerns, or if a research-related injury occurs, you 
should contact the researchers listed on the first page of this form. 
 
What if you have questions about your rights as a research participant? 
All research on human volunteers is reviewed by a committee that works to protect your rights 
and welfare.  If you have questions or concerns about your rights as a research subject, or if 
you would like to obtain information or offer input, you may contact the Institutional Review 
Board at 919-966-3113 or by email to IRB_subjects@unc.edu. 
Participant’s Agreement: 
 
I have read the information provided above.  I have asked all the questions I have at this time.  I 
voluntarily agree to participate in this research study. 
 
______________________________________________________ 





















Signature of Witness if applicable, e.g. literacy issues,  
visually impaired, physically unable to sign, witness/interpreter for 






Printed Name of Witness 
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APPENDIX 6: DETAILS OF KEY INFORMANTS INTERVIEWS 
 
1. Representative of Government Agency KII #1 7/25/2020 at 10:04 
2. Representative of Government Agency KII #2 7/25/2020 at 13:05 
3. Representative of Government Agency KII #3 7/25/2020 at 16:00 
4. Representative of Donor Agency KII #4 7/28/2020 at 16:52 
5. Representative of Donor Agency KII #5 8/3/20 at 9:06 
6. Representative of Civil Society organization for HIV in Nigeria KII #6 8/3/20 at 13:06 
7. HIV Program Manger KII #7 8/3/2020 at 16:49 
8. Representative of Donor Agency KII #8 8/4/2020 at 14:21 
9. Representative of Network of People Living with HIV KII #9 8/4/2020 at 18:18 
10. Representative of Government Agency KII #10 8/4/2020 at 21:08 
11. Representative of Donor Agency KII #11 8/7/2020 at 10:10 
12. Person Living with HIV KII #12 8/7/2020 at 15:38 
13. HIV Program Manger KII #13 8/10/2020 at 09:28 
14. Representative of Civil Society Organization for HIV in Nigeria KII #14 8/10/2020 at 
16:11 
15. Person Living with HIV KII #15 8/10/2020 at 19:01 
16. Representative of Civil Society Organization on HIV in Nigeria KII #16 8/12/2020 at 
10:19 
17. Representative of Donor Agency KII #17 8/12/2020 at 13:12 
18. HIV Program Manger KII #18 8/15/2020 at11:07  
19. Representative of Government Agency KII #19 8/15/2020 at 16:21 
20. Representative of Government Agency KII #20 8/18/2020 at 09:06 
21. Person Living with HIV KII #21 8/18/2020 at13:21 
22. Representative of Network of People Living with HIV KII #22 8/19/2020 at 18:32 
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23. Representative of Network of People Living with HIV KII #23 9/4/2020 at 21:08 
24. HIV Program Manger KII #24 9/9/2020 at 15:15 
25. Person Living with HIV KII #25 9/15/2020 at18:11 
26. Representative of Government Agency KII #26 10/9/20 at 11:16 
27. Person Living with HIV KII #27 10/9/20 at10:05 
28. Representative of Civil Society Organization for HIV KII #28 10/10/20 at 9:06 
29. Representative of Government Agency KII #29 10/10/20 at 12:06 
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